
<html lang="en"     class="pb-page"  data-request-id="979bee82-595f-4355-9704-6df67866f354"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.1c01115;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors" /></meta><meta name="dc.Creator" content="Scott H.  Henderson" /></meta><meta name="dc.Creator" content="Fiona  Sorrell" /></meta><meta name="dc.Creator" content="James  Bennett" /></meta><meta name="dc.Creator" content="Oleg  Fedorov" /></meta><meta name="dc.Creator" content="Marcus T.  Hanley" /></meta><meta name="dc.Creator" content="Paulo H.  Godoi" /></meta><meta name="dc.Creator" content="Roberta  Ruela de Sousa" /></meta><meta name="dc.Creator" content="Sean  Robinson" /></meta><meta name="dc.Creator" content="Alexander  Ashall-Kelly" /></meta><meta name="dc.Creator" content="Iva  Hopkins Navratilova" /></meta><meta name="dc.Creator" content="Daryl S.  Walter" /></meta><meta name="dc.Creator" content="Jonathan M.  Elkins" /></meta><meta name="dc.Creator" content="Simon E.  Ward" /></meta><meta name="dc.Description" content="Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted inte..." /></meta><meta name="Description" content="Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted inte..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 3, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c01115" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c01115" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c01115" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c01115" /></link>
        
    
    

<title>Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c01115" /></meta><meta property="og:title" content="Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0021.jpeg" /></meta><meta property="og:description" content="Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Down’s syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A’s role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure–activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c01115"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01115">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c01115&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c01115&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c01115&amp;href=/doi/10.1021/acs.jmedchem.1c01115" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00839" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c01136" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Scott H. Henderson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott H. Henderson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sussex Drug Discovery Centre, University of Sussex, Brighton BN1 9RH, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a7d4c4c8d3d389cfc2c9c3c2d5d4c8c9e7c5c2c9c2d1c8cbc2c9d389c6ce"><span class="__cf_email__" data-cfemail="671404081313490f0209030215140809270502090211080b02091349060e">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott+H.++Henderson">Scott H. Henderson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9504-5943" title="Orcid link">https://orcid.org/0000-0002-9504-5943</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fiona Sorrell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fiona Sorrell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fiona++Sorrell">Fiona Sorrell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Bennett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Bennett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Bennett">James Bennett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Oleg Fedorov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Oleg Fedorov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Oleg++Fedorov">Oleg Fedorov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marcus T. Hanley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marcus T. Hanley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marcus+T.++Hanley">Marcus T. Hanley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paulo H. Godoi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paulo H. Godoi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, Universidade Estadual de Campinas, Cidade Universitária Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paulo+H.++Godoi">Paulo H. Godoi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roberta Ruela de Sousa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roberta Ruela de Sousa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, Universidade Estadual de Campinas, Cidade Universitária Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roberta++Ruela+de+Sousa">Roberta Ruela de Sousa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sean Robinson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sean Robinson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Exscientia, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sean++Robinson">Sean Robinson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9312-7411" title="Orcid link">https://orcid.org/0000-0001-9312-7411</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexander Ashall-Kelly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexander Ashall-Kelly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Ashall-Kelly">Alexander Ashall-Kelly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Iva Hopkins Navratilova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Iva Hopkins Navratilova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Exscientia, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, U.K.</div><div class="loa-info-affiliations-info">University of Dundee, Dow Street, Dundee DD1 5EH, U.K</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Iva++Hopkins+Navratilova">Iva Hopkins Navratilova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daryl S. Walter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daryl S. Walter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Evotec (UK) Ltd., 112-114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daryl+S.++Walter">Daryl S. Walter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonathan M. Elkins</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan M. Elkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K.</div><div class="loa-info-affiliations-info">Structural Genomics Consortium, Universidade Estadual de Campinas, Cidade Universitária Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#29434647074c454240475a694a444d07465107484a075c42"><span class="__cf_email__" data-cfemail="97fdf8f9b9f2fbfcfef9e4d7f4faf3b9f8efb9f6f4b9e2fc">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+M.++Elkins">Jonathan M. Elkins</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-2858-8929" title="Orcid link">https://orcid.org/0000-0003-2858-8929</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Simon E. Ward</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon E. Ward</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#c99ea8bbad9af8f989aaa8bbada0afafe7a8aae7bca2"><span class="__cf_email__" data-cfemail="441325362017757404272536202d22226a25276a312f">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+E.++Ward">Simon E. Ward</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8745-8377" title="Orcid link">https://orcid.org/0000-0002-8745-8377</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c01115&amp;href=/doi/10.1021%2Facs.jmedchem.1c01115" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 3, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 June 2021</li><li><span class="item_label"><b>Published</b> online</span>3 August 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c01115" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c01115</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DScott%2BH.%2BHenderson%252C%2BFiona%2BSorrell%252C%2BJames%2BBennett%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c01115%26title%3DDiscovery%2Band%2BCharacterization%2Bof%2BSelective%2Band%2BLigand-Efficient%2BDYRK%2BInhibitors%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D20%26publicationDate%3DAugust%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c01115"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">-</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c01115" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;H. Henderson&quot;},{&quot;first_name&quot;:&quot;Fiona&quot;,&quot;last_name&quot;:&quot;Sorrell&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Bennett&quot;},{&quot;first_name&quot;:&quot;Oleg&quot;,&quot;last_name&quot;:&quot;Fedorov&quot;},{&quot;first_name&quot;:&quot;Marcus&quot;,&quot;last_name&quot;:&quot;T. Hanley&quot;},{&quot;first_name&quot;:&quot;Paulo&quot;,&quot;last_name&quot;:&quot;H. Godoi&quot;},{&quot;first_name&quot;:&quot;Roberta&quot;,&quot;last_name&quot;:&quot;Ruela de Sousa&quot;},{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;Robinson&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Ashall-Kelly&quot;},{&quot;first_name&quot;:&quot;Iva&quot;,&quot;last_name&quot;:&quot;Hopkins Navratilova&quot;},{&quot;first_name&quot;:&quot;Daryl&quot;,&quot;last_name&quot;:&quot;S. Walter&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;M. Elkins&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;E. Ward&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c01115&quot;},&quot;abstract&quot;:&quot;Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Down’s syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A’s role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure–activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of ne&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c01115&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c01115" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c01115&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c01115" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c01115&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c01115" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c01115&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c01115&amp;href=/doi/10.1021/acs.jmedchem.1c01115" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c01115" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c01115" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c01115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c01115%26sid%3Dliteratum%253Aachs%26pmid%3D34342227%26genre%3Darticle%26aulast%3DHenderson%26date%3D2021%26atitle%3DDiscovery%2Band%2BCharacterization%2Bof%2BSelective%2Band%2BLigand-Efficient%2BDYRK%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Down’s syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A’s role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure–activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-<i>b</i>]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound <b>11</b> exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of <b>11</b> in an <i>in vivo</i> setting. These pyrazolo[1,5-<i>b</i>]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Therapeutic applications of antagonists of the serine/threonine kinase, dual-specificity tyrosine-regulated kinase 1A (DYRK1A), have been under investigation for two decades. Diseases associated with the abnormal expression of DYRK1A (Alzheimer’s disease (AD), Down’s syndrome, cancer, and diabetes) represent significant unmet medical needs. Targeting the underlying mechanisms that cause these diseases is desirable in the search for novel approaches to treatment. DYRK1A plays a crucial role in neurogenesis and neuronal differentiation during embryonic development.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> DYRK1A is located on the Down’s syndrome critical region (DSCR) of chromosome 21; hence, individuals with Trisomy 21 (Down’s syndrome) express elevated levels of DYRK1A.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> As a result, overexpression of DYRK1A is thought to contribute to cognitive impairments associated with Down’s syndrome.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> AD has been associated with the accumulation of Aβ amyloid plaques and neurofibrillary tangles (NFTs) in the brain.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Increased DYRK1A activity promotes both NFT formation and aggregation,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> in addition to accelerating the cleavage of Aβ peptides that comprise amyloid plaques.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The ability of DYRK1A to effect the phosphorylation of nuclear factors of activated T cells (NFAT) and promote the proliferation of β-cells has piqued interest in DYRK1A inhibitors as a potential treatment for diabetes.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Several DYRK1A inhibitors have previously been developed.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Despite these efforts, few have progressed to <i>in vivo</i> models of disease, largely as a result of limited pharmacokinetics or poor selectivity for DYRK1A. Leucettine L41,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> SM07883 (structure not disclosed),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> GNF2133,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and compound 2-2c<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> represent DYRK1A antagonists that have been investigated <i>in vivo</i> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). However, Leucettine 41, SM07883, and GNF2133 potently inhibit other CMGC kinases, so they are more accurately described as dual DYRK1/CLK inhibitors.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Advanced DYRK1/CLK inhibitors reported in the literature (Leucettine 41,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> GNF2133,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and compound <b>2</b>–<b>2c</b><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a>) and previously characterized DYRK1A inhibitors <b>6b</b> and <b>8b</b> with DYRK1A IC<sub>50</sub> values of 186 and 76 nM, respectively. <b>6b</b> (shown in yellow) bound to DYRK1A such that the <i>N</i>-methyl group was directed toward a small pocket on the kinase hinge region (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1I">6S1I</a>). Key hydrogen-bonding interactions between <b>6b</b>, a consensus water, and DYRK1A (Leu241, Glu239, and Lys188) are depicted by black dotted lines. Compound <b>8b</b> had a selectivity score (S(40)) against DYRK1A of 0.01.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Previously, we reported the cheminformatics-based design of a series of selective DYRK1A inhibitors, exemplified by <b>8b</b> and <b>6b</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which had DYRK1A IC<sub>50</sub> values of 76 and 186 nM, respectively.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Here, we report the structure-guided development of this pyrazolo[1,5-<i>b</i>]pyridazine series, resulting in potent and selective inhibitors of DYRK1A with physical properties compatible with treatment of diseases associated with DYRK1A function. In agreement with our previous conclusions,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> the favorable selectivity profile of the series was achieved by maintaining hydrogen-bonding interactions between the ligand, a consensus water, and amino acid residues Glu239, Leu241, and Lys188, while directing a methyl substituent, or similar moiety, into a shallow lipophilic pocket, exclusive to the hinge of the DYRK and CLK kinases.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Three regions of <b>8b</b> were selected for structure–activity relationship (SAR) analysis: (a) the <i>N-</i>Me-aryl substituent, (b) the pyrazolo[1,5-<i>b</i>]pyridazine heterocycle, and (c) the pyrimidine hinge-binding moiety. To maintain and improve upon the selectivity of the series, it was important to preserve the unusual binding mode of the series in the ATP-binding site of DYRK1A. Therefore, a synthetic strategy was devised to access a range of <i>N</i>-alkyl analogues (<b>9</b>–<b>55</b>). The synthesis of key pyrazolo[1,5-<i>b</i>]pyridazine intermediates <b>6</b> and <b>8</b> followed literature procedures (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> N-Amination of pyridazine was completed with hydroxylamine-<i>O</i>-sulfonic acid. The pyrazolo[1,5-<i>b</i>]pyridazine heterocycle was constructed by reacting 1,3-dipole <b>2</b> with 3-butyne-2-one in a Huisgen cycloaddition. Dimethylformamide–dimethylacetamide (DMF–DMA) condensation of ketone <b>3</b> gave intermediate <b>4</b> in a high yield. Performing a urea melt on <b>4</b>, followed by dehydration and chlorination with phosphorus(V)oxychloride afforded key intermediate <b>6</b>. Alternatively, thioether <b>7</b> was accessed by treating <b>4</b> with thiourea and sodium methoxide, followed by iodomethane. Upon oxidation of <b>7</b> with <i>m</i>-CPBA, the key intermediate <b>8</b> was isolated.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Key Intermediates <b>6</b> and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) hydroxylamine-<i>O</i>-sulfonic acid, KHCO<sub>3</sub>, KI, H<sub>2</sub>O, 70 °C, 1.5 h, 94%; (ii) 3-butyne-2-one, KOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 60%; (iii) DMF–DMA, 100 °C, 16 h, 91%; (iv) urea, sodium hydride, 140 °C, 10 min, 91%; (v) phosphorus(V)oxychloride, 110 °C, 3 h, 92%; (vi) thiourea, sodium methoxide, <i>tert</i>-butanol, 90 °C, 16 h, then iodomethane, 30 °C, 4 h, 27%; (vii) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 67%.</p></p></figure><div class="NLM_p">Compounds <b>6</b> and <b>8</b> were used as key intermediates for nucleophilic aromatic substitution with assorted primary and secondary amines to afford <b>9</b>–<b>55</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). <i>N</i>-Alkyl analogues not prepared from commercially available amines were prepared in two steps: initial reaction of <b>6</b> or <b>8</b> with the primary amine was followed by alkylation with sodium hydride and appropriate haloalkane (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>9–55</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) amine, 2-propanol, 110–140 °C, 2–16 h; (ii) sodium hydride, haloalkane, DMF, rt, 5 h; (iii) secondary amine, 2-propanol, 140 °C, 16–96 h or microwave 25 min.</p></p></figure><div class="NLM_p">Aminopyrimidine <b>9</b> exhibited marginally weaker binding affinity for DYRK1A than <b>6b</b> but with superior LE (0.55 vs 0.41) and LLE (5.59 vs 3.55). Compound <b>10</b> bound with equal affinity to DYRK1A as <b>6b</b>, also conferring superior LE (0.56) and LLE (5.75). Compound <b>11</b> bound with stronger affinity than <b>6b</b>, while maintaining favorable lipophilicity (clog <i>P</i> = 1.62), LE (0.55) and LLE (5.50), representing a good starting point for further elaboration. Compound <b>12</b> showed similar binding affinity to <b>11</b>. Overall, maintaining one amino substituent as methyl while increasing the steric bulk of the other amino substituent was tolerated; however, two larger substituents (<b>13</b>–<b>15</b>) led to a reduction in DYRK1A binding affinity, a 10-fold reduction in the case of the matched-molecular pairs <b>12</b> and <b>13</b>, highlighting the importance of an <i>N</i>-methyl substituent for maintaining the binding mode seen in the co-crystal structure of DYRK1A:<b>6b</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The longer 4-carbon-chain amino substituent of <b>18</b> led to increased binding affinity compared to <b>17</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. DYRK1A Binding Affinity of Pyrazolo[1,5-<i>b</i>]pyridazines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">pIC<sub>50</sub> in TR-FRET-based ligand-binding displacement assay measured with two technical replicates (<i>n</i> = 1 biological replicate). LE = 1.4(pIC<sub>50</sub>)/nonhydrogen atoms. LLE = pIC50 – clog <i>P</i>.</p></div></div><div></div></div><div class="NLM_p">Co-crystal structures of DYRK1A bound to <b>10</b>, <b>11</b>, and <b>12</b> were determined at a high resolution (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The <i>N</i>-methyl and <i>N</i>-H matched pair, <b>11</b> and <b>10</b>, adopt the same binding mode in DYRK1A, respectively. The selectivity profiles of <i>N</i>-methyl and <i>N</i>-H matched pairs were previously shown to differ significantly, with <i>N</i>-methyl analogues being more selective for DYRK1A.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The <i>N</i>-methyl groups in <b>6b</b>, <b>11</b>, and <b>12</b> all occupy the same pocket on the kinase hinge region. The retention of binding mode gave confidence that the selectivity profile of <b>6b</b>, and by inference, <b>8b</b>, would be maintained in the chemical series.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Co-crystal structures of pyrazolo[1,5-<i>b</i>]pyridazines (compounds <b>6b</b>, <b>10</b>, <b>11</b>, <b>12</b>, and <b>30</b>) and compound <b>78</b> (yellow) in complex with DYRK1A. The backbones of the kinase N-lobe, hinge, and C-lobe are colored in gray, pink, and purple, respectively, and polar contacts are indicated by black dotted lines. The conserved water molecule at the back of the pocket is indicated by a red sphere. The electron density of each compound (2<i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> map) is shown contoured at 1.0σ (blue mesh). For clarity, DYRK1A strands β1 and β2 are hidden. (A) Previously identified compound <b>6b</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1I">6S1I</a>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (B) compound <b>10</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1B">6S1B</a>), (C) compound <b>11</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S17">6S17</a>), (D) compound <b>12</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S14">6S14</a>), (E) compound <b>30</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1J">6S1J</a>), and (F) compound <b>78</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1H">6S1H</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Data Collection and Refinement Statistics for DYRK1A Co-crystal Structures</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center"><b>10</b></th><th class="colsep0 rowsep0" align="center"><b>11</b></th><th class="colsep0 rowsep0" align="center"><b>12</b></th><th class="colsep0 rowsep0" align="center"><b>30</b></th><th class="colsep0 rowsep0" align="center"><b>78</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDB ID</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1B">6S1B</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S17">6S17</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S14">6S14</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1J">6S1J</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1H">6S1H</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>C</i>2</td><td class="colsep0 rowsep0" align="left"><i>C</i>2</td><td class="colsep0 rowsep0" align="left"><i>C</i>2</td><td class="colsep0 rowsep0" align="left"><i>C</i>2</td><td class="colsep0 rowsep0" align="left"><i>C</i>2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unit cell dimensions <i>a</i>, <i>b</i>, <i>c</i> (Å), α, β, γ (deg)</td><td class="colsep0 rowsep0" align="left">101.3, 70.4, 68.7, 90.0, 118.0, 90.0</td><td class="colsep0 rowsep0" align="left">100.9, 70.6, 68.3, 90.0, 117.8, 90.0</td><td class="colsep0 rowsep0" align="left">101.5, 70.3, 68.5, 90.0, 118.0, 90.0</td><td class="colsep0 rowsep0" align="left">99.2, 69.7, 67.4, 90.0, 117.5, 90.0</td><td class="colsep0 rowsep0" align="left">99.6, 69.7, 67.7, 90.0, 117.8, 90.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>Data collection</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution range (Å)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">30.60–1.30 (1.33–1.30)</td><td class="colsep0 rowsep0" align="left">30.46–1.10 (1.13–1.10)</td><td class="colsep0 rowsep0" align="left">30.39–1.05 (1.08–1.05)</td><td class="colsep0 rowsep0" align="left">59.80–1.41 (1.48–1.41)</td><td class="colsep0 rowsep0" align="left">30.11–1.05 (1.08–1.05)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unique observations<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">103 325 (7306)</td><td class="colsep0 rowsep0" align="left">137 242 (3030)</td><td class="colsep0 rowsep0" align="left">149 683 (1105)</td><td class="colsep0 rowsep0" align="left">75 809 (8676)</td><td class="colsep0 rowsep0" align="left">174 657 (6548)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">average multiplicity<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2.7 (2.0)</td><td class="colsep0 rowsep0" align="left">4.0 (2.0)</td><td class="colsep0 rowsep0" align="left">2.9 (1.1)</td><td class="colsep0 rowsep0" align="left">12.2 (8.8)</td><td class="colsep0 rowsep0" align="left">3.0 (1.7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">98.9 (95.0)</td><td class="colsep0 rowsep0" align="left">80.2 (24.3)</td><td class="colsep0 rowsep0" align="left">75.9 (7.6)</td><td class="colsep0 rowsep0" align="left">96.4 (76.0)</td><td class="colsep0 rowsep0" align="left">91.9 (47.0)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>merge</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.04 (0.70)</td><td class="colsep0 rowsep0" align="left">0.05 (0.06)</td><td class="colsep0 rowsep0" align="left">0.04 (0.61)</td><td class="colsep0 rowsep0" align="left">0.20 (2.68)</td><td class="colsep0 rowsep0" align="left">0.05 (0.63)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mean ((<i>I</i>)/σ(<i>I</i>))<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">10.1 (1.1)</td><td class="colsep0 rowsep0" align="left">11.7 (1.3)</td><td class="colsep0 rowsep0" align="left">15.4 (1.2)</td><td class="colsep0 rowsep0" align="left">9.5 (1.8)</td><td class="colsep0 rowsep0" align="left">11.1 (1.0)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mean CC(1/2)</td><td class="colsep0 rowsep0" align="left">0.999 (0.549)</td><td class="colsep0 rowsep0" align="left">0.998 (0.552)</td><td class="colsep0 rowsep0" align="left">0.999 (0.323)</td><td class="colsep0 rowsep0" align="left">0.996 (0.400)</td><td class="colsep0 rowsep0" align="left">0.997 (0.509)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>Refinement</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution range (Å)</td><td class="colsep0 rowsep0" align="left">30.60–1.30</td><td class="colsep0 rowsep0" align="left">30.46–1.10</td><td class="colsep0 rowsep0" align="left">30.39–1.05</td><td class="colsep0 rowsep0" align="left">59.80–1.41</td><td class="colsep0 rowsep0" align="left">30.11–1.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>-value, <i>R</i><sub>free</sub></td><td class="colsep0 rowsep0" align="left">0.16, 0.18</td><td class="colsep0 rowsep0" align="left">0.15, 0.17</td><td class="colsep0 rowsep0" align="left">0.15, 0.16</td><td class="colsep0 rowsep0" align="left">0.18, 0.18</td><td class="colsep0 rowsep0" align="left">0.14, 0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">r.m.s. deviation from ideal bond length (Å)</td><td class="colsep0 rowsep0" align="left">0.012</td><td class="colsep0 rowsep0" align="left">0.022</td><td class="colsep0 rowsep0" align="left">0.013</td><td class="colsep0 rowsep0" align="left">0.013</td><td class="colsep0 rowsep0" align="left">0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">r.m.s. deviation from ideal bond angle (deg)</td><td class="colsep0 rowsep0" align="left">1.15</td><td class="colsep0 rowsep0" align="left">1.62</td><td class="colsep0 rowsep0" align="left">1.22</td><td class="colsep0 rowsep0" align="left">1.28</td><td class="colsep0 rowsep0" align="left">1.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran Outliers<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> Most favored</td><td class="colsep0 rowsep0" align="left">0.0% 96.7%</td><td class="colsep0 rowsep0" align="left">0.0% 96.1%</td><td class="colsep0 rowsep0" align="left">0.0% 96.1%</td><td class="colsep0 rowsep0" align="left">0.0% 95.8%</td><td class="colsep0 rowsep0" align="left">0.0% 95.8%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Values within parentheses refer to the highest-resolution shell.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Values from Molprobity.</p></div></div></div><div class="NLM_p">With multiple crystal structures and SAR analysis supporting the existence of a shallow pocket on DYRK1A’s hinge motif that could be occupied by small substituents such as methyl, <i>in silico</i> modeling was used to identify possible replacements. The modeling suggested that a constrained methylene unit would be an appropriate substitution for the methyl group. Therefore, a range of cyclic amine analogues were synthesized to probe the size of the lipophilic pocket (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. DYRK1A Binding Affinity of Pyrazolo[1,5-<i>b</i>]pyridazines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0014.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">pIC<sub>50</sub> in TR-FRET-based ligand-binding displacement assay measured with two technical replicates (<i>n</i> = 1 biological replicate). LE = 1.4(pIC<sub>50</sub>)/nonhydrogen atoms. LLE = pIC50 – clog <i>P</i>.</p></div></div><div></div></div><div class="NLM_p">Several cyclic amine analogues exhibited a similar level of binding affinity for DYRK1A as former lead compound <b>8b</b> but with superior LE.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> All analogues exhibited lower LE than <b>11</b>, but a small number exhibited comparable levels of binding affinity (<b>22</b>, <b>24</b>, <b>28</b>, <b>30</b>, <b>31</b>, <b>33</b> and <b>34</b>) and superior LLE (<b>22</b>, <b>33</b> and <b>34</b>). Analogues bearing substituents with smaller ring sizes (4 or 5 carbon atoms) showed, in general, greater DYRK1A binding affinity than analogues with larger rings (>5 carbon atoms), reinforcing the hypothesis that steric bulk is permitted, but limited, close to the hinge of the kinase. The X-ray co-crystal structure of <b>30</b> bound to DYRK1A (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) showed a retention of the binding mode, with a methylene group of the cyclopentyl ring occupying the same pocket as the methyl groups of <b>6b</b>, <b>11</b>, and <b>12</b>, validating the prediction made by molecular modeling. Compound <b>22</b> and single <i>R</i>-enantiomers <b>31</b> and <b>34</b> were the only compounds with binding affinity for DYRK1A (IC<sub>50</sub>) of less than 100 nM.</div><div class="NLM_p">At this stage, as <b>11</b> possessed favorable LE (0.55) and had been shown to maintain the same binding mode as <b>6b</b>, it was used as the reference compound/matched-molecular pair for further SAR analysis. The data so far had not identified which of the atoms within the pyrazolo[1,5-<i>b</i>]pyridazine core contributed to selectivity and binding affinity, and were therefore, essential pharmacophoric features to maintain. The pyrazolo[1,5-<i>b</i>]pyridazine core, although not prevalent in the literature, is not novel and was being explored by others as antibiotic adjuvants<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and as treatments against neglected tropical diseases.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Therefore changes to the pyrazolo[1,5-<i>b</i>]pyridazine were investigated for their effects on DYRK1A affinity and selectivity as well as on compound solubility and metabolic stability. Close inspection of the DYRK1A:<b>11</b> co-crystal structure revealed the presence of a water molecule located toward the back of the DYRK1A binding site, with hydrogen bonds to the inhibitor and to the backbone amide nitrogen of Asp307 and the carboxylic acid of Glu203 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). We hypothesized that changing the pyrazolo[1,5-<i>b</i>]pyridazine head for a bioisostere or other heteroaromatic group might affect binding affinity and selectivity through replacement of the water, or perturbation or enhancement of the H-bonding network between the water, Glu203 and the catalytic lysine, Lys188. Iterative addition of substituents around the pyrazolo[1,5-<i>b</i>]pyridazine heterocycle was also hypothesized as a method to achieve selectivity over closely related kinases.</div><div class="NLM_p">Synthesis of heterocyclic analogues of the pyrazolo[1,5-<i>b</i>]pyridazine motif required bespoke routes; the 2-methyl analogue <b>60</b> was synthesized following the literature procedure,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> until the 1,3-dipolar cycloaddition step (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>A). For the first time with 1,3-dipole <b>2</b>, we report the organic base-catalyzed cycloaddition to furnish <b>58</b>. The main advantage of this procedure is that it avoids the formation of a KOH/CH<sub>2</sub>Cl<sub>2</sub> emulsion that occurs under the usual biphasic reaction conditions. The DBU catalyzed cycloaddition was found to be rather versatile. The 4-, 5- and 6- substituted pyrazolo[1,5-<i>b</i>]pyridazines were all accessed using the appropriately substituted pyridazine, following closely the literature procedure described for similar analogues.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> It was discovered that isolation and purification of intermediates were not a prerequisite for the synthesis of compounds <b>62</b>–<b>66</b>. In this instance purification was performed on the final products only. 5,6-Nitrogeneous heterocyclic analogues were synthesized using one of two major routes; the 5,6-heterocyclic ketone was constructed from commercially available building blocks, then treated, in a similar manner to the pyrazolo[1,5-<i>b</i>]pyridazines (<i>cf.</i><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), with DMF–DMA condensation, followed by cyclization with suitable guanidine (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>B,C).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 5,6-Heterocyclic Replacements of the Pyrazolo[1,5-<i>b</i>]pyridazine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (A) (i) Bis(triphenylphosphine)palladium(II) dichloride, copper iodide, TEA, propyne (<i>ca.</i> 5% in THF, <i>ca.</i> 1 mol/L), THF, rt, overnight, 87%; (ii) pyridazin-1-ium-1-amine iodide, DBU, acetonitrile, 50 °C, 16 h, 73%; (iii) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight, 80%; (iv) 2 M dimethylamine in THF, 110 °C, 2 h, 74%. (B) (i) Hydroxylamine-<i>O</i>-sulfonic acid, KHCO<sub>3</sub>, KI, H<sub>2</sub>O, 70 °C, 2 h; (ii) 3-butyne-2-one, KOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (iii) DMF–DMA, 75 °C, 16 h; (iv) 2-methoxyethanol, potassium carbonate, 1,1-dimethylguanidine sulfate salt, 125 °C, overnight. (C) (i) DMF–DMA, toluene, 90 °C, 2 h—overnight then chloroacetone, EtOH, reflux, overnight; (ii) DMF–DMA, 75 °C, 16 h; (iii) 2-methoxyethanol, potassium carbonate, 1,1-dimethylguanidine sulfate salt, 125 °C, overnight.</p></p></figure><div class="NLM_p">Alternatively, 4-chloro-<i>N</i>,<i>N</i>-dimethyl-pyrimidin-2-amine (compound <b>74</b>) was reacted with appropriate boronic heterocycle, either purchased commercially or produced following literature procedures, under Suzuki conditions (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Heterocyclic Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Sodium hydride, iodomethane, THF, rt, 16 h, 89%; (ii) bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium, boronic acid or ester, 1,4-dioxane, 70 °C, 16 h, 24–83%; (iii) 2-methyl-2-propanyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-1-carboxylate, tris(dibenzylideneacetone)dipalladium(0), potassium fluoride, tri-<i>tert</i>-butylphosphonium tetrafluoroborate, 120 °C, 20 min, microwave, then 4 N HCl in 1,4-dioxane, rt, 2 h, 91%; (iv) sodium hydride, haloalkane, DMF, rt, 1 h; (v) tetrabutylammonium hydrogensulfate, 33% sodium hydroxide, <i>p</i>-toluenesulfonyl chloride, toluene, rt, overnight, 92%; (vi) <i>N</i>-bromosuccinimide, DMF, rt, overnight, 14%; (vii) bis(pinacolato)diboron, bis(triphenylphosphine)palladium(II) dichloride, potassium acetate, 1,4-dioxane, 100 °C, 2 h, 85%; (viii) compound <b>85</b>, potassium fluoride, tris(dibenzylideneacetone)dipalladium(0), tri-<i>tert</i>-butylphosphonium tetrafluoroborate, acetonitrile/water (4:1), 120 °C, 5 h, then 1 M sodium hydroxide, 100 °C, 1 h, microwave, 12%; (ix) sodium hydride, iodomethane, DMF, rt, 30 min, 15%.</p></p></figure><div class="NLM_p">Compound <b>60</b> showed no binding affinity for DYRK1A (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), probably due to unfavorable clashes with the phenylalanine (Phe238) gatekeeper residue of DYRK1A. Substitution in the 6-position resulted in more than a 10-fold drop in DYRK1A binding affinity for <b>62</b> and <b>65</b>. This is likely due to unfavorable clashes between the molecules and the DYRK1A protein surface close to Lys188. Compound <b>64</b>, bearing a methyl substituent at the 4-position, also showed an approximate 10-fold loss in DYRK1A binding affinity, while the 4-methoxy analogue <b>66</b> showed approximately a 2-fold reduction in affinity, despite the potential change in orientation. A methyl substituent in the 5-position (<b>63</b>) was well tolerated.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. DYRK1A Binding Affinity of Pyrazolo[1,5-<i>b</i>]pyridazine Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0016.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0017.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">pIC<sub>50</sub> in TR-FRET-based ligand-binding displacement assay measured with two technical replicates (<i>n</i> = 1 biological replicate). LE = 1.4(pIC<sub>50</sub>)/nonhydrogen atoms. LLE = pIC50 – clog <i>P</i>.</p></div></div><div></div></div><div class="NLM_p">All bioisosteric replacements of the pyrazolo[1,5-<i>b</i>]pyridazine motif, and compounds <b>70</b>–<b>87</b>, designed to interact with, or to displace the structural water molecule, exhibited diminished DYRK1A binding affinity. Potentially, the loss of hydrogen bonding from the water to the inhibitor and to the protein was not compensated for by any other interaction, leading to a reduction in binding affinity. Another possibility is that the phenylalanine gatekeeper obstructs access to the back-pocket of DYRK1A, preventing the ligand from being able to displace the consensus water. Compound <b>70</b> showed strong binding affinity for DYRK1A, comparable to <b>63</b> and <b>66</b> but with better LE (0.53) and LLE (6.18).</div><div class="NLM_p">The binding affinity and LE of <b>78</b> were favorable, despite the change in binding orientation of compound <b>78</b> relative to the pyrazolo[1,5-<i>b</i>]pyridazine series (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F). Compound <b>78</b> could be considered as a distinct series and would potentially serve as an alternative scaffold for DYRK1A inhibition.</div><div class="NLM_p">The final point of diversification to investigate was the pyrimidine motif while retaining the pyrazolo[1,5-<i>b</i>]pyridazine moiety and the <i>N</i>,<i>N</i>-dimethylamine appendage. Several synthetic strategies were employed to furnish 5-substituted pyrimidine analogues. Compounds <b>95</b>–<b>100</b> were accessed via Suzuki reaction between pyrazolo[1,5-<i>b</i>]pyridazine boronic ester and appropriate 5-substituted pyrimidine. To construct the pyrazolo[1,5-<i>b</i>]pyridazine boronic ester, 1-aminopyridinium iodide <b>2</b> underwent 1,3-dipolar cycloaddition with methyl propiolate. Ester hydrolysis with lithium hydroxide furnished carboxylic acid <b>90</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>A). Facile bromodecarboxylation under mild conditions gave the 3-bromo intermediate <b>91</b>. Miyaura borylation of <b>91</b> furnished the desired boronic ester <b>92</b>, which was used crude in subsequent Suzuki reactions.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Key Boronic Ester and Pyrazolo[1,5-<i>b</i>]pyridazines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (A) (i) Intermediate <b>2</b>, potassium carbonate, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 36%; (ii) lithium hydroxide, MeOH, rt, 16 h then 1 M HCl, rt, 30 min, 74%; (iii) <i>N</i>-bromosuccinimide, DMF, rt, 3 h, 78%; (iv) bis(pinacolato)diboron, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with CH<sub>2</sub>Cl<sub>2</sub>, potassium acetate, 1,4-dioxane, 90 °C, 16 h. (B) (i) Sodium hydride, iodomethane, DMF, rt, 16 h; (ii) <b>92</b>, bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium, sodium carbonate, acetonitrile/water (10:1), 140 °C overnight. (C) (i) <b>92</b>, bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium, potassium carbonate, DMF, 60 °C, 1.5 h; (ii) 2 M dimethylamine in THF, 100 °C, 2 h. (D) (i) NXS, acetonitrile, rt, 2 h; (ii) sodium hydride, iodomethane, THF, rt, overnight.</p></p></figure><div class="NLM_p">The 5-substituted pyrimidine was prepared from either the commercial aminopyrimidine or 2,4-dichloropyrimidine (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>B,C). Alkylation with sodium hydride and iodomethane gave the required <i>N</i>,<i>N</i>-dimethylamine substituent (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>B). Alternatively, starting from the 2,4-dichloropyrimidine, the Suzuki reaction was performed first to install the pyrazolo[1,5-<i>b</i>]pyridazine moiety, followed by displacement of the chloride with dimethylamine, in a two-step one-pot reaction (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>C). After some investigation, it was found that 5-halo analogues <b>105</b>–<b>107</b> could be accessed reliably via electrophilic halogenation of compound <b>9</b>, followed by alkylation of the free amino group (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>D).</div><div class="NLM_p">Triazine <b>109</b> and pyridine <b>111</b> were prepared from 2,4-dichlorotriazine and 2,6-dibromopyridine, respectively (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>); nucleophilic aromatic substitution with dimethylamine followed by installation of the pyrazolo[1,5-<i>b</i>]pyridazine motif via Suzuki protocol gave <b>109</b> and <b>111</b>. Dimethylation of building block <b>112</b> under the usual conditions followed by Suzuki protocol to install the pyrazolo[1,5-<i>b</i>]pyridazine motif gave compound <b>113</b>.</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Pyrimidine Isosteres<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) dimethylamine hydrochloride, <i>N</i>,<i>N</i>-diisopropylethylamine, THF, rt, 3 h; (ii) <b>92</b>, bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium, 2 M potassium carbonate, 1,4-dioxane, 80 °C, 16 h; (iii) iodomethane, sodium hydride, DMF, rt, overnight.</p></p></figure><div class="NLM_p">Of the pyrimidine motif alterations, only the 5-fluoro analogue, <b>95</b>, exhibited stronger DYRK1A binding affinity than <b>11</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Increasing the size of the halogen (F → Cl → Br → I) was detrimental to DYRK1A binding affinity for the series. This suggests that when the pyrazolo[1,5-<i>b</i>]pyridazine series binds to DYRK1A, the space around the phenylalanine gatekeeper is restricted, limiting the size of substituent that can be placed favorably in the 5-position. The increased binding affinity observed for compound <b>95</b> may be the result of a combination of factors. A favorable interaction may have been established between the lipophilic fluorine atom and the phenylalanine gatekeeper (F−π interaction).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> A second possibility for the increased binding affinity observed for compound <b>95</b> could be the result of a conformational effect. The fluorine at the 5-position of pyrimidine may be acting as a weak hydrogen-bond acceptor with the proton of the 2-position of the pyrazolo[1,5-<i>b</i>]pyridazine, limiting rotation around the Ar-Ar bond, and preorganizing the molecule into an energetically favorable binding conformation. Substituents added to the 6-position of the pyrimidine were not well tolerated, probably as a result of unfavorable clashes between the ligand and the amino acid residues on the hinge region of DYRK1A.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. DYRK1A Binding Affinity of Pyrazolo[1,5-<i>b</i>]pyridazines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0018.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0019.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">pIC<sub>50</sub> in TR-FRET-based ligand-binding displacement assay measured with two technical replicates (<i>n</i> = 1 biological replicate). LE = 1.4(pIC<sub>50</sub>)/nonhydrogen atoms. LLE = pIC50 – clog <i>P</i>.</p></div></div><div></div></div><div class="NLM_p">Scaffold hopping from the pyrimidine to all other nitrogenous heterocycles resulted in reduced binding affinity for DYRK1A (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Removal of the nitrogen atom that serves as a hydrogen-bond acceptor to the hinge region of DYRK1A in compound <b>111</b> led to an approximately 10-fold reduction in binding affinity. Likewise, removal of the nitrogen atom from the 3-position of the pyrimidine and replacement with C–H (compound <b>113</b>) also resulted in a 10-fold loss in binding affinity. The diminished binding affinity observed for compound <b>113</b> is likely the result of a conformational effect. Co-crystal structures of the pyrazolo[1,5-<i>b</i>]pyridazine series (compounds <b>10</b>, <b>11</b>, <b>12</b>, and <b>30</b>) show retention in the relative orientation of the pyrimidine and pyrazolo[1,5-<i>b</i>]pyridazine rings (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_004.pdf" class="ext-link">SI</a> Figure 2). It is possible that the N3 of the pyrimidine and the C–H at the 4-position of the pyrazolo[1,5-<i>b</i>]pyridazine form an attractive interaction, preorganizing some compounds into an energetically favorable conformation for binding. Removal of N3 (compound <b>113</b>) may prevent the prearrangement of the energetically favorable binding conformation. Although triazine <b>109</b> exhibits >2-fold weaker affinity than <b>11</b>, the LE is still high (0.52). If potency could be improved by other alterations, then the triazine may lead to a molecular probe for DYRK1A with superior properties to the pyrimidine.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. DYRK1A Binding Affinity of Pyrazolo[1,5-<i>b</i>]pyridazines<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0020.gif" alt="" id="fx9" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center">B</th><th class="colsep0 rowsep0" align="center">C</th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center" char=".">clog <i>P</i></th><th class="colsep0 rowsep0" align="center" char=".">LE</th><th class="colsep0 rowsep0" align="center" char=".">LLE</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>109</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">6.74</td><td class="colsep0 rowsep0" align="char" char=".">1.88</td><td class="colsep0 rowsep0" align="char" char=".">0.52</td><td class="colsep0 rowsep0" align="char" char=".">4.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>111</b></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="char" char=".">6.04</td><td class="colsep0 rowsep0" align="char" char=".">2.25</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="char" char=".">3.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>113</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="char" char=".">6.17</td><td class="colsep0 rowsep0" align="char" char=".">1.86</td><td class="colsep0 rowsep0" align="char" char=".">0.48</td><td class="colsep0 rowsep0" align="char" char=".">4.31</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">pIC<sub>50</sub> in TR-FRET-based ligand-binding displacement assay measured with two technical replicates (<i>n</i> = 1 biological replicate). LE = 1.4(pIC<sub>50</sub>)/nonhydrogen atoms. LLE = pIC50 – clog <i>P</i>.</p></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Surface Plasmon Resonance Measurement of Lead Compounds</h3><div class="NLM_p">A set of the most potent compounds were assessed for DYRK1A binding by surface plasmon resonance (SPR) to measure the binding constants and association and dissociation rates (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). The measured <i>K</i><sub>D</sub> values were in good agreement with the data from the TR-FRET-based binding displacement assay. All compounds showed fast binding kinetics. Compound <b>95</b> had the slowest off-rate (longest residence time) of 0.06 s<sup>–1</sup>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. SPR Measurement of Lead Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="."><i>k</i><sub>a</sub> (M<sup>–1</sup> s<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>k</i><sub>d</sub> (s<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">7.3 (±0.1) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.97 (±0.02)</td><td class="colsep0 rowsep0" align="left">134.1 (±0.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0 (±0.1) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.33 (±0.1)</td><td class="colsep0 rowsep0" align="left">55.0 (±0.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">2.8 (±0.1) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.24 (±0.01)</td><td class="colsep0 rowsep0" align="left">85 (±1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">6.3 (±0.2) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.57 (±0.01)</td><td class="colsep0 rowsep0" align="left">90.4 (±0.0.3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">3.9 (±0.4) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.25 (±0.03)</td><td class="colsep0 rowsep0" align="left">64 (±2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">2.2 (±0.1) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.16 (±0.01)</td><td class="colsep0 rowsep0" align="left">72.8 (±0.3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">1.8 (±0.1) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.12 (±0.02)</td><td class="colsep0 rowsep0" align="left">65.5 (±0.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95</b></td><td class="colsep0 rowsep0" align="char" char=".">4.7 (±0.1) ×10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.06 (±0.01)</td><td class="colsep0 rowsep0" align="left">12.0 (±0.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>105</b></td><td class="colsep0 rowsep0" align="char" char=".">1.6 (±0.1) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">1.58 (±0.02)</td><td class="colsep0 rowsep0" align="left">963 (±2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>109</b></td><td class="colsep0 rowsep0" align="char" char=".">2.9 (±0.1) × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="char" char=".">0.44 (±0.01)</td><td class="colsep0 rowsep0" align="left">153.2 (±0.5)</td></tr></tbody></table></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Metabolic Stability and Solubility Profiles of Lead Compounds</h3><div class="NLM_p">Several analogues had emerged with superior LE, LLE and binding affinity for DYRK1A compared to the original starting point <b>6b</b> (LE = 0.41, LLE = 3.55 and pIC<sub>50</sub> = 6.73). These analogues also possessed a lower cLog <i>P</i>, a reduced number of aromatic rings, and were analyzed to determine whether the improvements in physicochemical properties would translate to improvements in metabolic stability and solubility (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), aiming to identify the compounds most suitable for development into <i>in vivo</i> chemical probes.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Metabolic Stability and Solubility</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A pIC<sub>50</sub><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">HLM (μL/(min mg))</th><th class="colsep0 rowsep0" align="center">RLM (μL/(min mg))</th><th class="colsep0 rowsep0" align="center" char=".">solubility (mg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.73</td><td class="colsep0 rowsep0" align="left">449.8<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">340.3<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="char" char=".">7.10</td><td class="colsep0 rowsep0" align="left">75 ± 5</td><td class="colsep0 rowsep0" align="left">783.7 ± 31</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">7.12</td><td class="colsep0 rowsep0" align="left">242 ± 32</td><td class="colsep0 rowsep0" align="left">231 ± 31</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">6.94</td><td class="colsep0 rowsep0" align="left">71 ± 2</td><td class="colsep0 rowsep0" align="left">434 ± 58</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">7.10</td><td class="colsep0 rowsep0" align="left">126 ± 9</td><td class="colsep0 rowsep0" align="left">119 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">6.96</td><td class="colsep0 rowsep0" align="left">328 ± 25</td><td class="colsep0 rowsep0" align="left">929 ± 116</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char=".">6.94</td><td class="colsep0 rowsep0" align="left">378 ± 66</td><td class="colsep0 rowsep0" align="left">448 ± 20</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char=".">6.83</td><td class="colsep0 rowsep0" align="left">389 ± 23</td><td class="colsep0 rowsep0" align="left">184 ± 18</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">7.18</td><td class="colsep0 rowsep0" align="left">296 ± 14</td><td class="colsep0 rowsep0" align="left">130 ± 17</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">6.87</td><td class="colsep0 rowsep0" align="left">199<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">48 ± 23</td><td class="colsep0 rowsep0" align="char" char=".">1.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">7.14</td><td class="colsep0 rowsep0" align="left">40<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">66 ± 24</td><td class="colsep0 rowsep0" align="char" char=".">4.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="char" char=".">6.94</td><td class="colsep0 rowsep0" align="left">160 ± 66</td><td class="colsep0 rowsep0" align="left">164<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="char" char=".">6.86</td><td class="colsep0 rowsep0" align="left">89 ± 11</td><td class="colsep0 rowsep0" align="left">77 ± 17</td><td class="colsep0 rowsep0" align="char" char=".">0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="char" char=".">6.80</td><td class="colsep0 rowsep0" align="left">154 ± 6</td><td class="colsep0 rowsep0" align="left">96 ± 25</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="char" char=".">6.87</td><td class="colsep0 rowsep0" align="left">153.9 ± 39</td><td class="colsep0 rowsep0" align="left">234.2 ± 17</td><td class="colsep0 rowsep0" align="char" char=".">0.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95</b></td><td class="colsep0 rowsep0" align="char" char=".">7.24</td><td class="colsep0 rowsep0" align="left">697 ± 50</td><td class="colsep0 rowsep0" align="left">983 ± 39</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>109</b></td><td class="colsep0 rowsep0" align="char" char=".">6.74</td><td class="colsep0 rowsep0" align="left">93.6 ± 1</td><td class="colsep0 rowsep0" align="left">105.3 ± 7.0</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">pIC<sub>50</sub> in TR-FRET-based ligand-binding displacement assay measured with two technical replicates (<i>n</i> = 1 biological replicate). HLM and RLM determinations mean of <i>n</i> = 2 ± standard deviation (unless otherwise stated).</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Data derived from single experiment. HLM = human liver microsomes, RLM = rat liver microsomes; thermodynamic solubility data was derived from a single experiment at pH 6.8.</p></div></div></div><div class="NLM_p last">In general, a reduction in lipophilicity and aromatic ring count led to modest improvements in <i>in vitro</i> metabolic stability and solubility. Larger reductions in lipophilicity, observed for compounds <b>11</b>, <b>22</b>, <b>33</b>, <b>34</b>, and <b>70</b>, showed marked improvements in solubility and metabolic stability. It is likely that a number of other factors are affecting the solubility of the series, including π-stacking due to the planarity of the series. In terms of metabolic stability, N-dealkylation is likely to be a major issue, especially for <i>N</i>,<i>N</i>-dimethylamine analogues, and to some extent cyclic analogues <b>33</b> and <b>34</b> circumvent this issue. Notably, an increase in polarity led to better solubility and metabolic stability (<b>22</b>, <b>33</b>, and <b>34</b>). The addition of substituents onto the pyrazolo[1,5-<i>b</i>]pyridazine motif <b>66</b> and substitution of the pyrazolo[1,5-<i>b</i>]pyridazine heterocycle for <b>70</b> also appears to improve solubility and metabolic stability.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Selectivity Profiles of Lead Compounds</h3><div class="NLM_p">During inhibitor development selected compounds were analyzed for selectivity against an in-house panel of 48 representative kinases by measuring the change in thermal stabilization of the kinase in the presence and absence of inhibitor (<a href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_004.pdf" class="ext-link">Supporting Information</a>). This data revealed that the series showed generally good selectivity for DYRK1A, DYRK2, CLK1, and Haspin (GSG2). Compound <b>78</b> was a notable exception which cross-reacted with several additional kinases including the NAK kinases AAK1 and BMP2K, indicating the importance of the binding mode of the pyrazolo[1,5-<i>b</i>]pyridazine core for selectivity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). In contrast to the pyrazolo[1,5-<i>b</i>]pyridazine series, compound <b>78</b> appears unable to establish a hydrogen-bonding interaction with the consensus water at the back-pocket of DYRK1A and lacks a substituent, such as a methyl, to occupy the shallow cleft on the hinge of DYRK1A (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><div class="NLM_p">The kinome-wide selectivity of key pyrazolo[1,5-<i>b</i>]pyridazines was further assessed at a 1 μM inhibitor concentration, using the KINOMEscan panel (DiscoverX) of >400 wild-type human kinases (summary <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, whole datasets in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_004.pdf" class="ext-link">Supporting Information</a>). The analysis revealed good selectivity scores (<i>S</i><sub>35</sub>) for key compounds with common off-targets of the series being the CDC-like kinases (CLKs) and other DYRKs. Crucially, all lead exemplars were selective against the majority of the human kinome and maintained selectivity for DYRK1A and CLKs over CMGC kinases CDK2 and GSK3β, which were known targets of the pyrazolo[1,5-<i>b</i>]pyridazine chemotype and are involved in some of the same mechanistic pathways as DYRK1A.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Selectivity Profiles of Lead Compounds<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A</th><th class="colsep0 rowsep0" align="center" char=".">DYRK1B</th><th class="colsep0 rowsep0" align="center" char=".">DYRK2</th><th class="colsep0 rowsep0" align="center" char=".">CLK1</th><th class="colsep0 rowsep0" align="center" char=".">CLK2</th><th class="colsep0 rowsep0" align="center" char=".">CLK3</th><th class="colsep0 rowsep0" align="center" char=".">CDK2</th><th class="colsep0 rowsep0" align="center" char=".">GSK3β</th><th class="colsep0 rowsep0" align="center" char="."><i>S</i> score (35)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">0.042</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">0.050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">0.035</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">72</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">0.032</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">7.8</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">0.022</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">0.022</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95</b></td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char=".">53</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">% Remaining activity as determined by DiscoverX KINOMEscan experiment. Inhibitor concentration = 1 μM.</p></div></div></div><div class="NLM_p">The selectivity profile of <b>11</b> was further investigated by acquiring <i>K</i><sub>D</sub> values for kinase off-targets identified in the KINOMEscan analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). Compound <b>11</b> showed approximately 20-fold selectivity for DYRK1A over DYRK1B, 100-fold selectivity over DYRK2, more than 20-fold selectivity over CLK1 and CLK4 and approximately 70-fold selectivity over CLK2, making <b>11</b> one of the most target-specific DYRK1A inhibitors reported. Other potential off-targets, such as JAK3, which had been identified in the KINOMEscan analysis were determined to be false positives following dose–response <i>K</i><sub>D</sub> measurement (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). The only kinase apart from DYRK1A with strong affinity for <b>11</b> was the mitotic kinase Haspin. The lead compounds in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a> have comparable selectivity profiles to <b>11</b> with good physical properties and would serve as advanced starting points for future studies. Our data shows that modifications could be made to the series that result in improved kinome selectivity and more desirable physicochemical properties.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Selectivity Profile of Compound <b>11</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub><a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DYRK1A</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Haspin</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DYRK1B</td><td class="colsep0 rowsep0" align="left">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK4</td><td class="colsep0 rowsep0" align="left">61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK1</td><td class="colsep0 rowsep0" align="left">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK2</td><td class="colsep0 rowsep0" align="left">220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DYRK2</td><td class="colsep0 rowsep0" align="left">360</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIPK2</td><td class="colsep0 rowsep0" align="left">1200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MKNK2</td><td class="colsep0 rowsep0" align="left">1800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAMK1B</td><td class="colsep0 rowsep0" align="left">10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3 (JH1domain-catalytic)</td><td class="colsep0 rowsep0" align="left">1800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STK39</td><td class="colsep0 rowsep0" align="left">10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WNK2</td><td class="colsep0 rowsep0" align="left">10 000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>D</sub> (nM) determined in competition binding assay (DiscoverX, <i>n</i> = 2).</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Inhibition of DYRK1A Phosphorylation</h3><div class="NLM_p">To demonstrate the DYRK1A inhibitory activity of the series, compound <b>11</b> was profiled in a radiometric kinase assay (<sup>33</sup>PanQinase Activity Assay) provided by Proqinase GMBH. The assay measured the kinase activity of DYRK1A in the presence and absence of an inhibitor at 1 μM concentration. Follow-up IC<sub>50</sub> profiling confirmed that the phosphorylation activity of DYRK1A was inhibited by compound <b>11</b> with an IC<sub>50</sub> of 220 nM (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>).</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. DYRK1A Phosphorylation Inhibition by Compound <b>11</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">% inhibition<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub><a class="ref internalNav" href="#t11fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DYRK1A</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">220</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">% inhibition at 1 μM inhibitor concentration determined in <sup>33</sup>PanQinase Activity Assay (Proqinase, <i>n</i> = 1).</p></div><div class="footnote" id="t11fn2"><sup><sup>b</sup></sup><p class="last">10-point IC<sub>50</sub> (nM) determined in <sup>33</sup>PanQinase Activity Assay (Proqinase, <i>n</i> = 1).</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Cellular Profiling of Lead Compound <b>11</b></h3><div class="NLM_p">Compound <b>11</b> was tested for direct binding to DYRK1A in live cells using a nanoluciferase (nanoLuc) bioluminescence resonance energy transfer (BRET) (NanoBRET, Promega) target engagement assay (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The NanoBRET assay measured the ability of compound <b>11</b> to displace a fluorescent tracer molecule from the ATP-binding site of DYRK1A protein N-terminally fused with NanoLuc luciferase (Nluc) in HEK293 cells. In the absence of compound <b>11</b>, the fusion protein and tracer molecule were in proximity and able to generate a detectable BRET signal. Compound <b>11</b> demonstrated acceptable cellular activity, with IC<sub>50</sub> of 434 nM compared to the enzymatic IC<sub>50</sub> of 75 nM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. NanoBRET analysis of the direct binding of <b>11</b> to DYRK1A in HEK293 cells. Two biological replicates were made at different tracer concentrations, plotted separately on the graph. The IC<sub>50</sub> values were 576 nM in the presence of a 2 μM tracer and 434 nM in the presence of a 1 μM tracer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>11</b> and <b>95</b> were profiled in the ClariCELL DYRK1A/Tau cellular phosphorylation assay to demonstrate a functional effect <i>in vitro</i>. The tau phosphorylation activity of DYRK1A was measured in the absence or presence of various concentrations of compound in human embryonic kidney cells (HEK293) transiently transfected with DYRK1A and tau. The activity of <b>11</b> was compared to the activity of harmine, a known DYRK1A inhibitor. <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a> shows that compounds <b>11</b> and <b>95</b> inhibited tau phosphorylation with IC<sub>50</sub>’s of 0.59 and 0.25 μM, respectively, and are comparable to harmine (IC<sub>50</sub> 0.20 μM).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Inhibition of Tau Phosphorylation by DYRK1A by Selected Compounds<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> for tau phosphorylation (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">0.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95</b></td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Harmine</b></td><td class="colsep0 rowsep0" align="char" char=".">0.20</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> determined in ClariCELL DYRK1A/Tau cellular phosphorylation assay (Cell Assay Innovations, <i>n</i> = 2).</p></div></div></div><div class="NLM_p">Compound <b>11</b> was also progressed to a Madin–Darby canine kidney cells transfected with the human MDR1 gene (MDCK-MDR1) assay to determine whether there would be any issues with P-gp liability or permeability (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>). The high central nervous system multiparameter optimization (CNS MPO) score calculated for compound <b>11</b> correlated with good levels of permeability and low P-gp efflux, suggesting that <b>11</b> is a good starting point for development into a CNS-penetrant DYRK1A chemical probe.</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. DYRK1A CNS MPO and MDCK-MDR1</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="left" char="."> </th><th class="rowsep1 colsep0" align="center" char="±">direction = A2B</th><th class="rowsep1 colsep0" align="center" char="±">direction = B2A</th><th class="colsep0 rowsep0" align="left" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">CNS MPO<a class="ref internalNav" href="#t13fn1" aria-label="a">a</a> score</th><th class="colsep0 rowsep0" colspan="2" align="center" char="±">mean <i>P</i><sub>app</sub> (10<sup>–6</sup> cms<sup>–1</sup>)<a class="ref internalNav" href="#t13fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">efflux ratio (mean <i>P</i><sub>app</sub> B2A/mean <i>P</i><sub>app</sub> A2B)<a class="ref internalNav" href="#t13fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char="±">71.4 ± 0.65</td><td class="colsep0 rowsep0" align="char" char="±">58.7 ± 1.45</td><td class="colsep0 rowsep0" align="char" char=".">0.822</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t13fn1"><div class="footnote" id="t13fn1"><sup><sup>a</sup></sup><p class="last">CNS MPO score calculated using CNS MPO KNIME workflow with ChemAxon nodes.</p></div><div class="footnote" id="t13fn2"><sup><sup>b</sup></sup><p class="last">Data generated by Cyprotex in MDCK-MDR1 assay. Permeability coefficient (<i>P</i><sub>app</sub>) calculated across cells in direction: A2B (Apical to Basolateral) and B2A (Basolateral to Apical). Determinations ± standard deviation (mean of <i>n</i> = 2 unless otherwise stated).</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>In Vivo</i> Pharmacokinetic Profiling of Lead Compound <b>11</b></h3><div class="NLM_p">Compound <b>11</b> had good physicochemical properties and had demonstrated high levels of enzymatic potency, favorable aqueous solubility, exquisite kinome selectivity, and promising on-target <i>in vitro</i> inhibition. Although compound <b>11</b> was not optimized for <i>in vitro</i> clearance, we sought to benchmark <b>11</b> as a DYRK1A tool for future optimization.</div><div class="NLM_p">Compound <b>11</b> was dosed intravenously at 1 mg/kg in Sprague–Dawley rats (<i>n</i> = 3) in the fed state. Plasma and brain samples were collected. Consistent with the <i>in vitro</i> findings, high clearance was observed for compound <b>11</b><i>in vivo</i>. As a consequence of the high clearance and low volume of distribution, the half-life of compound <b>11</b> is not optimal (<a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a>). There were no adverse effects reported in the study and the brain:plasma ratio indicated good brain penetration for compound <b>11</b> (total br/pl > 0.35), consistent with what was predicted from the MDCK-MDR1 assay.</div><div class="NLM_table-wrap" id="tbl14"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 14. <i>In Vivo</i> Pharmacokinetic Study of Compound <b>11</b><a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameter</th><th class="colsep0 rowsep0" align="center" char=".">compound <b>11</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">half-life (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">1082.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>last</sub> (h·ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">275.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>inf</sub> (h·ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">276.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/(min kg))</td><td class="colsep0 rowsep0" align="char" char=".">61.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>0</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">1331.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t14fn1"><div class="footnote" id="t14fn1"><sup><sup>a</sup></sup><p class="last">Compound <b>11</b> was dosed as a suspension of the amorphous solid at 1 mg/kg i.v.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting from DYRK1A inhibitors previously published by our group (<b>6b</b> and <b>8b</b>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> we were able to design compound <b>11</b>, and derivatives thereof, that maintained and improved upon the selectivity profiles of <b>6b</b> and <b>8b</b>. The binding mode appeared to be the same for compounds <b>11</b> and <b>6b</b>, providing further evidence that this unusual binding mode, and in particular, possession of a motif that occupies a shallow lipophilic pocket close to the hinge of DYRK1A, further stabilized by a hydrogen-bonding interaction between the ligand and consensus water, appears to afford isoform and kinome-selective DYRK1A inhibitors. Iterative crystallography and structure-based design using the elucidated binding mode of <b>6b</b>, <b>11</b>, and other pyrazolo[1,5-<i>b</i>]pyridazine analogues allowed rapid expansion to selective and high-affinity binders of DYRK1A with improved physicochemical properties.</div><div class="NLM_p last">Through focused design to reduce the number of aromatic rings and lipophilicity, compounds such as <b>11</b> showed improvements in metabolic stability and solubility relative to <b>6b</b>. The permeability and on-target cellular activity of <b>11</b> were demonstrated. Compound <b>11</b> was not a P-gp substrate, giving confidence that <b>11</b>, and analogues thereof, can be used with confidence as tool compounds to determine the role of DYRK1A. Compound <b>11</b> represents a small, highly selective, and ligand-efficient starting point for future drug discovery efforts on DYRK1A in any area of medicine. Further optimization of the <i>in vivo</i> clearance of the series may lead to clinical DYRK1A inhibitors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38727" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38727" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of lead compounds (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) are described below. The synthetic procedures for all other compounds are found in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_004.pdf" class="ext-link">Supporting Information</a>. The purity of all target compounds was confirmed to be >95% by HPLC or <sup>1</sup>H NMR.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Methods</h3><div class="NLM_p">All commercial reagents were purchased from Sigma-Aldrich, Alfa Aesar, Apollo Scientific, Fluorochem, or Tokyo Chemical Industry and were of the highest available purity. Unless otherwise stated, chemicals were used as supplied without further purification. Anhydrous solvents were purchased from Acros (AcroSeal) or Sigma-Aldrich (SureSeal) and were stored under nitrogen. Anhydrous solvents and reagents were used as purchased. Thin-layer chromatography (TLC) was carried out using glass plates precoated with Merck silica gel 60 F254. Melting point measurements are recorded on an MPA100 OptiMelt apparatus and are uncorrected. Proton nuclear magnetic resonance spectra were recorded at 500 MHz on a Varian VNMRS 500 MHz spectrometer or at 500 MHz on a Bruker Biospin GmbH 500 MHz spectrometer or at 600 MHz on a Varian VNMRS 600 MHz spectrometer, using residual isotopic solvent (CHCl<sub>3</sub>, δ<sub>H</sub> = 7.27 ppm, DMSO δ<sub>H</sub> = 2.50 ppm, MeOH δ<sub>H</sub> = 3.31 ppm, DMF δ<sub>H</sub> = 2.92) as an internal reference. Chemical shifts are quoted in parts per million (ppm). Coupling constants (<i>J</i>) are recorded in hertz (Hz). Carbon nuclear magnetic resonance spectra were recorded at 125 MHz on a Varian 500 MHz spectrometer or 151 MHz on a Varian 600 MHz spectrometer, using residual isotopic solvent (CHCl<sub>3</sub>, δ<sub>C</sub> = 77.00 ppm, DMSO δ<sub>C</sub> = 39.52 ppm, MeOH δ<sub>C</sub> = 49.00 ppm) as an internal reference. Proton and carbon spectra assignments are supported by DEPT editing. Chemical shifts (δC) are quoted in ppm. High-resolution mass spectrometry data (ESI) were recorded on Bruker Daltonics, Apex III, ESI source: Apollo ESI with methanol as spray solvent. Only molecular ions, fractions from molecular ions, and other major peaks are reported as mass/charge (<i>m</i>/<i>z</i>) ratios. LCMS-LCQ data was recorded on a Waters 2695 HPLC using a Waters 2487 UV detector and a Thermo LCQ ESI-MS. Samples were eluted through a Phenomenex Lunar 3 μm C18 50 mm × 4.6 mm column, using water and acetonitrile acidified by 0.1% formic acid at 1 mL/min and detected at 254 nm. The gradient employed was a 5 min method 10–90% MeCN over a 4 min gradient, held at 90% MeCN for 1 min, then reequilibrated over 1 min. LCMS-MDAP analytical data was recorded on a Shimadzu Prominence Series coupled to an LCMS-2020 ESi and APCI mass spectrometer. Samples were eluted through a Phenomenex Gemini 5μ C18 110A 250 mm × 4.6 mm column, using water and acetonitrile acidified by 0.1% formic acid at 1 mL/min and detected at 254 nm. The gradient employed was a 30 min method either (A) 5–95% MeCN over a 20 min gradient, held at 95% MeCN for 4 min, then reequilibrated to 30% MeCN over 5 min or (B) 30–95% MeCN over 20 min gradient, held at 95% MeCN for 4 min, then reequilibrated to 30% MeCN over 5 min. Specific Optical Rotations were measured using Schmidt and Haensch UniPol L polarimeter, in cells with a path length of 5 cm. The light source was maintained at 589 nm. The concentration (<i>c</i>) is expressed in g/100 mL (equivalent to g/0.1 dm<sup>3</sup>). Specific rotations are denoted [α]<sub class="stack">D</sub><sup class="stack">T</sup> and are given in implied units of 10<sup>–1</sup> deg cm<sup>2</sup> g<sup>–1</sup> (<i>T</i> = ambient temperature in °C).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Pyridazin-1-ium-1-amine Iodide (<b>2</b>)</h4><div class="NLM_p last">Aminosulfuric acid (13.10 g, 115.84 mmol) was dissolved in water (25 mL), and the reaction mixture was cooled to 10 °C in an ice bath. Potassium bicarbonate solution (48 mL, 2.4 M, 115.2 mmol) was added to the reaction mixture until it was at pH 5. Pyridazine (5.62 mL, 77.4 mmol) was added in one portion, and the reaction mixture was heated to 70 °C for 1.5 h. The pH was adjusted to pH 7 by the addition of a 2.4 M potassium bicarbonate solution (10.0 mL, 24 mmol). The reaction mixture was cooled to 40 °C and was stirred for 1 h. Potassium iodide (12.85 g, 77.41 mmol) in water (25 mL) was added to the reaction mixture, and the reaction was stirred for a further 1 h. The solvent was removed under reduced pressure. A solution of 5% MeOH in EtOH (100 mL) was then added to the residue. The resulting solids were collected by filtration and dried under reduced pressure to furnish the title compound, pyridazin-1-ium-1-amine iodide, <b>2</b>, as a yellow solid (17 g, 72.3 mmol, 94% yield). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 9.82 (s, 2H), 9.29–9.22 (m, 1H), 9.11 (d, <i>J</i> = 6.2 Hz, 1H), 8.52–8.43 (m, 1H), 8.12 (dd, <i>J</i> = 8.2, 5.2 Hz, 1H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-Pyrazolo[1,5-<i>b</i>]pyridazin-3-ylethanone (<b>3</b>)</h4><div class="NLM_p last">To a slurry of pyridazin-1-ium-1-amine iodide (16.0 g, 71.74 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL) was added 3-butyn-2-one (2.76 mL, 35.26 mmol). The reaction flask was cooled in an ice bath before adding a solution of potassium hydroxide (5.0 g, 89.11 mmol) in water (100 mL) in one portion. The reaction mixture was stirred at rt for 16 h. The organic layer was separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 200 mL). The combined organic components were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford the title compound, 1-pyrazolo[1,5-<i>b</i>]pyridazin-3-ylethanone, <b>3</b>, as a red-black solid (3.43 g, 21.28 mmol, 60% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.78 (s, 1H), 8.71–8.63 (m, 2H), 7.57 (dd, <i>J</i> = 8.9, 4.6 Hz, 1H), 2.56 (s, 3H). LC-MS (ESI): calculated for C<sub>8</sub>H<sub>8</sub>N<sub>3</sub>O [M + H]<sup>+</sup> is 162.1, found 162.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>E</i>)-3-(Dimethylamino)-1-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-prop-2-en-1-one (<b>4</b>)</h4><div class="NLM_p last">To a flask containing 1-pyrazolo[1,5-<i>b</i>]pyridazin-3-ylethanone (0.68 g, 4.22 mmol) was added DMF–DMA (3.78 mL, 28.44 mmol). The reaction mixture was heated to 100 °C for 16 h. The reaction mixture was concentrated under reduced pressure and triturated with diethyl ether to afford the title compound, (<i>E</i>)-3-(dimethylamino)-1-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-prop-2-en-1-one, <b>4</b>, as a black solid (0.87 g, 3.82 mmol, 91% yield). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.73 (dd, <i>J</i> = 9.0, 2.0 Hz, 1H), 8.70 (s, 1H), 8.57 (dd, <i>J</i> = 4.5, 2.0 Hz, 1H), 7.68 (d, <i>J</i> = 12.3 Hz, 1H), 7.41 (dd, <i>J</i> = 9.0, 4.4 Hz, 1H), 5.83 (d, <i>J</i> = 12.3 Hz, 1H), 3.20–2.80 (m, 6H). LC-MS (ESI): calculated for C<sub>11</sub>H<sub>13</sub>N<sub>4</sub>O [M + H]<sup>+</sup> is 217.1, found 217.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-Pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-ol (<b>5</b>)</h4><div class="NLM_p last">To (<i>E</i>)-3-(dimethylamino)-1-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-prop-2-en-1-one (2.5 g, 11.56 mmol) was added urea (15 g, 250 mmol) followed by sodium hydride (1.25 g, 31.25 mmol), and the reaction mixture was heated to 140 °C under nitrogen until melted fully. The melt was then maintained at this temperature for a further 5 min. Once the melt had cooled to rt, water (10 mL) was added slowly while stirring. The solution was made to pH 3 with 1 M HCl solution and stirred overnight at rt. The solid formed was filtered and triturated with ethanol to afford the title compound, 4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-ol, <b>5</b>, as a brown solid (2.3 g, 9.71 mmol, 84% yield). <i>R</i><sub><i>f</i></sub> 0.32 (MeOH/CH<sub>2</sub>Cl<sub>2</sub> 1:9); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 11.60 (s, 1H), 8.94 (dd, <i>J</i> = 9.0, 1.9 Hz, 1H), 8.89 (s, 1H), 8.61 (dd, <i>J</i> = 4.5, 2.0 Hz, 1H), 7.90 (d, <i>J</i> = 6.5 Hz, 1H), 7.50 (dd, <i>J</i> = 9.1, 4.5 Hz, 1H), 6.93 (d, <i>J</i> = 6.6 Hz, 1H); HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>10</sub>H<sub>8</sub>N<sub>5</sub>O [M + H]<sup>+</sup> is 214.0723, found: 214.0721 [M + H]<sup>+</sup>; LC-MS (ESI): calculated for C<sub>10</sub>H<sub>8</sub>N<sub>5</sub>O [M + H]<sup>+</sup> is 214.1, found 214.3 [M + H]<sup>+</sup></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3-(2-Chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (<b>6</b>)</h4><div class="NLM_p last">To a pressure vial were added 6-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-1<i>H</i>-pyrimidin-2-one (500 mg, 2.35 mmol) and phosphorus(V) oxychloride (2 mL, 21.46 mmol). The vial was sealed and heated to 110 °C for 6 h. The crude reaction mixture was added slowly to a water/ice mix and stirred at rt for 1 h. The brown suspension that formed was filtered and washed with water to afford the title compound, 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine, <b>6</b>, as a brown solid (540 mg, 2.17 mmol, 92% yield). <i>R</i><sub><i>f</i></sub> 0.83 (MeOH/CH<sub>2</sub>Cl<sub>2</sub> 1:9); mp 293–295 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 9.00 (s, 1H), 8.88 (dd, <i>J</i> = 9.1, 1.9 Hz, 1H), 8.70 (d, <i>J</i> = 5.3 Hz, 1H), 8.66 (dd, <i>J</i> = 4.5, 1.9 Hz, 1H), 8.04 (d, <i>J</i> = 5.4 Hz, 1H), 7.56 (dd, <i>J</i> = 9.1, 4.5 Hz, 1H); LC-MS (ESI): calculated for C<sub>10</sub>H<sub>6</sub>N<sub>5</sub><sup>35</sup>Cl [M]<sup>+</sup> is 231.0 and C<sub>10</sub>H<sub>6</sub>N<sub>5</sub><sup>37</sup>Cl [M + 2]<sup>+</sup> is 233.0, found 231.9 [M]<sup>+</sup> and 233.9 [M + 2]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N,N</i>-Dimethyl-4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-amine (<b>11</b>)</h4><div class="NLM_p last">To a microwave vial containing 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (80 mg, 0.35 mmol) was added dimethylamine (0.03 mL, 0.69 mmol). The reaction mixture was heated at 110 °C for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–50% 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford the title compound, <i>N,N</i>-dimethyl-4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-amine, <b>11</b>, as an off-white solid (70 mg, 0.26 mmol, 77% yield). <i>R</i><sub><i>f</i></sub> 0.68 (MeOH/ CH<sub>2</sub>Cl<sub>2</sub> 1:9); mp 241–242 °C; <sup>1</sup>H NMR (500 MHz DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.96 (dd, <i>J</i> = 9.0, 1.9 Hz, 1H), 8.84 (s, 1H), 8.61–8.58 (m, 1H), 8.35 (d, <i>J</i> = 5.2 Hz, 1H), 7.46 (dd, <i>J</i> = 9.0, 4.4 Hz, 1H), 7.14 (d, <i>J</i> = 5.2 Hz, 1H), 3.22 (s, 6H);<sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 161.9, 159.9, 157.9, 143.9, 139.7, 132.3, 129.1, 118.9, 110.5, 104.6, 37.0; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>12</sub>H<sub>12</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 241.1196, found: 241.1197 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 3.6 min, >95% (method B); LC-MS (ESI): calculated for C<sub>12</sub>H<sub>12</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 241.1, found 241.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N-</i>Cyclopropyl-<i>N-</i>methyl-4-pyrazolo[1,5<i>-b</i>]pyridazin-3-yl-pyrimidin-2-amine (<b>12</b>)</h4><div class="NLM_p last">To a microwave vial containing 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (80 mg, 0.35 mmol) in 2-propanol (2 mL) was added <i>N</i>-cyclopropyl-methylamine hydrochloride (74 mg, 0.69 mmol). The vial was sealed and heated at 150 °C for 30 min under microwave irradiation. The reaction was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–50% 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford the title compound, <i>N-</i>cyclopropyl-<i>N-</i>methyl-4-pyrazolo[1,5<i>-b</i>]pyridazin-3-yl-pyrimidin-2-amine, <b>12</b>, as an off-white solid (10 mg, 0.04 mmol, 10% yield). Mp 162–164 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 9.13–9.09 (m, 1H), 8.86 (s, 1H), 8.60–8.56 (m, 1H), 8.38 (d, <i>J</i> = 5.1 Hz, 1H), 7.46 (dd, <i>J</i> = 9.0, 4.4 Hz, 1H), 7.23 (d, <i>J</i> = 5.1 Hz, 1H), 3.15 (s, 3H), 2.90–2.80 (m, 1H), 0.95–0.89 (m, 2H), 0.70–0.64 (m, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 163.2, 158.8, 157.8, 144.0, 139.7, 132.5, 129.4, 118.9, 110.4, 105.7, 35.7, 31.6, 8.3; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>14</sub>H<sub>15</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 267.1353, found: 267.1348 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 9.93 min, >95% (method A); LC-MS (ESI): calculated for C<sub>14</sub>H<sub>15</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 267.1, found 267.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-(4-Pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-yl)-6-oxa-1-azaspiro[3.3]heptane (<b>22</b>)</h4><div class="NLM_p last">To a pressure vial containing 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (60 mg, 0.26 mmol) in 2-propanol (2 mL) was added 6-oxa-1-azaspiro[3.3]heptane (51 mg, 0.52 mmol). The vial was sealed and heated to 140 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was adsorbed onto solid load material. The crude was purified using flash silica column chromatography on a Biotage system (12 g silica, elution with 0–100% EtOAc/petroleum ether gradient). Desired fractions were combined and concentrated under reduced pressure. The crude was purified using reversed-phase column chromatography on a Biotage system (12 g C-18, elution with 10–100% MeOH/water gradient) to afford the title compound, 1-(4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-yl)-6-oxa-1-azaspiro[3.3]heptane, <b>22</b>, as a colorless solid (17 mg, 0.05 mmol, 21% yield). <i>R</i><sub><i>f</i></sub> 0.29 (EtOAc); decomposed > 246 °C; <sup>1</sup>H NMR (600 MHz, MeOD) δ<sub>H</sub> 9.50 (br.s, 1H), 8.74 (s, 1H), 8.52–8.49 (m, 1H), 8.34 (d, <i>J</i> = 5.2 Hz, 1H), 7.35 (dd, <i>J</i> = 8.8, 4.4 Hz, 1H), 7.24 (d, <i>J</i> = 5.2 Hz, 1H), 5.64 (d, <i>J</i> = 7.1 Hz, 2H), 4.95–4.76 (m, 2H), 4.02 (t, <i>J</i> = 7.1 Hz, 2H), 2.71 (t, <i>J</i> = 7.2 Hz, 2H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ<sub>C</sub> 160.9, 159.8, 158.3, 143.2, 139.6, 133.5, 130.5, 118.4, 110.5, 106.2, 81.5, 68.3, 45.6, 29.1; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>15</sub>H<sub>15</sub>N<sub>6</sub>O [M + H]<sup>+</sup> is 295.1302, found: 295.1301 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 11.9 min, >95% (method A); LC-MS (ESI): calculated for C<sub>15</sub>H<sub>15</sub>N<sub>6</sub>O [M + H]<sup>+</sup> is 295.1, found 295.0 [M + H]<sup>+</sup></div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 3-[2-(2-Methylpyrrolidin-1-yl)pyrimidin-4-yl]pyrazolo[1,5-<i>b</i>]pyridazine (<b>24</b>)</h4><div class="NLM_p last">To a microwave vial containing 3-(2-methylsulfonylpyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (100 mg, 0.33 mmol) in 2-propanol (1 mL) was added 2-methylpyrrolidine (0.03 mL, 0.33 mmol). The vial was sealed and heated to 140 °C overnight. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–100% EtOAc/petroleum ether gradient) to afford the title compound 3-[2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]pyrazolo[1,5-<i>b</i>]pyridazine, <b>24</b>, as a white solid (96 mg, 0.33 mmol, 99% yield). <i>R</i><sub><i>f</i></sub> 0.38 (EtOAc/petroleum ether 1:1); mp 205–207 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.98 (d, <i>J</i> = 9.1 Hz, 1H), 8.84 (s, 1H), 8.61–8.57 (m, 1H), 8.36–8.32 (m, 1H), 7.46 (dd, <i>J</i> = 9.1, 4.4 Hz, 1H), 7.13 (d, <i>J</i> = 5.0 Hz, 1H), 4.42–4.21 (m, 1H), 3.79–3.22 (m, 2H), 2.15–2.02 (m, 2H), 2.02–1.89 (m, 1H), 1.77–1.67 (m, 1H), 1.26 (s, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 159.8, 159.0, 158.0, 143.9, 139.6, 132.4, 129.2, 118.9, 110.4, 104.5, 52.6, 46.8, 32.3, 22.8, 19.3; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 281.1509, found: 281.1519 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 11.2 min, >95% (method A); LC-MS (ESI): calculated for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 281.2, found 281.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-[2-[(3<i>S</i>)-3-Methylpyrrolidin-1-yl]pyrimidin-4-yl]pyrazolo[1,5-<i>b</i>]pyridazine (<b>28</b>)</h4><div class="NLM_p last">To a microwave vial containing a suspension of 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (60 mg, 0.26 mmol) in 2-propanol (2 mL) was added (<i>S</i>)-3-methyl-pyrrolidine hydrochloride (63 mg, 0.52 mmol). The vial was sealed, and the reaction mixture was heated to 140 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–100% EtOAc/petroleum ether gradient). Desired fractions were combined and concentrated under reduced pressure. The crude was purified using flash reversed-phase column chromatography on a Biotage system (12 g silica, elution with 10–100% MeOH/water gradient) to afford the title compound, 3-[2-[(3<i>S</i>)-3-methylpyrrolidin-1-yl]pyrimidin-4-yl]pyrazolo[1,5-<i>b</i>]pyridazine, <b>28</b>, as a colorless solid (21 mg, 0.07 mmol, 27% yield). <i>R</i><sub><i>f</i></sub> 0.34 (EtOAc/petroleum ether 1:1); [α]<sub class="stack">D</sub><sup class="stack">25</sup> = −60.1 (<i>c</i> = 3.3 × 10<sup>–4</sup> g/mL, CHCl<sub>3</sub>); mp 213–215 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.99 (app. d, <i>J</i> = 9.0 Hz, 1H), 8.84 (s, 1H), 8.61–8.57 (m, 1H), 8.33 (d, <i>J</i> = 5.1 Hz, 1H), 7.46 (dd, <i>J</i> = 9.2, 4.4 Hz, 1H), 7.13 (d, <i>J</i> = 5.1 Hz, 1H), 3.96–3.40 (m, 3H), 3.25–2.97 (m, 1H), 2.46–2.31 (m, 1H), 2.23–2.04 (m, 1H), 1.71–1.53 (m, 1H), 1.12 (s, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 160.0, 159.0, 158.0, 143.9, 139.6, 132.4, 129.4, 118.9, 110.3, 104.4, 53.4, 46.1, 32.9, 32.6, 17.9; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 281.1509, found: 281.1508 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 11.6 min, >95% (method A); LC-MS (ESI): calculated for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 281.2, found 281.0 [M + H]<sup>+</sup>. Chiral HPLC, chiralcel OJ column (20:80 heptane: isopropanol (0.2% v/v NH<sub>3</sub>), 1.0 mL/min). Retention time = 8.04 min > 98% e.e.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 3-[2-[(3<i>R</i>)-3-Methylpyrrolidin-1-yl]pyrimidin-4-yl]pyrazolo[1,5-<i>b</i>]pyridazine (<b>29</b>)</h4><div class="NLM_p last">To a microwave vial containing a suspension of 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (60 mg, 0.26 mmol) in 2-propanol (2 mL) was added (<i>R</i>)-3-methyl-pyrrolidine hydrochloride (63 mg, 0.52 mmol). The vial was sealed, and the reaction mixture was heated to 140 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–100% EtOAc/petroleum ether gradient). Desired fractions were combined and concentrated under reduced pressure. The crude was purified using flash reversed-phase column chromatography on a Biotage system (12 g silica, elution with 10–100% MeOH/water gradient) to afford the title compound, 3-[2-[(3<i>R</i>)-3-methylpyrrolidin-1-yl]pyrimidin-4-yl]pyrazolo[1,5-<i>b</i>]pyridazine, <b>29</b>, as a pale yellow solid (13 mg, 0.04 mmol, 17% yield). <i>R</i><sub><i>f</i></sub> 0.34 (EtOAc/petroleum ether 1:1); [α]<sub class="stack">D</sub><sup class="stack">25</sup> = +60.1 (<i>c</i> = 3.3 × 10<sup>–4</sup> g/mL, CHCl<sub>3</sub>); mp 213–215 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 9.00 (app. d, <i>J</i> = 9.0 Hz, 1H), 8.84 (s, 1H), 8.61–8.58 (m, 1H), 8.34 (d, <i>J</i> = 5.1 Hz, 1H), 7.47 (dd, <i>J</i> = 9.2, 4.4 Hz, 1H), 7.13 (d, <i>J</i> = 5.1 Hz, 1H), 3.96–3.43 (m, 3H), 3.24–2.94 (m, 1H), 2.45–2.32 (m, 1H), 2.21–2.05 (m, 1H), 1.70–1.54 (m, 1H), 1.13 (s, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 160.0, 159.0, 158.0, 143.9, 139.6, 132.4, 129.4, 118.9, 110.4, 104.4, 53.4, 46.1, 32.9, 32.6, 17.9; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 281.1509, found: 281.1508 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 11.6 min, >95% (method A); LC-MS (ESI): calculated for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 281.2, found 281.0 [M + H]<sup>+</sup>. Chiral HPLC, chiralcel OJ column (20:80 heptane: isopropanol (0.2% v/v NH<sub>3</sub>), 1.0 mL/min). Retention time = 7.07 min > 96% e.e.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-[2-[(3<i>R</i>)-3-Fluoropyrrolidin-1-yl]pyrimidin-4-yl]pyrazolo[1,5-<i>b</i>]pyridazine (<b>31</b>)</h4><div class="NLM_p last">To a microwave vial containing 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (67 mg, 0.29 mmol) in 2-propanol (1 mL) was added <i>R</i>-(−)-3-fluoropyrrolidine hydrochloride (36 mg, 0.29 mmol). The vial was sealed and heated to 140 °C for 6 h. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–100% EtOAc/petroleum ether gradient) to afford the title compound 3-[2-[(3<i>R</i>)-3-fluoropyrrolidin-1-yl]pyrimidin-4-yl]pyrazolo[1,5-<i>b</i>]pyridazine, <b>31</b>, as a cream solid (70 mg, 0.23 mmol, 80% yield). <i>R</i><sub><i>f</i></sub> 0.24 (EtOAc/petroleum ether 1:1); [α]<sub class="stack">D</sub><sup class="stack">25</sup> = −60.1 (<i>c</i> = 3.67 × 10<sup>–3</sup> g/mL, CHCl<sub>3</sub>); mp 228–230 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.97 (app. d, <i>J</i> = 9.0 Hz, 1H), 8.82 (s, 1H), 8.59–8.55 (m, 1H), 8.34 (d, <i>J</i> = 5.1 Hz, 1H), 7.43 (dd, <i>J</i> = 9.2, 4.4 Hz, 1H), 7.16 (d, <i>J</i> = 5.1 Hz, 1H), 5.47 (d, <i>J</i> = 53.3 Hz, 1H), 4.05–3.46 (m, 4H), 2.37–2.12 (m, 2H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 160.0, 159.1, 158.1, 143.9, 139.7, 132.5, 129.4, 119.0, 110.2, 105.1, 93.2 (d, <i>J</i> = 170.5 Hz), 53.2 (d, <i>J</i> = 22.5 Hz), 44.2, 31.6 (d, <i>J</i> = 22.0 Hz); HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>14</sub>H<sub>14</sub>FN<sub>6</sub> [M + H]<sup>+</sup> is 285.1258, found: 285.1267 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 11.6 min, >95% (method A); LC-MS (ESI): calculated for C<sub>14</sub>H<sub>14</sub>FN<sub>6</sub> [M + H]<sup>+</sup> is 285.1, found 285.0 [M + H]<sup>+</sup>; Chiral SFC, Lux A2 column (50:50 isopropanol:CO<sub>2</sub> (0.2% v/v NH<sub>3</sub>), 4.0 mL/min). Retention time = 2.04 min > 99% e.e.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (3<i>S</i>)-1-(4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-yl)pyrrolidin-3-amine (<b>33</b>)</h4><div class="NLM_p last">To a microwave vial containing a suspension of 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (60 mg, 0.26 mmol) in 2-propanol (2 mL) was added (3<i>S</i>)-(−)-3-aminopyrrolidine (22 mg, 0.26 mmol). The vial was sealed, and the reaction mixture was heated to 140 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–50% 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford the title compound. Desired fractions were combined and concentrated under reduced pressure. The crude was purified using flash reversed-phase column chromatography on a Biotage system (12 g silica, elution with 10–100% MeOH/water gradient) to afford the title compound, (3<i>S</i>)-1-(4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-yl)pyrrolidin-3-amine, <b>33</b>, as a pale yellow solid (32 mg, 0.11 mmol, 42% yield). <i>R</i><sub><i>f</i></sub> 0.09 (MeOH/ CH<sub>2</sub>Cl<sub>2</sub> 1:9); [α]<sub class="stack">D</sub><sup class="stack">25</sup> = +89.6 (<i>c</i> = 6.7 × 10<sup>–4</sup> g/mL, CHCl<sub>3</sub>); decomposed > 210 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.99 (app. d, <i>J</i> = 9.1 Hz, 1H), 8.82 (s, 1H), 8.60–8.56 (m, 1H), 8.32 (d, <i>J</i> = 5.1 Hz, 1H), 7.45 (dd, <i>J</i> = 9.1, 4.4 Hz, 1H), 7.11 (d, <i>J</i> = 5.1 Hz, 1H), 3.92–2.90 (m, 5H), 2.30–1.52 (m, 4H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 160.1, 158.9, 158.0, 143.9, 139.6, 132.4, 129.3, 118.8, 110.4, 104.4, 54.9, 50.7, 44.9, 34.1; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>14</sub>H<sub>16</sub>N<sub>7</sub> [M + H]<sup>+</sup> is 282.1462, found: 282.1455 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 8.1 min, >95% (method A); LC-MS (ESI): calculated for C<sub>14</sub>H<sub>16</sub>N<sub>7</sub> [M + H]<sup>+</sup> is 282.1, found 282.0 [M + H]<sup>+</sup>. Chiral HPLC, Lux C1 column (50:50 heptane/EtOH (0.2% v/v NH<sub>3</sub>), 1.0 mL/min). Retention time = 12.50 min > 99% e.e.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (3<i>R</i>)-1-(4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-yl)pyrrolidin-3-amine (<b>34</b>)</h4><div class="NLM_p last">To a microwave vial containing a suspension of 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-<i>b</i>]pyridazine (60 mg, 0.26 mmol) in 2-propanol (2 mL) was added (<i>R</i>)-pyrrolidin-3-amine (22 mg, 0.26 mmol). The vial was sealed, and the reaction mixture was heated to 140 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–50% 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford the title compound. Desired fractions were combined and concentrated under reduced pressure. The crude was purified using flash reversed-phase column chromatography on a Biotage system (12 g silica, elution with 10–100% MeOH/water gradient) to afford the title compound, (3<i>R</i>)-1-(4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-yl)pyrrolidin-3-amine, <b>34</b>, as a pale yellow solid (36 mg, 0.12 mmol, 44% yield). <i>R</i><sub><i>f</i></sub> 0.09 (MeOH/ CH<sub>2</sub>Cl<sub>2</sub> 1:9); [α]<sub class="stack">D</sub><sup class="stack">25</sup> = −59.7 (<i>c</i> = 6.7 × 10<sup>–4</sup> g/mL, CHCl<sub>3</sub>); decomposed > 210 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.99 (app. d, <i>J</i> = 9.1 Hz, 1H), 8.82 (s, 1H), 8.60–8.56 (m, 1H), 8.32 (d, <i>J</i> = 5.1 Hz, 1H), 7.45 (dd, <i>J</i> = 9.1, 4.4 Hz, 1H), 7.11 (d, <i>J</i> = 5.1 Hz, 1H), 3.96–2.78 (m, 5H), 2.36–1.68 (m, 4H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 160.1, 158.9, 158.0, 143.9, 139.6, 132.4, 129.3, 118.8, 110.4, 104.4, 54.7, 50.7, 44.9, 34.0; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>14</sub>H<sub>16</sub>N<sub>7</sub> [M + H]<sup>+</sup> is 282.1462, found: 282.1456 [M + H]<sup>+</sup>; LCMS (MDAP): <i>R</i><sub>t</sub> = 7.9 min, >95% (method A); LC-MS (ESI): calculated for C<sub>14</sub>H<sub>16</sub>N<sub>7</sub> [M + H]<sup>+</sup> is 282.1, found 282.0 [M + H]<sup>+</sup>. Chiral HPLC, Lux C1 column (50:50 heptane/EtOH (0.2% v/v NH<sub>3</sub>), 1.0 mL/min). Retention time = 9.55 min > 99% e.e.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>,<i>N</i>-Dimethyl-4-(5-methylpyrazolo[1,5-<i>b</i>]pyridazin-3-yl)pyrimidin-2-amine (<b>63</b>)</h4><div class="NLM_p last">To a solution of 4-methylpyridazine (256 mg, 2.72 mmol) in pH 5 acetate buffer (1.5 mL) was added aminosulfuric acid (462 mg, 1.36 mmol) in water (0.1 mL). The reaction mixture was neutralized to pH 7.5 by slow addition of 2.4 M potassium bicarbonate (1.98 mL, 4.75 mmol). The reaction mixture was heated to 70 °C and was stirred for 2 h. The reaction mixture was cooled to rt, and CH<sub>2</sub>Cl<sub>2</sub> (4.5 mL) was added. The reaction mixture was cooled in an ice bath, and 3-butyn-2-one (0.09 mL, 1.15 mmol) was added in one portion followed by dropwise addition of potassium hydroxide (171 mg, 3.05 mmol) in water (0.45 mL). The reaction mixture was allowed to warm to rt and stirred overnight. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 20 mL). The combined organic layers were washed with water (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. To the residue was added <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (3.37 mL, 25.38 mmol). The reaction mixture was heated to 75 °C for 16 h. The reaction mixture was concentrated under reduced pressure. To the crude were added 1,1-dimethylguanidine sulfate salt (600 mg, 2.2 mmol), 2-methoxyethanol (30 mL), and potassium carbonate (400 mg, 2.89 mmol). The reaction mixture was heated to 125 °C overnight. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc (50 mL) and water (50 mL), and the organic layer was separated. The aqueous layer was extracted with further EtOAc (2 × 50 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–100% EtOAc/petroleum ether gradient), trituration with petroleum ether followed by recrystallization in EtOAc furnished the title compound, <i>N</i>,<i>N</i>-dimethyl-4-(5-methylpyrazolo[1,5-<i>b</i>]pyridazin-3-yl)pyrimidin-2-amine, <b>63</b>, as a salmon pink solid (15 mg, 0.05 mmol, 9% yield). <i>R</i><sub><i>f</i></sub> 0.46 (EtOAc/ petroleum ether 2:3); mp 236–238 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.77 (s, 1H), 8.70–8.66 (m, 1H), 8.48 (d, <i>J</i> = 2.4 Hz, 1H), 8.33 (d, <i>J</i> = 5.1 Hz, 1H), 7.10 (d, <i>J</i> = 5.1 Hz, 1H), 3.22 (s, 6H), 2.45 (s, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 161.9, 159.0, 157.8, 145.8, 139.9, 132.1, 129.3, 126.7, 109.2, 104.4, 36.9, 18.3; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>13</sub>H<sub>15</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 255.1353, found: 255.1350 [M + H]<sup>+</sup>; LCMS (MDAP): 11.6 min, >95% (method A); LC-MS (ESI): calculated for C<sub>13</sub>H<sub>15</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 255.1, found 255.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-(4-Methoxypyrazolo[1,5-<i>b</i>]pyridazin-3-yl)-<i>N</i>,<i>N</i>-dimethyl-pyrimidin-2-amine (<b>66</b>)</h4><div class="NLM_p last">To a solution of 4-methoxypyridazine (300 mg, 2.72 mmol) in pH 5 acetate buffer (1.5 mL) was added aminosulfuric acid (462 mg, 1.36 mmol) in water (0.1 mL). The reaction mixture was neutralized to pH 7.5 by slow addition of 2.4 M potassium bicarbonate (1.98 mL, 4.75 mmol). The reaction mixture was heated to 70 °C and was stirred for 2 h. The reaction mixture was cooled to rt, and CH<sub>2</sub>Cl<sub>2</sub> (4.5 mL) was added. The reaction mixture was cooled in an ice bath, and 3-butyn-2-one (0.09 mL, 1.15 mmol) was added in one portion followed by dropwise addition of potassium hydroxide (171 mg, 3.05 mmol) in water (0.45 mL). The reaction mixture was allowed to warm to rt and stirred overnight. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 20 mL). The combined organic layers were washed with water (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. To the residue was added <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (3.37 mL, 25.38 mmol). The reaction mixture was heated to 75 °C for 16 h. The reaction mixture was concentrated under reduced pressure. To the crude were added 1,1-dimethylguanidine sulfate salt (600 mg, 2.2 mmol), 2-methoxyethanol (30 mL), and potassium carbonate (400 mg, 2.89 mmol). The reaction mixture was heated to 125 °C overnight. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc (50 mL) and water (50 mL), and the organic layer was separated. The aqueous layer was extracted with further EtOAc (2 × 50 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–100% EtOAc/petroleum ether gradient), trituration with petroleum ether followed by recrystallization in EtOAc furnished the title compound, 4-(4-methoxypyrazolo[1,5-<i>b</i>]pyridazin-3-yl)-<i>N</i>,<i>N</i>-dimethyl-pyrimidin-2-amine, <b>66</b>, as a white solid (12 mg, 0.04 mmol, 8% yield). <i>R</i><sub><i>f</i></sub> 0.41 (EtOAc); mp 180–182 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.54 (s, 1H), 8.42 (d, <i>J</i> = 5.6 Hz, 1H), 8.34 (d, <i>J</i> = 5.1 Hz, 1H), 7.13 (d, <i>J</i> = 5.1 Hz, 1H), 6.88 (d, <i>J</i> = 5.6 Hz, 1H), 4.08 (s, 3H), 3.18 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 161.8, 158.3, 157.9, 157.7, 144.0, 139.8, 126.5, 112.6, 108.2, 96.9, 56.8, 36.6; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>13</sub>H<sub>15</sub>N<sub>6</sub>O [M + H]<sup>+</sup> is 271.1302, found: 271.1298 [M + H]<sup>+</sup>; LCMS (MDAP): 11.5 min, >95% (method A); LC-MS (ESI): calculated for C<sub>13</sub>H<sub>15</sub>N<sub>6</sub>O [M + H]<sup>+</sup> is 271.1, found 271.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 1-Imidazo[1,2-<i>a</i>]pyrimidin-3-ylethanone (<b>68a</b>)</h4><div class="NLM_p last">Pyrimidin-2-amine (1 g, 10.52 mmol) was dissolved in toluene (7 mL), and <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (3 mL, 22.58 mmol) was added. The reaction mixture was heated to 90 °C for 2 h. The reaction mixture was concentrated under reduced pressure. The crude was dissolved in EtOH (10 mL), and chloroacetone (1.6 mL, 20.1 mmol) was added to the mixture. The reaction mixture was heated to reflux and stirred overnight. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (24 g silica, elution with 0–50% 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford 1-imidazo[1,2-<i>a</i>]pyrimidin-3-ylethanone, <b>68a</b>, as a gold solid (800 mg, 4.59 mmol, 44% yield). <i>R</i><sub><i>f</i></sub> 0.10 (EtOAc); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 9.79 (dd, <i>J</i> = 6.8, 2.1 Hz, 1H), 8.83 (dd, <i>J</i> = 4.2, 2.1 Hz, 1H), 8.78 (s, 1H), 7.40 (dd, <i>J</i> = 6.8, 4.2 Hz, 1H), 2.58 (s, 3H); LC-MS (ESI): calculated for C<sub>8</sub>H<sub>8</sub>N<sub>3</sub>O [M + H]<sup>+</sup> is 162.07, found 162.13 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>E</i>)-3-(Dimethylamino)-1-imidazo[1,2-<i>a</i>]pyrimidin-3-yl-prop-2-en-1-one (<b>69a</b>)</h4><div class="NLM_p last">To 1-imidazo[1,2-<i>a</i>]pyrimidin-3-ylethanone (100 mg, 0.62 mmol) was added <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (4 mL, 30.11 mmol). The reaction mixture was heated to 75 °C for 16 h. The reaction mixture was concentrated under reduced pressure to afford the title compound, (<i>E</i>)-3-(dimethylamino)-1-imidazo[1,2-<i>a</i>]pyrimidin-3-yl-prop-2-en-1-one, <b>69a</b>, as a red solid (150 mg, 0.62 mmol, 99% yield) plus impurities. <i>R</i><sub><i>f</i></sub> 0.23 (MeOH/CH<sub>2</sub>Cl<sub>2</sub> 5:95); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ<sub>H</sub> 10.05 (dd, <i>J</i> = 6.9, 2.1 Hz, 1H), 8.66 (dd, <i>J</i> = 4.1, 2.1 Hz, 1H), 8.35 (s, 1H), 7.79 (d, <i>J</i> = 12.3 Hz, 1H), 7.03 (dd, <i>J</i> = 6.9, 4.1 Hz, 1H), 5.66 (d, <i>J</i> = 12.3 Hz, 1H), 3.28–2.76 (m, 6H); LC-MS (ESI): calculated for C<sub>11</sub>H<sub>13</sub>N<sub>4</sub>O [M + H]<sup>+</sup> is 217.1, found 217.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-Imidazo[1,2-<i>a</i>]pyrimidin-3-yl-<i>N</i>,<i>N</i>-dimethyl-pyrimidin-2-amine (<b>70</b>)</h4><div class="NLM_p last">To a solution of (<i>E</i>)-3-(dimethylamino)-1-imidazo[1,2-<i>a</i>]pyrimidin-3-yl-prop-2-en-1-one (100 mg, 0.46 mmol) in 2-methoxyethanol (35 mg, 0.46 mmol) were added 1,1-dimethylguanidine sulfate salt (190 mg, 0.70 mmol) and potassium carbonate (133 mg, 0.96 mmol). The reaction mixture was heated to 125 °C overnight. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc (50 mL) and water (50 mL), and the organic layer was separated. The aqueous layer was extracted with further EtOAc (2 × 50 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–50% 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford the title compound, 4-imidazo[1,2-<i>a</i>]pyrimidin-3-yl-<i>N</i>,<i>N</i>-dimethyl-pyrimidin-2-amine, <b>70</b>, as a pale yellow solid (21 mg, 0.08 mmol, 18% yield). <i>R</i><sub><i>f</i></sub> 0.63 (EtOAc); mp 237–239 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 10.12 (dd, <i>J</i> = 7.0, 2.0 Hz, 1H), 8.70–8.65 (m, 2H), 8.35 (d, <i>J</i> = 5.2 Hz, 1H), 7.32 (dd, <i>J</i> = 7.0, 4.1 Hz, 1H), 7.17 (d, <i>J</i> = 5.2 Hz, 1H), 3.19 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>C</sub> 161.5, 157.9, 156.3, 151.4, 150.2, 138.9, 136.6, 120.2, 110.3, 104.0, 37.2; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>12</sub>H<sub>12</sub>N<sub>6</sub>Na [M + Na]<sup>+</sup> is 263.1016, found: 263.1012 [M + Na]<sup>+</sup>; LCMS (MDAP): 10.1 min, >95% (method A); LC-MS (ESI): calculated for C<sub>12</sub>H<sub>13</sub>N<sub>6</sub> [M + H]<sup>+</sup> is 241.1, found 241.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Methyl pyrazolo[1,5-<i>b</i>]pyridazine-3-carboxylate (<b>89</b>)</h4><div class="NLM_p last">To a slurry of pyridazin-1-ium-1-amine iodide (3.13 g, 14.05 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added methyl propiolate (0.5 mL, 5.62 mmol). The reaction flask was cooled in an ice bath before slowly adding a solution of potassium carbonate (2.33 g, 16.86 mmol) in water (100 mL) in one portion. The reaction mixture was stirred at rt for 16 h. The organic layer was separated. The aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The combined organic layers were washed with brine solution (200 mL), and dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–100% EtOAc/petroleum ether gradient) to afford the title compound, methyl pyrazolo[1,5-<i>b</i>]pyridazine-3-carboxylate, <b>89</b>, as a pale yellow solid (380 mg, 2.04 mmol, 36% yield). <i>R</i><sub><i>f</i></sub> 0.38 (CH<sub>2</sub>Cl<sub>2</sub>); mp 119–121 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.70–8.65 (m, 1H), 8.58–8.53 (m, 2H), 7.55 (dd, <i>J</i> = 9.1, 4.5 Hz, 1H), 3.86 (s, 3H); LC-MS (ESI): calculated for C<sub>8</sub>H<sub>8</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> is 178.1, found 178.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Pyrazolo[1,5-<i>b</i>]pyridazine-3-carboxylic Acid (<b>90</b>)</h4><div class="NLM_p last">To a solution of methyl pyrazolo[1,5-<i>b</i>]pyridazine-3-carboxylate (350 mg, 1.98 mmol) in MeOH (2.5 mL) was added lithium hydroxide (135 mg, 3.22 mmol) in water (2.5 mL). The reaction mixture was stirred at rt for 16 h. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was added to the residue, and the resulting solution was cooled in an ice bath. HCl (10 mL, 1 M) was added, and the mixture was stirred at rt for 30 min. A suspension immediately formed and was filtered and washed with water. The resulting solid was dried under reduced pressure to afford the title compound pyrazolo[1,5-<i>b</i>]pyridazine-3-carboxylic acid, <b>90</b>, as a white solid (250 mg, 1.46 mmol, 74% yield). <i>R</i><sub><i>f</i></sub> 0 (EtOAc/petroleum ether 1:1); decomposed > 295 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 12.83 (s, 1H), 8.63 (dd, <i>J</i> = 4.4, 2.1 Hz, 1H), 8.55–8.44 (m, 2H), 7.50 (dd, <i>J</i> = 9.1, 4.4 Hz, 1H); LC-MS (ESI): calculated for C<sub>7</sub>H<sub>6</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> is 164.0, found 164.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-Bromopyrazolo[1,5-<i>b</i>]pyridazine (<b>91</b>)</h4><div class="NLM_p last">To a solution of pyrazolo[1,5-<i>b</i>]pyridazine-3-carboxylic acid (360 mg, 2.21 mmol) in DMF (4 mL) was added <i>N</i>-bromosuccinimide (790 mg, 4.41 mmol), and the reaction was stirred at rt for 3 h. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–60% EtOAc/petroleum ether gradient) to afford 3-bromopyrazolo[1,5-<i>b</i>]pyridazine, <b>91</b>, as a white crystalline solid (360 mg, 1.73 mmol, 78% yield). <i>R</i><sub><i>f</i></sub> 0.74 (EtOAc/petroleum ether 1:1); mp 102–104 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.52 (dd, <i>J</i> = 4.4, 1.8 Hz, 1H), 8.28 (s, 1H), 8.20 (dd, <i>J</i> = 9.0, 1.8 Hz, 1H), 7.31 (dd, <i>J</i> = 9.0, 4.4 Hz, 1H); LC-MS (ESI): calculated for C<sub>6</sub>H<sub>5</sub>BrN<sub>3</sub> [M]<sup>+</sup> is 198.0 and [M + 2]<sup>+</sup> is 200.0, found 198.0 [M]<sup>+</sup> and 200.0 [M + 2]<sup>+</sup>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-<i>b</i>]pyridazine (<b>92</b>)</h4><div class="NLM_p last">To a solution of 3-bromopyrazolo[1,5-<i>b</i>]pyridazine (100 mg, 0.50 mmol) in 1,4-dioxane (1 mL) were added bis(pinacolato)diboron (141 mg, 0.56 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with CH<sub>2</sub>Cl<sub>2</sub> (21 mg, 0.03 mmol), and potassium acetate (99 mg, 1.01 mmol). The reaction mixture was heated to 90 °C and stirred for 16 h. The reaction mixture was filtered through celite and concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–50% EtOAc/petroleum ether gradient). Desired fractions were combined and concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–50% 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford the title compound, 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-<i>b</i>]pyridazine, <b>92</b>, as a white crystalline solid (30 mg, 0.12 mmol, 23% yield). <i>R</i><sub><i>f</i></sub> 0.38 (EtOAc/petroleum ether 1:1); mp 160–162 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ<sub>H</sub> 8.53 (dd, <i>J</i> = 4.4, 1.9 Hz, 1H), 8.27 (dd, <i>J</i> = 9.0, 1.9 Hz, 1H), 8.23 (s, 1H), 7.34 (dd, <i>J</i> = 9.0, 4.4 Hz, 1H), 1.30 (s, 12H); LC-MS (ESI): calculated for C<sub>12</sub>H<sub>17</sub>BN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> is 246.1, found 246.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 5-Fluoro-<i>N</i>,<i>N</i>-dimethyl-4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-amine (<b>95</b>)</h4><div class="NLM_p">To a solution of 4-chloro-5-fluoropyrimidin-2-amine (100 mg, 0.68 mmol) in DMF (2 mL) was added sodium hydride (81 mg, 3.39 mmol) at 0 °C. After warming to rt and stirring for 5 min, iodomethane (0.08 mL, 1.36 mmol) was added dropwise, and the reaction was stirred at rt for 16 h. The reaction mixture was concentrated under reduced pressure. The crude was dissolved in water (100 mL) and extracted into EtOAc (3 × 100 mL). The combined EtOAc phases were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford the intermediate, 4-chloro-5-fluoro-<i>N</i>,<i>N</i>-dimethyl-pyrimidin-2-amine, as a crude orange solid (130 mg). LC-MS (ESI<sup>+</sup>): calculated for intermediate C<sub>6</sub>H<sub>8</sub>ClFN<sub>3</sub> [M + H]<sup>+</sup> is 176.1, found 176.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">To a solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-<i>b</i>]pyridazine (80 mg, 0.3 mmol) in acetonitrile (4.5 mL) and water (0.45 mL) were added sodium carbonate (70 mg, 0.65 mmol), bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron (dichloropalladium) (11 mg, 0.02 mmol), and the crude orange solid [4-chloro-5-fluoro-<i>N</i>,<i>N</i>-dimethyl-pyrimidin-2-amine] (80 mg, 0.21 mmol). The reaction mixture was heated to 140 °C overnight. The reaction mixture was concentrated under reduced pressure. The crude was purified using flash silica column chromatography on an Isco Combiflash system (12 g silica, elution with 0–60% EtOAc/petroleum ether gradient). Desired fractions were concentrated under reduced pressure. The crude was purified using flash reversed-phase column chromatography on a Biotage system (12 g silica, elution with 10–100% MeOH/water gradient) to afford the title compound, 5-fluoro-<i>N</i>,<i>N</i>-dimethyl-4-pyrazolo[1,5-<i>b</i>]pyridazin-3-yl-pyrimidin-2-amine, <b>95</b>, as an off-white solid (50 mg, 0.18 mmol, 57% yield). <i>R</i><sub><i>f</i></sub> 0.57 (EtOAc/petroleum ether 1:1); mp 181–183 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ<sub>H</sub> 9.00 (dd, <i>J</i> = 9.0, 2.0 Hz, 1H), 8.66 (d, <i>J</i> = 3.1 Hz, 1H), 8.41 (dd, <i>J</i> = 4.4, 2.0 Hz, 1H), 8.23 (d, <i>J</i> = 3.2 Hz, 1H), 7.19 (dd, <i>J</i> = 9.0, 4.4 Hz, 1H), 3.25 (s, 6H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ<sub>C</sub> 159.2, 148.6 (d, <i>J</i> = 249.1 Hz), 147.1 (d, <i>J</i> = 11.6 Hz), 145.4 (d, <i>J</i> = 24.3 Hz), 143.2, 141.8 (d, <i>J</i> = 16.2 Hz), 133.4, 129.7, 118.0, 107.1, 38.2; HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calculated for C<sub>12</sub>H<sub>11</sub>FN<sub>6</sub>Na [M + Na]<sup>+</sup> is 281.0921, found: 281.0918 [M + Na]<sup>+</sup>; LCMS (MDAP): 19.6 min, >95% (method A); LC-MS (ESI): calculated for C<sub>12</sub>H<sub>12</sub>FN<sub>6</sub> [M + H]<sup>+</sup> is 259.1, found 259.9 [M + H]<sup>+</sup>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57"><a href="/doi/suppl/10.1021/acs.jmedchem.1c01115" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c01115?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01115</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">DSF analysis of selected compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_001.xlsx" class="ext-link">XLSX</a>)</p></li><li><p class="inline">KINOMEscan analysis of compounds in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_002.xlsx" class="ext-link">XLSX</a>)</p></li><li><p class="inline">SMILES (<a href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_003.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Materials and methods for synthetic chemistry, protein expression, purification, crystallization, data collection, and structure determination; characterization of compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_004.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_001.xlsx">jm1c01115_si_001.xlsx (20.36 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_002.xlsx">jm1c01115_si_002.xlsx (155.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_003.csv">jm1c01115_si_003.csv (4.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_004.pdf">jm1c01115_si_004.pdf (7.94 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c01115" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67612" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67612" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott H. Henderson</span> - <span class="hlFld-Affiliation affiliation">Sussex
Drug Discovery Centre, University of Sussex, Brighton BN1 9RH, U.K.</span>; 
    <span>Present Address:
                        BenevolentAI, Minerva Building, Babraham Hall, Babraham, Cambridge, CB22 3AT, UK. (S.H.H.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9504-5943" title="Orcid link">https://orcid.org/0000-0002-9504-5943</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9fecfcf0ebebb1f7faf1fbfaedecf0f1dffdfaf1fae9f0f3faf1ebb1fef6"><span class="__cf_email__" data-cfemail="a3d0c0ccd7d78dcbc6cdc7c6d1d0cccde3c1c6cdc6d5cccfc6cdd78dc2ca">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan M. Elkins</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, Universidade Estadual
de Campinas, Cidade Universitária
Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-2858-8929" title="Orcid link">https://orcid.org/0000-0003-2858-8929</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2d4742430348414644435e6d4e4049034255034c4e035846"><span class="__cf_email__" data-cfemail="244e4b4a0a41484f4d4a57644749400a4b5c0a45470a514f">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon E. Ward</span> - <span class="hlFld-Affiliation affiliation">Medicines
Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8745-8377" title="Orcid link">https://orcid.org/0000-0002-8745-8377</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b2e5d3c0d6e18382f2d1d3c0d6dbd4d49cd3d19cc7d9"><span class="__cf_email__" data-cfemail="4f182e3d2b1c7e7f0f2c2e3d2b262929612e2c613a24">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fiona Sorrell</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Bennett</span> - <span class="hlFld-Affiliation affiliation">Target
Discovery Institute, University of Oxford, Oxford OX3 7FZ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oleg Fedorov</span> - <span class="hlFld-Affiliation affiliation">Target
Discovery Institute, University of Oxford, Oxford OX3 7FZ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcus T. Hanley</span> - <span class="hlFld-Affiliation affiliation">Medicines
Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paulo H. Godoi</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, Universidade Estadual
de Campinas, Cidade Universitária
Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roberta Ruela de Sousa</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, Universidade Estadual
de Campinas, Cidade Universitária
Zeferino Vaz, Av. Dr. André Tosello, 550, Barão Geraldo, Campinas, SP 13083-886, Brazil</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean Robinson</span> - <span class="hlFld-Affiliation affiliation">Exscientia, The Schrödinger Building,
Oxford Science Park, Oxford OX4 4GE, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9312-7411" title="Orcid link">https://orcid.org/0000-0001-9312-7411</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Ashall-Kelly</span> - <span class="hlFld-Affiliation affiliation">Medicines
Discovery Institute, Cardiff University, Cardiff CF10 3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iva Hopkins Navratilova</span> - <span class="hlFld-Affiliation affiliation">Exscientia, The Schrödinger Building,
Oxford Science Park, Oxford OX4 4GE, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Dundee, Dow Street, Dundee DD1
5EH, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daryl S. Walter</span> - <span class="hlFld-Affiliation affiliation">Evotec (UK)
Ltd., 112-114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.H.H. was involved in the conception and design, acquisition of data, analysis and interpretation of data, and drafting and revising of the article. F.S. was involved in the conception and design, acquisition of data, analysis and interpretation of data, and drafting and revising of the article. J.B., O.F., P.H.G., and R.R.d.S. were involved in the acquisition, analysis, and interpretation of data. M.T.H was involved in the acquisition of data. S.R. and A.A.-K. were involved in the acquisition of data. I.H.N was involved in the acquisition of data and revising of the article. D.S.W. was involved in the analysis and interpretation of data. J.M.E. was involved in the conception of the project, analysis and interpretation of data, and drafting and revising of the article. S.E.W. was involved in the conception of the project, analysis and interpretation of data, and revising of the article. All authors approved the final version to be published.</p></li><li><span class="author-information-subsection-header">Funding</span><p>S.H.H. is funded by the BBSRC (BB/L017105/1). S.E.W. is funded by the Wellcome Trust, MRC, BBSRC and the European Structural Funding via Sêr Cymru scheme. R.R.d.S. is funded by São Paulo Research Foundation-FAPESP 2016/17469-0 and 13/50724-5. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z].</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">PDB X-ray structures: PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1B">6S1B</a> (compound <b>10</b>); PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S17">6S17</a> (compound <b>11</b>); PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S14">6S14</a> (compound <b>12</b>); PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1J">6S1J</a> (compound <b>30</b>); PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1H">6S1H</a> (compound <b>78</b>). The authors released the atomic coordinates on June 26, 2019.</p></div></li></ul></div><div class="ack" id="ACK-d7e6471-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Kamal R. Abdul Azeez for help with protein purification. S.H.H. acknowledges industrial sponsorship from Evotec (U.K.) Ltd. and is grateful for the use of laboratory facilities to undertake part of this work. An academic license for ChemAxon (<a href="https://www.chemaxon.com" class="extLink">https://www.chemaxon.com</a>) and a license for ChemAxon Infocom KNIME nodes are gratefully acknowledged. They also acknowledge the platform KNIME (<a href="https://www.knime.com" class="extLink">https://www.knime.com</a>).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CLK</td><td class="NLM_def"><p class="first last">CDC-like kinases</p></td></tr><tr><td class="NLM_term">CMGC</td><td class="NLM_def"><p class="first last">including cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAP kinases), glycogen synthase kinases (GSK) and CDK-like kinases</p></td></tr><tr><td class="NLM_term">CNS MPO</td><td class="NLM_def"><p class="first last">central nervous system multiparameter optimization</p></td></tr><tr><td class="NLM_term">DYRK</td><td class="NLM_def"><p class="first last">dual-specificity tyrosine phosphorylation-regulated kinase</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">glycogen synthase kinases</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">hydrogen-bond acceptor</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">MDCK-MDR1</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney cells transfected with the human MDR1 gene</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matched-molecular pair</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Databank</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">permeability glycoprotein 1</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 16 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejedor, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerle, B.</span></span> <span> </span><span class="NLM_article-title">MNB/DYRK1A as a Multiple Regulator of Neuronal Development</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2010.07954.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1111%2Fj.1742-4658.2010.07954.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=21156027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFGru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=223-235&author=F.+J.+Tejedorauthor=B.+Hammerle&title=MNB%2FDYRK1A+as+a+Multiple+Regulator+of+Neuronal+Development&doi=10.1111%2Fj.1742-4658.2010.07954.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">MNB/DYRK1A as a multiple regulator of neuronal development</span></div><div class="casAuthors">Tejedor, Francisco J.; Hammerle, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-235</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  MNB/DYRK1A kinase is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family that has been strongly conserved across evolution.  There are substantial data implicating MNB/DYRK1A in brain development and adult brain function, as well as in neurodegeneration and Down syndrome pathologies.  Here, the authors review the current understanding of the neurodevelopmental activity of MNB/DYRK1A.  The authors discuss how MNB/DYRK1A fulfils several sequential roles in neuronal development and the mol. mechanisms possibly underlying these functions.  The authors also summarize the evidence behind the hypotheses to explain how the imbalance in MNB/DYRK1A gene dosage might be implicated in the neurodevelopmental alterations assocd. with Down syndrome.  Finally, the authors highlight some research directions that may help to clarify the mechanisms and functions of MNB/DYRK1A signaling in the developing brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaEobI2pCfCLVg90H21EOLACvtfcHk0lhWq7XqTc6Efw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFGru70%253D&md5=9f16a9bd441f24d2b860f1c322528162</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2010.07954.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2010.07954.x%26sid%3Dliteratum%253Aachs%26aulast%3DTejedor%26aufirst%3DF.%2BJ.%26aulast%3DHammerle%26aufirst%3DB.%26atitle%3DMNB%252FDYRK1A%2520as%2520a%2520Multiple%2520Regulator%2520of%2520Neuronal%2520Development%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D223%26epage%3D235%26doi%3D10.1111%2Fj.1742-4658.2010.07954.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wegiel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczmarski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frackowiak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur-Kolecka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Leon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adayev, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C. X.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Link Between DYRK1A Overexpression and Several-fold Enhancement of Neurofibrillary Degeneration with 3-Repeat Tau Protein in Down Syndrome</span>. <i>J. Neuropathol. Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1097/NEN.0b013e318202bfa1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1097%2FNEN.0b013e318202bfa1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=21157379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A280%3ADC%252BC3M3htl2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=36-50&author=J.+Wegielauthor=W.+Kaczmarskiauthor=M.+Baruaauthor=I.+Kuchnaauthor=K.+Nowickiauthor=K.+C.+Wangauthor=S.+M.+Yangauthor=J.+Frackowiakauthor=B.+Mazur-Koleckaauthor=W.+P.+Silvermanauthor=B.+Reisbergauthor=I.+Monteiroauthor=M.+de+Leonauthor=T.+Wisniewskiauthor=A.+Daltonauthor=F.+Laiauthor=Y.+W.+Hwangauthor=T.+Adayevauthor=F.+Liuauthor=K.+Iqbalauthor=I.+G.+Iqbalauthor=C.+X.+Gong&title=Link+Between+DYRK1A+Overexpression+and+Several-fold+Enhancement+of+Neurofibrillary+Degeneration+with+3-Repeat+Tau+Protein+in+Down+Syndrome&doi=10.1097%2FNEN.0b013e318202bfa1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome</span></div><div class="casAuthors">Wegiel Jerzy; Kaczmarski Wojciech; Barua Madhabi; Kuchna Izabela; Nowicki Krzysztof; Wang Kuo-Chiang; Wegiel Jarek; Yang Shuang Ma; Frackowiak Janusz; Mazur-Kolecka Bozena; Silverman Wayne P; Reisberg Barry; Monteiro Isabel; de Leon Mony; Wisniewski Thomas; Dalton Arthur; Lai Florence; Hwang Yu-Wen; Adayev Tatyana; Liu Fei; Iqbal Khalid; Iqbal Inge-Grundke; Gong Cheng-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuropathology and experimental neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triplication of chromosome 21 in Down syndrome (DS) results in overexpression of the minibrain kinase/dual-specificity tyrosine phosphorylated and regulated kinase 1A gene (DYRK1A).  DYRK1A phosphorylates cytoplasmic tau protein and appears in intraneuronal neurofibrillary tangles (NFTs).  We have previously shown significantly more DYRK1A-positive NFTs in DS brains than in sporadic Alzheimer disease (AD) brains.  This study demonstrates a gene dosage-proportional increase in the level of DYRK1A in DS in the cytoplasm and the cell nucleus, and enhanced cytoplasmic and nuclear immunoreactivity of DYRK1A in DS.  The results suggest that overexpressed DYRK1A may alter both phosphorylation of tau and alternative splicing factor (ASF).  Two-dimensional electrophoresis revealed modification of ASF phosphorylation in DS/AD and AD in comparison to controls.  Altered phosphorylation of ASF by overexpressed nuclear DYRK1A may contribute to the alternative splicing of the tau gene and an increase by 2.68 × of the 3R/4R ratio in DS/AD, and a several-fold increase in the number of 3R tau-positive NFTs in DS/AD subjects compared with that in sporadic AD subjects.  These data support the hypothesis that phosphorylation of ASF by overexpressed DYRK1A may contribute to alternative splicing of exon 10, increased expression of 3R tau, and early onset of neurofibrillary degeneration in DS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQohJz0qPg38DToTC3aBaesfW6udTcc2eZGAqAajIRhuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3htl2gsA%253D%253D&md5=70efaba307a11a62f14e822978642aec</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2FNEN.0b013e318202bfa1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FNEN.0b013e318202bfa1%26sid%3Dliteratum%253Aachs%26aulast%3DWegiel%26aufirst%3DJ.%26aulast%3DKaczmarski%26aufirst%3DW.%26aulast%3DBarua%26aufirst%3DM.%26aulast%3DKuchna%26aufirst%3DI.%26aulast%3DNowicki%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DK.%2BC.%26aulast%3DYang%26aufirst%3DS.%2BM.%26aulast%3DFrackowiak%26aufirst%3DJ.%26aulast%3DMazur-Kolecka%26aufirst%3DB.%26aulast%3DSilverman%26aufirst%3DW.%2BP.%26aulast%3DReisberg%26aufirst%3DB.%26aulast%3DMonteiro%26aufirst%3DI.%26aulast%3Dde%2BLeon%26aufirst%3DM.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DDalton%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DF.%26aulast%3DHwang%26aufirst%3DY.%2BW.%26aulast%3DAdayev%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DIqbal%26aufirst%3DI.%2BG.%26aulast%3DGong%26aufirst%3DC.%2BX.%26atitle%3DLink%2520Between%2520DYRK1A%2520Overexpression%2520and%2520Several-fold%2520Enhancement%2520of%2520Neurofibrillary%2520Degeneration%2520with%25203-Repeat%2520Tau%2520Protein%2520in%2520Down%2520Syndrome%26jtitle%3DJ.%2520Neuropathol.%2520Exp.%2520Neurol.%26date%3D2011%26volume%3D70%26spage%3D36%26epage%3D50%26doi%3D10.1097%2FNEN.0b013e318202bfa1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s Disease: the Amyloid Cascade Hypothesis: an Update and Reappraisal</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.3233/JAD-2006-9S317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.3233%2FJAD-2006-9S317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=16914853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=151-153&author=J.+Hardy&title=Alzheimer%E2%80%99s+Disease%3A+the+Amyloid+Cascade+Hypothesis%3A+an+Update+and+Reappraisal&doi=10.3233%2FJAD-2006-9S317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal</span></div><div class="casAuthors">Hardy, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">151-153</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  Here I recap the scientific and personal background of the delineation of the amyloid cascade hypothesis for Alzheimer's disease that I wrote with Gerry Higgins and the events leading to the writing of that influential review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO9h63kZgivLVg90H21EOLACvtfcHk0lhWq7XqTc6Efw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKkt7Y%253D&md5=9c91d6b0cf34cfdffbd2b0bb4b9429d6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3233%2FJAD-2006-9S317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2006-9S317%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DAlzheimer%25E2%2580%2599s%2520Disease%253A%2520the%2520Amyloid%2520Cascade%2520Hypothesis%253A%2520an%2520Update%2520and%2520Reappraisal%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2006%26volume%3D9%26spage%3D151%26epage%3D153%26doi%3D10.3233%2FJAD-2006-9S317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunckley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulme, C.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: a New Avenue for a Disease Modifying Treatment of Alzheimer’s?</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1021/cn300094k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300094k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KmsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=857-872&author=B.+Smithauthor=F.+Meddaauthor=V.+Gokhaleauthor=T.+Dunckleyauthor=C.+Hulme&title=Recent+Advances+in+the+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Selective+DYRK1A+Inhibitors%3A+a+New+Avenue+for+a+Disease+Modifying+Treatment+of+Alzheimer%E2%80%99s%3F&doi=10.1021%2Fcn300094k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?</span></div><div class="casAuthors">Smith, Breland; Medda, Federico; Gokhale, Vijay; Dunckley, Travis; Hulme, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">857-872</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  With 24.3 million people affected in 2005 and an estd. rise to 42.3 million in 2020, dementia is currently a leading unmet medical need and costly burden on public health.  Seventy percent of these cases have been attributed to Alzheimer's disease (AD), a neurodegenerative pathol. whose most evident symptom is a progressive decline in cognitive functions.  Dual specificity tyrosine phosphorylation regulated kinase-1A (DYRK1A) is important in neuronal development and plays a variety of functional roles within the adult central nervous system.  The DYRK1A gene is located within the Down syndrome crit. region (DSCR) on human chromosome 21 and current research suggests that overexpression of DYRK1A may be a significant factor leading to cognitive deficits in people with Alzheimer's disease (AD) and Down syndrome (DS).  Currently, treatment options for cognitive deficiencies assocd. with Down syndrome, as well as Alzheimer's disease, are extremely limited and represent a major unmet therapeutic need.  Small mol. inhibition of DYRK1A activity in the brain may provide an avenue for pharmaceutical intervention of mental impairment assocd. with AD and other neurodegenerative diseases.  We herein review the current state of the art in the development of DYRK1A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSAw8CXNiP7Vg90H21EOLACvtfcHk0lhmSlE8I9p-Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KmsL3K&md5=2009c25bc00389971cd71f64ead2da4a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fcn300094k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300094k%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DMedda%26aufirst%3DF.%26aulast%3DGokhale%26aufirst%3DV.%26aulast%3DDunckley%26aufirst%3DT.%26aulast%3DHulme%26aufirst%3DC.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Selective%2520DYRK1A%2520Inhibitors%253A%2520a%2520New%2520Avenue%2520for%2520a%2520Disease%2520Modifying%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%253F%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D857%26epage%3D872%26doi%3D10.1021%2Fcn300094k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwen, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radnabaazar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. H.</span></span> <span> </span><span class="NLM_article-title">Dyrk1A-Mediated Phosphorylation of Presenilin 1: a Functional Link Between Down Syndrome and Alzheimer’s Disease</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">574</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2010.06769.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1111%2Fj.1471-4159.2010.06769.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=20456003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGlsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=574-584&author=Y.+S.+Ryuauthor=S.+Y.+Parkauthor=M.+S.+Jungauthor=S.+H.+Yoonauthor=M.+Y.+Kwenauthor=S.+Y.+Leeauthor=S.+H.+Choiauthor=C.+Radnabaazarauthor=M.+K.+Kimauthor=H.+Kimauthor=K.+Kimauthor=W.+J.+Songauthor=S.+H.+Chung&title=Dyrk1A-Mediated+Phosphorylation+of+Presenilin+1%3A+a+Functional+Link+Between+Down+Syndrome+and+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Fj.1471-4159.2010.06769.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dyrk1A-mediated phosphorylation of presenilin 1: a functional link between Down syndrome and Alzheimer's disease</span></div><div class="casAuthors">Ryu, Young Shin; Park, So Young; Jung, Min-Su; Yoon, Song-Hee; Kwen, Mi-Yang; Lee, Sun-Young; Choi, Sun-Hee; Radnaabazar, Chinzorig; Kim, Mi-Kyoung; Kim, Hangun; Kim, Kwonseop; Song, Woo-Joo; Chung, Sul-Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">574-584</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The dual-specificity tyrosine(Y)-phosphorylation-regulated kinase 1A (Dyrk1A) gene is located on human chromosome 21 and encodes a proline-directed protein kinase that might be responsible for mental retardation and early onset of Alzheimer's disease (AD) in Down syndrome (DS) patients.  Presenilin 1 (PS1) is a key component of the γ-secretase complex in the generation of β-amyloid (Aβ), an important trigger protein in the pathogenesis of AD.  Increased Dyrk1A expression has been reported in human AD and DS brains.  We previously showed that Dyrk1A increased Aβ prodn. in mammalian cells and transgenic mice that over-express Dyrk1A.  In this study, we describe a potential mechanism by which Aβ is increased in Dyrk1A-over-expressing DS and AD brains.  First, we show that PS1 is phosphorylated by the Dyrk1A at Thr354 and that this phosphorylation increases γ-secretase activity.  Then, using transgenic mice that over-express human Dyrk1A, we demonstrate that phospho-Thr354-PS1 (pT354-PS1) expression is enhanced when Dyrk1A level is increased.  We also show that pT354-PS1 is more stable than the unphosphorylated form of PS1.  These results reveal a potential regulatory link between Dyrk1A and PS1 in the Aβ pathway of DS and AD brains, suggesting that up-regulated Dyrk1A may accelerate AD pathogenesis through PS1 phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLqQna1ZNRMLVg90H21EOLACvtfcHk0lhmSlE8I9p-Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGlsb%252FJ&md5=c34feb9505bd69bb8e5242e0a23e8197</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2010.06769.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2010.06769.x%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DJung%26aufirst%3DM.%2BS.%26aulast%3DYoon%26aufirst%3DS.%2BH.%26aulast%3DKwen%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DRadnabaazar%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DW.%2BJ.%26aulast%3DChung%26aufirst%3DS.%2BH.%26atitle%3DDyrk1A-Mediated%2520Phosphorylation%2520of%2520Presenilin%25201%253A%2520a%2520Functional%2520Link%2520Between%2520Down%2520Syndrome%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neurochem.%26date%3D2010%26volume%3D115%26spage%3D574%26epage%3D584%26doi%3D10.1111%2Fj.1471-4159.2010.06769.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7687</span>– <span class="NLM_lpage">7699</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00658</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00658" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7687-7699&author=K.+Kumarauthor=P.+Wangauthor=R.+Sanchezauthor=E.+A.+Swartzauthor=A.+F.+Stewartauthor=R.+J.+DeVita&title=Development+of+Kinase-Selective%2C+Harmine-Based+DYRK1A+Inhibitors+that+Induce+Pancreatic+Human+%CE%B2-Cell+Proliferation&doi=10.1021%2Facs.jmedchem.8b00658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Sanchez, Roberto; Swartz, Ethan A.; Stewart, Andrew F.; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7687-7699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DYRK1A has been implicated as an important drug target in various therapeutic areas, including neurol. disorders and oncol.  DYRK1A has more recently been shown to be involved in pathways regulating human β-cell proliferation, thus making it a potential therapeutic target for both Type 1 and Type 2 diabetes.  Our group, using a high-throughput phenotypic screen identified harmine that is able to induce beta cell proliferation both in vitro and in vivo.  Since harmine has suboptimal kinase selectivity we sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity, while retaining human β-cell proliferation capability.  We carried out the optimization of the 1-position of harmine and synthesized 15 harmine analogs.  6 Compds. showed excellent DYRK1A inhibition with IC50 in the range of 49.5-264 nM.  Two compds., 2-2 and 2-8, exhibited excellent human β-cell proliferation at doses of 3-30 μM and compd. 2-2 showed improved kinase selectivity as compared to harmine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmFSDNEicChLVg90H21EOLACvtfcHk0ljLdpi3j3gXpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsb7M&md5=e1b748db912ac5b0ef93b8729ad4b13e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00658%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DDevelopment%2520of%2520Kinase-Selective%252C%2520Harmine-Based%2520DYRK1A%2520Inhibitors%2520that%2520Induce%2520Pancreatic%2520Human%2520%25CE%25B2-Cell%2520Proliferation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7687%26epage%3D7699%26doi%3D10.1021%2Facs.jmedchem.8b00658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohilla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yar, M. S.</span></span> <span> </span><span class="NLM_article-title">DYRK1A Kinase Inhibition with Emphasis on Neurodegeneration: A Comprehensive Evolution Story-cum-perspective</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1016%2Fj.ejmech.2018.08.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=30243157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=559-592&author=A.+Pathakauthor=A.+Rohillaauthor=T.+Guptaauthor=M.+J.+Akhtarauthor=M.+R.+Haiderauthor=K.+Sharmaauthor=K.+Haiderauthor=M.+S.+Yar&title=DYRK1A+Kinase+Inhibition+with+Emphasis+on+Neurodegeneration%3A+A+Comprehensive+Evolution+Story-cum-perspective&doi=10.1016%2Fj.ejmech.2018.08.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective</span></div><div class="casAuthors">Pathak, Ankita; Rohilla, Ankit; Gupta, Tanya; Akhtar, Md Jawaid; Haider, Md Rafi; Sharma, Kalicharan; Haider, Kashif; Yar, M. Shahar</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">559-592</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Alzheimer, the fourth leading cause of death embodies a key responsible event including formation of β-amyloid protein clustering to amyloid plaque on blood vessels.  The origin of above events is Amyloid precursor protein (APP) which is an integral membrane protein known for its function in synapses formation.  Modern research had proposed that the over expression of DYRK1A (Dual specificity tyrosine phosphorylation regulated kinase1A), a family of protein kinases, positioned within the Down's syndrome crit. region (DSCR) on human chromosome 21 causes phosphorylation of APP protein resulting in its cleavage to Aβ 40, 42 and tau proteins (regulated by beta and gamma secretase) which plays crit. role in early onset of Alzheimer's disease (AD) detected in Down's syndrome (DS), leading to permanent functional and structural deformities which results ultimately into neuro-degeneration and neuronal death.  Therefore, DYRK1A emerges as a potential target for prevention of neuro-degeneration and hence Alzheimer.  Presently, the treatment methods for Down's syndrome, as well as Alzheimer's disease are extremely biased and represent a major deficiency for therapeutic necessities.  We hereby, focus our review on the current status of the research and contributions in the development of DYRK1A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHdKzoMC45tLVg90H21EOLACvtfcHk0ljLdpi3j3gXpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FJ&md5=e13399fd58d17c25fdd19e63239c8cf5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.093%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DA.%26aulast%3DRohilla%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DT.%26aulast%3DAkhtar%26aufirst%3DM.%2BJ.%26aulast%3DHaider%26aufirst%3DM.%2BR.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DHaider%26aufirst%3DK.%26aulast%3DYar%26aufirst%3DM.%2BS.%26atitle%3DDYRK1A%2520Kinase%2520Inhibition%2520with%2520Emphasis%2520on%2520Neurodegeneration%253A%2520A%2520Comprehensive%2520Evolution%2520Story-cum-perspective%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D559%26epage%3D592%26doi%3D10.1016%2Fj.ejmech.2018.08.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmström, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreaux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazureau, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Leucettine L41, a DYRK1A-preferential DYRKs/CLKs Inhibitor, Prevents Memory Impairments and Neurotoxicity Induced by Oligomeric Aβ25-35 Peptide Administration in Mice</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_fpage">2170</span>– <span class="NLM_lpage">2182</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2015.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1016%2Fj.euroneuro.2015.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=26381812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFemsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=2170-2182&author=G.+Naertauthor=V.+Ferr%C3%A9author=J.+Meunierauthor=E.+Kellerauthor=S.+Malmstr%C3%B6mauthor=L.+Givaloisauthor=F.+Carreauxauthor=J.+P.+Bazureauauthor=T.+Maurice&title=Leucettine+L41%2C+a+DYRK1A-preferential+DYRKs%2FCLKs+Inhibitor%2C+Prevents+Memory+Impairments+and+Neurotoxicity+Induced+by+Oligomeric+A%CE%B225-35+Peptide+Administration+in+Mice&doi=10.1016%2Fj.euroneuro.2015.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice</span></div><div class="casAuthors">Naert, Gaelle; Ferre, Valentine; Meunier, Johann; Keller, Emeline; Malmstrom, Susanna; Givalois, Laurent; Carreaux, Francois; Bazureau, Jean-Pierre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2170-2182</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) are implicated in the onset and progression of Down syndrome (DS) and Alzheimer's disease (AD).  DYRK1A has emerged as a possible link between amyloid-β (Aβ) and Tau, the major pathol. proteins in AD.  We here assessed the neuroprotective potential of a novel inhibitor of DYRKs/CLKs.  The Leucettine L41, acting preferentially on DYRK1A, was tested in Aβ25-35-treated mice, a nontransgenic model of AD-like toxicity.  We co-injected intracerebroventricularly oligomeric Aβ25-35 peptide and L41 in Swiss male mice.  After 7 days, they were submitted to behavioral tests addressing spatial and non-spatial, short- and long-term memories.  The oxidative stress, apoptotic markers, kinases involved in Tau phosphorylation, and synaptic integrity were analyzed by Western blot and ELISA in the hippocampus.  L41, tested at 0.4, 1.2, 4 μg, prevented the Aβ25-35-induced memory deficits in the Y-maze, passive avoidance and water-maze tests, with the most active dose being 4 μg.  The inhibitor prevented the Aβ25-35-induced oxidative stress, as revealed by measures of lipid peroxidn. levels and reactive oxygen species accumulation, and abolished Aβ25-35-induced expression of pro-apoptotic markers.  L41 prevented the Aβ25-35-induced decrease of AKT activation and increase of glycogen synthase kinase-3β (GSK-3β) activation, resulting in a decrease of Tau phosphorylation.  Finally, L41 restored Aβ25-35-reduced levels of synaptic markers.  The novel DYRK1A-preferential inhibitor L41 therefore prevented Aβ25-35-induced memory impairments and neurotoxicity in the mouse hippocampus.  These in vivo data highlighted particularly DYRK1A as a major kinase involved in Aβ pathol. and suggested therapeutic developments for DYRK1A inhibitors in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSRN-4HYiJs7Vg90H21EOLACvtfcHk0ljLdpi3j3gXpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFemsro%253D&md5=0ddd499193f1ef57d02b46a39f225abb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2015.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2015.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DNaert%26aufirst%3DG.%26aulast%3DFerr%25C3%25A9%26aufirst%3DV.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DS.%26aulast%3DGivalois%26aufirst%3DL.%26aulast%3DCarreaux%26aufirst%3DF.%26aulast%3DBazureau%26aufirst%3DJ.%2BP.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DLeucettine%2520L41%252C%2520a%2520DYRK1A-preferential%2520DYRKs%252FCLKs%2520Inhibitor%252C%2520Prevents%2520Memory%2520Impairments%2520and%2520Neurotoxicity%2520Induced%2520by%2520Oligomeric%2520A%25CE%25B225-35%2520Peptide%2520Administration%2520in%2520Mice%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2015%26spage%3D2170%26epage%3D2182%26doi%3D10.1016%2Fj.euroneuro.2015.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melchior, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittapalli, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Polk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Güner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofilena, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjitro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellamary, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swearingen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunil, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazici, Y.</span></span> <span> </span><span class="NLM_article-title">Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor: A Potential Therapeutic for Alzheimer’s Disease</span>. <i>Aging Cell.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">e13000</span> <span class="refDoi"> DOI: 10.1111/acel.13000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1111%2Facel.13000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=31267651" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&author=B.+Melchiorauthor=G.+K.+Mittapalliauthor=C.+Laiauthor=K.+Duong-Polkauthor=J.+Stewartauthor=B.+G%C3%BCnerauthor=B.+Hofilenaauthor=A.+Tjitroauthor=S.+D.+Andersonauthor=D.+S.+Hermanauthor=L.+Dellamaryauthor=C.+J.+Swearingenauthor=K.+C.+Sunilauthor=Y.+Yazici&title=Tau+Pathology+Reduction+with+SM07883%2C+a+Novel%2C+Potent%2C+and+Selective+Oral+DYRK1A+Inhibitor%3A+A+Potential+Therapeutic+for+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Facel.13000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Facel.13000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Facel.13000%26sid%3Dliteratum%253Aachs%26aulast%3DMelchior%26aufirst%3DB.%26aulast%3DMittapalli%26aufirst%3DG.%2BK.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DDuong-Polk%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DG%25C3%25BCner%26aufirst%3DB.%26aulast%3DHofilena%26aufirst%3DB.%26aulast%3DTjitro%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DS.%2BD.%26aulast%3DHerman%26aufirst%3DD.%2BS.%26aulast%3DDellamary%26aufirst%3DL.%26aulast%3DSwearingen%26aufirst%3DC.%2BJ.%26aulast%3DSunil%26aufirst%3DK.%2BC.%26aulast%3DYazici%26aufirst%3DY.%26atitle%3DTau%2520Pathology%2520Reduction%2520with%2520SM07883%252C%2520a%2520Novel%252C%2520Potent%252C%2520and%2520Selective%2520Oral%2520DYRK1A%2520Inhibitor%253A%2520A%2520Potential%2520Therapeutic%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAging%2520Cell.%26date%3D2019%26volume%3D18%26doi%3D10.1111%2Facel.13000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrassi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span> <span> </span><span class="NLM_article-title">Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2958</span>– <span class="NLM_lpage">2973</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01624</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01624" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlSqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2958-2973&author=Y.+A.+Liuauthor=Q.+Jinauthor=Y.+Zouauthor=Q.+Dingauthor=S.+Yanauthor=Z.+Wangauthor=X.+Haoauthor=B.+Nguyenauthor=X.+Zhangauthor=J.+Panauthor=T.+Moauthor=K.+Jacobsenauthor=T.+Lamauthor=T.+Y.+Wuauthor=H.+M.+Petrassiauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=W.+P.+Gordonauthor=B.+Liuauthor=J.+Baatenauthor=R.+Hillauthor=V.+Nguyen-Tranauthor=M.+Qiuauthor=Y.+Q.+Zhangauthor=A.+Kamireddyauthor=S.+Espinolaauthor=L.+Deatonauthor=S.+Haauthor=G.+Harbauthor=Y.+Jiaauthor=J.+Liauthor=W.+Shenauthor=A.+M.+Schumacherauthor=K.+Colmanauthor=R.+Glynneauthor=S.+Panauthor=P.+McNamaraauthor=B.+Laffitteauthor=S.+Meeusenauthor=V.+Molteniauthor=J.+Loren&title=Selective+DYRK1A+Inhibitor+for+the+Treatment+of+Type+1+Diabetes%3A+Discovery+of+6-Azaindole+Derivative+GNF2133&doi=10.1021%2Facs.jmedchem.9b01624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133</span></div><div class="casAuthors">Liu, Yahu A.; Jin, Qihui; Zou, Yefen; Ding, Qiang; Yan, Shanshan; Wang, Zhicheng; Hao, Xueshi; Nguyen, Bao; Zhang, Xiaoyue; Pan, Jianfeng; Mo, Tingting; Jacobsen, Kate; Lam, Thanh; Wu, Tom Y.-H.; Petrassi, H. Michael; Bursulaya, Badry; Di Donato, Michael; Gordon, W. Perry; Liu, Bo; Baaten, Janine; Hill, Robert; Nguyen-Tran, Van; Qiu, Minhua; Zhang, You-Qing; Kamireddy, Anwesh; Espinola, Sheryll; Deaton, Lisa; Ha, Sukwon; Harb, George; Jia, Yong; Li, Jing; Shen, Weijun; Schumacher, Andrew M.; Colman, Karyn; Glynne, Richard; Pan, Shifeng; McNamara, Peter; Laffitte, Bryan; Meeusen, Shelly; Molteni, Valentina; Loren, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2958-2973</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Autoimmune deficiency and destruction in either β-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes.  Thus, promoting β-cell proliferation could be one approach toward diabetes intervention.  In this report we describe the discovery of a potent and selective DYRK1A inhibitor GNF2133, which was identified through optimization of a 6-azaindole screening hit.  In vitro, GNF2133 is able to proliferate both rodent and human β-cells.  In vivo, GNF2133 demonstrated significant dose-dependent glucose disposal capacity and insulin secretion in response to glucose-potentiated arginine-induced insulin secretion (GPAIS) challenge in rat insulin promoter and diphtheria toxin A (RIP-DTA) mice.  The work described here provides new avenues to disease altering therapeutic interventions in the treatment of type 1 diabetes (T1D).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKP8bWozWpHrVg90H21EOLACvtfcHk0lgzyalgbI1RKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlSqs7g%253D&md5=0ec2402f79b1b3fa338aab9672b8b669</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01624%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BA.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DJacobsen%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DT.%2BY.%26aulast%3DPetrassi%26aufirst%3DH.%2BM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DBaaten%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%2BQ.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DEspinola%26aufirst%3DS.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DSchumacher%26aufirst%3DA.%2BM.%26aulast%3DColman%26aufirst%3DK.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DLoren%26aufirst%3DJ.%26atitle%3DSelective%2520DYRK1A%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25201%2520Diabetes%253A%2520Discovery%2520of%25206-Azaindole%2520Derivative%2520GNF2133%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2958%26epage%3D2973%26doi%3D10.1021%2Facs.jmedchem.9b01624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamrui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2986</span>– <span class="NLM_lpage">3003</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01379</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01379" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2986-3003&author=K.+Kumarauthor=P.+Wangauthor=J.+Wilsonauthor=V.+Zlatanicauthor=C.+Berrouetauthor=S.+Khamruiauthor=C.+Secorauthor=E.+A.+Swartzauthor=M.+Lazarusauthor=R.+Sanchezauthor=A.+F.+Stewartauthor=A.+Garcia-Ocanaauthor=R.+J.+DeVita&title=Synthesis+and+Biological+Validation+of+a+Harmine-Based%2C+Central+Nervous+System+%28CNS%29-Avoidant%2C+Selective%2C+Human+%CE%B2-Cell+Regenerative+Dual-Specificity+Tyrosine+Phosphorylation-Regulated+Kinase+A+%28DYRK1A%29+Inhibitor&doi=10.1021%2Facs.jmedchem.9b01379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Wilson, Jessica; Zlatanic, Viktor; Berrouet, Cecilia; Khamrui, Susmita; Secor, Cody; Swartz, Ethan A.; Lazarus, Michael; Sanchez, Roberto; Stewart, Andrew F.; Garcia-Ocana, Adolfo; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2986-3003</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, our group identified that harmine is able to induce β-cell proliferation both in vitro and in vivo, mediated via the DYRK1A-NFAT pathway.  Since, harmine suffers from a lack of selectivity, both against other kinases and CNS off-targets, we therefore sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity for off-targets while retaining human β-cell proliferation activity.  We carried out optimization of the 9-N-position of harmine to synthesize 29 harmine-based analogs.  Several novel inhibitors showed excellent DYRK1A inhibition and human β-cell proliferation capability.  An optimized DYRK1A inhibitor, compd. I, was identified as a novel, efficacious in vivo lead candidate.  Compd. I also demonstrates improved selectivity for kinases and CNS off-targets, as well as in vivo efficacy for β-cell proliferation and regeneration at lower doses than harmine.  Collectively, these findings demonstrate that compd. I is a much improved in vivo lead candidate as compared to harmine for the treatment of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZXVR-g2rCbbVg90H21EOLACvtfcHk0lgUQkBpWfHngg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOgsr8%253D&md5=c739edc1358acafc412a122c272edceb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01379%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DZlatanic%26aufirst%3DV.%26aulast%3DBerrouet%26aufirst%3DC.%26aulast%3DKhamrui%26aufirst%3DS.%26aulast%3DSecor%26aufirst%3DC.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DLazarus%26aufirst%3DM.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520and%2520Biological%2520Validation%2520of%2520a%2520Harmine-Based%252C%2520Central%2520Nervous%2520System%2520%2528CNS%2529-Avoidant%252C%2520Selective%252C%2520Human%2520%25CE%25B2-Cell%2520Regenerative%2520Dual-Specificity%2520Tyrosine%2520Phosphorylation-Regulated%2520Kinase%2520A%2520%2528DYRK1A%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2986%26epage%3D3003%26doi%3D10.1021%2Facs.jmedchem.9b01379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins Navratilova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. E.</span></span> <span> </span><span class="NLM_article-title">Mining Public Domain Data to Develop Selective DYRK1A Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1620</span>– <span class="NLM_lpage">1626</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSju7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1620-1626&author=S.+H.+Hendersonauthor=F.+Sorrellauthor=J.+Bennettauthor=M.+T.+Hanleyauthor=S.+Robinsonauthor=I.+Hopkins+Navratilovaauthor=J.+M.+Elkinsauthor=S.+E.+Ward&title=Mining+Public+Domain+Data+to+Develop+Selective+DYRK1A+Inhibitors&doi=10.1021%2Facsmedchemlett.0c00279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mining Public Domain Data to Develop Selective DYRK1A Inhibitors</span></div><div class="casAuthors">Henderson, Scott H.; Sorrell, Fiona; Bennett, James; Hanley, Marcus T.; Robinson, Sean; Hopkins Navratilova, Iva; Elkins, Jonathan M.; Ward, Simon E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1620-1626</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases represent one of the most intensively pursued groups of targets in modern-day drug discovery.  Often it is desirable to achieve selective inhibition of the kinase of interest over the remaining ~ 500 kinases in the human kinome.  This is esp. true when inhibitors are intended to be used to study the biol. of the target of interest.  We present a pipeline of open-source software that analyzes public domain data to repurpose compds. that have been used in previous kinase inhibitor development projects.  We define the dual-specificity tyrosine-regulated kinase 1A (DYRK1A) as the kinase of interest, and by addn. of a single Me group to the chosen starting point we remove glycogen synthase kinase β (GSK3β) and cyclin-dependent kinase (CDK) inhibition.  Thus, in an efficient manner we repurpose a GSK3β/CDK chemotype to deliver 8b(I), a highly selective DYRK1A inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4_KxvU0_m5LVg90H21EOLACvtfcHk0lgKjhhVIho3qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSju7bK&md5=d08a310f2b7f61243c46418d946d2d50</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00279%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DS.%2BH.%26aulast%3DSorrell%26aufirst%3DF.%26aulast%3DBennett%26aufirst%3DJ.%26aulast%3DHanley%26aufirst%3DM.%2BT.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DHopkins%2BNavratilova%26aufirst%3DI.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DWard%26aufirst%3DS.%2BE.%26atitle%3DMining%2520Public%2520Domain%2520Data%2520to%2520Develop%2520Selective%2520DYRK1A%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1620%26epage%3D1626%26doi%3D10.1021%2Facsmedchemlett.0c00279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preugschat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. Q.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-Phenyl-4-pyrazolo[1,5-<i>b</i>]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4716</span>– <span class="NLM_lpage">4730</span>, <span class="refDoi"> DOI: 10.1021/jm040063i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040063i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4716-4730&author=F.+X.+Tavaresauthor=J.+A.+Boucheronauthor=S.+H.+Dickersonauthor=R.+J.+Griffinauthor=F.+Preugschatauthor=S.+A.+Thomsonauthor=T.+Y.+Wangauthor=H.+Q.+Zhou&title=N-Phenyl-4-pyrazolo%5B1%2C5-b%5Dpyridazin-3-ylpyrimidin-2-amines+as+Potent+and+Selective+Inhibitors+of+Glycogen+Synthase+Kinase+3+with+Good+Cellular+Efficacy&doi=10.1021%2Fjm040063i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy</span></div><div class="casAuthors">Tavares, Francis X.; Boucheron, Joyce A.; Dickerson, Scott H.; Griffin, Robert J.; Preugschat, Frank; Thomson, Stephen A.; Wang, Tony Y.; Zhou, Hui-Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4716-4730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 regulates glycogen synthase, the rate-detg. enzyme for glycogen synthesis.  Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels.  Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics.  Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compds. with good cellular efficacy.  Mol. modeling studies have given insights into the mode of binding of these inhibitors.  Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b]pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2.  In addn., these inhibitors also exhibited very good cell efficacy and functional response.  A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting.  These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY8mmZ2qIdFLVg90H21EOLACvtfcHk0lgKjhhVIho3qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFSgtL4%253D&md5=934bcecaed8f087510bfc8fb41e2e7a5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm040063i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040063i%26sid%3Dliteratum%253Aachs%26aulast%3DTavares%26aufirst%3DF.%2BX.%26aulast%3DBoucheron%26aufirst%3DJ.%2BA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DPreugschat%26aufirst%3DF.%26aulast%3DThomson%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DT.%2BY.%26aulast%3DZhou%26aufirst%3DH.%2BQ.%26atitle%3DN-Phenyl-4-pyrazolo%255B1%252C5-b%255Dpyridazin-3-ylpyrimidin-2-amines%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Glycogen%2520Synthase%2520Kinase%25203%2520with%2520Good%2520Cellular%2520Efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4716%26epage%3D4730%26doi%3D10.1021%2Fjm040063i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaenzer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarchak, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, J-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striker, R.</span></span> <span> </span><span class="NLM_article-title">GW779439X and its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act as Antibiotic Adjuvants Against β-Lactam-Resistant Staphylococcus Aureus</span>. <i>ACS Infect Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1508</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSnt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=1508-1518&author=A.+J.+Schaenzerauthor=N.+Wlodarchakauthor=D.+H.+Drewryauthor=W.+J.+Zuercherauthor=W.+E.+Roseauthor=C.+A.+Ferrerauthor=J-D.+Sauerauthor=R.+Striker&title=GW779439X+and+its+Pyrazolopyridazine+Derivatives+Inhibit+the+Serine%2FThreonine+Kinase+Stk1+and+Act+as+Antibiotic+Adjuvants+Against+%CE%B2-Lactam-Resistant+Staphylococcus+Aureus&doi=10.1021%2Facsinfecdis.8b00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against β-Lactam-Resistant Staphylococcus aureus</span></div><div class="casAuthors">Schaenzer, Adam J.; Wlodarchak, Nathan; Drewry, David H.; Zuercher, William J.; Rose, Warren E.; Ferrer, Carla A.; Sauer, John-Demian; Striker, Rob</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1508-1518</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As antibiotic resistance rises, there is a need for strategies such as antibiotic adjuvants to conserve already-established antibiotics.  A family of bacterial kinases known as the Penicillin-binding-protein And Serine/Threonine kinase-Assocd. (PASTA) kinases has attracted attention as targets for antibiotic adjuvants for β-lactams.  Here, we report that the pyrazolopyridazine GW779439X sensitizes methicillin-resistant Staphylococcus aureus (MRSA) to various β-lactams through inhibition of the PASTA kinase Stk1.  GW779439X potentiates β-lactam activity against multiple MRSA and MSSA isolates, including the sensitization of a ceftaroline-resistant isolate to ceftaroline.  In silico modeling was used to guide the synthesis of GW779439X derivs.  The presence and orientation of GW779439X's methylpiperazine moiety was crucial for robust biochem. and microbiol. activity.  Taken together, our data provide a proof of concept for developing the pyrazolopyridazines as Stk1 inhibitors which act across S. aureus isolates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokgmvad7sEv7Vg90H21EOLACvtfcHk0ljUlHsnqzDJpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSnt7nJ&md5=d74112a692aef57e265862755bdc4dda</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00136%26sid%3Dliteratum%253Aachs%26aulast%3DSchaenzer%26aufirst%3DA.%2BJ.%26aulast%3DWlodarchak%26aufirst%3DN.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DRose%26aufirst%3DW.%2BE.%26aulast%3DFerrer%26aufirst%3DC.%2BA.%26aulast%3DSauer%26aufirst%3DJ-D.%26aulast%3DStriker%26aufirst%3DR.%26atitle%3DGW779439X%2520and%2520its%2520Pyrazolopyridazine%2520Derivatives%2520Inhibit%2520the%2520Serine%252FThreonine%2520Kinase%2520Stk1%2520and%2520Act%2520as%2520Antibiotic%2520Adjuvants%2520Against%2520%25CE%25B2-Lactam-Resistant%2520Staphylococcus%2520Aureus%26jtitle%3DACS%2520Infect%2520Dis.%26date%3D2018%26volume%3D4%26spage%3D1508%26epage%3D1518%26doi%3D10.1021%2Facsinfecdis.8b00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tear, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceballos-Pérez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas-Barros, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordon-Obras, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Moreno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Hernández, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Perez, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamarro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez Pacanowska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-<i>b</i>]pyridazines for the Treatment of Human African Trypanosomiasis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01741</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01741" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=756-783&author=W.+F.+Tearauthor=S.+Bagauthor=R.+Diaz-Gonzalezauthor=G.+Ceballos-P%C3%A9rezauthor=D.+I.+Rojas-Barrosauthor=C.+Cordon-Obrasauthor=G.+P%C3%A9rez-Morenoauthor=R.+Garc%C3%ADa-Hern%C3%A1ndezauthor=M.+S.+Martinez-Martinezauthor=L.+M.+Ruiz-Perezauthor=F.+Gamarroauthor=D.+Gonzalez+Pacanowskaauthor=C.+R.+Caffreyauthor=L.+Ferrinsauthor=P.+Manzanoauthor=M.+Navarroauthor=M.+P.+Pollastri&title=Selectivity+and+Physicochemical+Optimization+of+Repurposed+Pyrazolo%5B1%2C5-b%5Dpyridazines+for+the+Treatment+of+Human+African+Trypanosomiasis&doi=10.1021%2Facs.jmedchem.9b01741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis</span></div><div class="casAuthors">Tear, Westley F.; Bag, Seema; Diaz-Gonzalez, Rosario; Ceballos-Perez, Gloria; Rojas-Barros, Domingo I.; Cordon-Obras, Carlos; Perez-Moreno, Guiomar; Garcia-Hernandez, Raquel; Martinez-Martinez, Maria Santos; Ruiz-Perez, Luis Miguel; Gamarro, Francisco; Gonzalez Pacanowska, Dolores; Caffrey, Conor R.; Ferrins, Lori; Manzano, Pilar; Navarro, Miguel; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">756-783</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From a high-throughput screen of 42 444 known human kinases inhibitors, a pyrazolo[1,5-b]pyridazine scaffold was identified to begin optimization for the treatment of human African trypanosomiasis.  Previously reported data for analogous compds. against human kinases GSK-3β, CDK-2, and CDK-4 were leveraged to try to improve the selectivity of the series, resulting in 23a which showed selectivity for T. b. brucei over these three human enzymes.  In parallel, properties known to influence the absorption, distribution, metab., and excretion (ADME) profile of the series were optimized resulting in 20g being progressed into an efficacy study in mice.  Though 20g showed toxicity in mice, it also demonstrated CNS penetration in a PK study and significant redn. of parasitemia in four out of the six mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnVej-9mnZibVg90H21EOLACvtfcHk0ljUlHsnqzDJpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqsLnJ&md5=a214fe962c7e0b38f45b27eedb37fe2a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01741%26sid%3Dliteratum%253Aachs%26aulast%3DTear%26aufirst%3DW.%2BF.%26aulast%3DBag%26aufirst%3DS.%26aulast%3DDiaz-Gonzalez%26aufirst%3DR.%26aulast%3DCeballos-P%25C3%25A9rez%26aufirst%3DG.%26aulast%3DRojas-Barros%26aufirst%3DD.%2BI.%26aulast%3DCordon-Obras%26aufirst%3DC.%26aulast%3DP%25C3%25A9rez-Moreno%26aufirst%3DG.%26aulast%3DGarc%25C3%25ADa-Hern%25C3%25A1ndez%26aufirst%3DR.%26aulast%3DMartinez-Martinez%26aufirst%3DM.%2BS.%26aulast%3DRuiz-Perez%26aufirst%3DL.%2BM.%26aulast%3DGamarro%26aufirst%3DF.%26aulast%3DGonzalez%2BPacanowska%26aufirst%3DD.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26aulast%3DFerrins%26aufirst%3DL.%26aulast%3DManzano%26aufirst%3DP.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DSelectivity%2520and%2520Physicochemical%2520Optimization%2520of%2520Repurposed%2520Pyrazolo%255B1%252C5-b%255Dpyridazines%2520for%2520the%2520Treatment%2520of%2520Human%2520African%2520Trypanosomiasis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D756%26epage%3D783%26doi%3D10.1021%2Facs.jmedchem.9b01741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heroven, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganotra, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfreys, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Montalván, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Halogen-Aromatic π Interactions Modulate Inhibitor Residence Times</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7220</span>– <span class="NLM_lpage">7224</span>, <span class="refDoi"> DOI: 10.1002/anie.201801666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1002%2Fanie.201801666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFSmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=7220-7224&author=C.+Herovenauthor=V.+Georgiauthor=G.+K.+Ganotraauthor=P.+Brennanauthor=F.+Wolfreysauthor=R.+C.+Wadeauthor=A.+E.+Fern%C3%A1ndez-Montalv%C3%A1nauthor=A.+Chaikuadauthor=S.+Knapp&title=Halogen-Aromatic+%CF%80+Interactions+Modulate+Inhibitor+Residence+Times&doi=10.1002%2Fanie.201801666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen-aromatic π interactions modulate inhibitor residence times</span></div><div class="casAuthors">Heroven, Christina; Georgi, Victoria; Ganotra, Gaurav K.; Brennan, Paul; Wolfreys, Finn; Wade, Rebecca C.; Fernandez-Montalvan, Amaury E.; Chaikuad, Apirat; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7220-7224</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Prolonged drug residence times may result in longer-lasting drug efficacy, improved pharmacodynamic properties, and "kinetic selectivity" over off-targets with high drug dissocn. rates.  However, few strategies have been elaborated to rationally modulate drug residence time and thereby to integrate this key property into the drug development process.  Herein, we show that the interaction between a halogen moiety on an inhibitor and an arom. residue in the target protein can significantly increase inhibitor residence time.  By using the interaction of the serine/threonine kinase haspin with 5-iodotubercidin (5-iTU) derivs. as a model for an archetypal active-state (type I) kinase-inhibitor binding mode, we demonstrate that inhibitor residence times markedly increase with the size and polarizability of the halogen atom.  The halogen-arom. π interactions in the haspin-inhibitor complexes were characterized by means of kinetic, thermodn., and structural measurements along with binding-energy calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWtgKql8TUw7Vg90H21EOLACvtfcHk0lgPXe5BjAI--g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFSmt7Y%253D&md5=6356e6800c6a03801cf4fef66af7e76a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fanie.201801666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201801666%26sid%3Dliteratum%253Aachs%26aulast%3DHeroven%26aufirst%3DC.%26aulast%3DGeorgi%26aufirst%3DV.%26aulast%3DGanotra%26aufirst%3DG.%2BK.%26aulast%3DBrennan%26aufirst%3DP.%26aulast%3DWolfreys%26aufirst%3DF.%26aulast%3DWade%26aufirst%3DR.%2BC.%26aulast%3DFern%25C3%25A1ndez-Montalv%25C3%25A1n%26aufirst%3DA.%2BE.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DHalogen-Aromatic%2520%25CF%2580%2520Interactions%2520Modulate%2520Inhibitor%2520Residence%2520Times%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D7220%26epage%3D7224%26doi%3D10.1002%2Fanie.201801666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Advanced DYRK1/CLK inhibitors reported in the literature (Leucettine 41,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> GNF2133,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and compound <b>2</b>–<b>2c</b><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a>) and previously characterized DYRK1A inhibitors <b>6b</b> and <b>8b</b> with DYRK1A IC<sub>50</sub> values of 186 and 76 nM, respectively. <b>6b</b> (shown in yellow) bound to DYRK1A such that the <i>N</i>-methyl group was directed toward a small pocket on the kinase hinge region (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1I">6S1I</a>). Key hydrogen-bonding interactions between <b>6b</b>, a consensus water, and DYRK1A (Leu241, Glu239, and Lys188) are depicted by black dotted lines. Compound <b>8b</b> had a selectivity score (S(40)) against DYRK1A of 0.01.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Key Intermediates <b>6</b> and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) hydroxylamine-<i>O</i>-sulfonic acid, KHCO<sub>3</sub>, KI, H<sub>2</sub>O, 70 °C, 1.5 h, 94%; (ii) 3-butyne-2-one, KOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 60%; (iii) DMF–DMA, 100 °C, 16 h, 91%; (iv) urea, sodium hydride, 140 °C, 10 min, 91%; (v) phosphorus(V)oxychloride, 110 °C, 3 h, 92%; (vi) thiourea, sodium methoxide, <i>tert</i>-butanol, 90 °C, 16 h, then iodomethane, 30 °C, 4 h, 27%; (vii) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 67%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>9–55</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) amine, 2-propanol, 110–140 °C, 2–16 h; (ii) sodium hydride, haloalkane, DMF, rt, 5 h; (iii) secondary amine, 2-propanol, 140 °C, 16–96 h or microwave 25 min.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Co-crystal structures of pyrazolo[1,5-<i>b</i>]pyridazines (compounds <b>6b</b>, <b>10</b>, <b>11</b>, <b>12</b>, and <b>30</b>) and compound <b>78</b> (yellow) in complex with DYRK1A. The backbones of the kinase N-lobe, hinge, and C-lobe are colored in gray, pink, and purple, respectively, and polar contacts are indicated by black dotted lines. The conserved water molecule at the back of the pocket is indicated by a red sphere. The electron density of each compound (2<i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> map) is shown contoured at 1.0σ (blue mesh). For clarity, DYRK1A strands β1 and β2 are hidden. (A) Previously identified compound <b>6b</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1I">6S1I</a>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (B) compound <b>10</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1B">6S1B</a>), (C) compound <b>11</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S17">6S17</a>), (D) compound <b>12</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S14">6S14</a>), (E) compound <b>30</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1J">6S1J</a>), and (F) compound <b>78</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1H">6S1H</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 5,6-Heterocyclic Replacements of the Pyrazolo[1,5-<i>b</i>]pyridazine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (A) (i) Bis(triphenylphosphine)palladium(II) dichloride, copper iodide, TEA, propyne (<i>ca.</i> 5% in THF, <i>ca.</i> 1 mol/L), THF, rt, overnight, 87%; (ii) pyridazin-1-ium-1-amine iodide, DBU, acetonitrile, 50 °C, 16 h, 73%; (iii) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight, 80%; (iv) 2 M dimethylamine in THF, 110 °C, 2 h, 74%. (B) (i) Hydroxylamine-<i>O</i>-sulfonic acid, KHCO<sub>3</sub>, KI, H<sub>2</sub>O, 70 °C, 2 h; (ii) 3-butyne-2-one, KOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (iii) DMF–DMA, 75 °C, 16 h; (iv) 2-methoxyethanol, potassium carbonate, 1,1-dimethylguanidine sulfate salt, 125 °C, overnight. (C) (i) DMF–DMA, toluene, 90 °C, 2 h—overnight then chloroacetone, EtOH, reflux, overnight; (ii) DMF–DMA, 75 °C, 16 h; (iii) 2-methoxyethanol, potassium carbonate, 1,1-dimethylguanidine sulfate salt, 125 °C, overnight.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Heterocyclic Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Sodium hydride, iodomethane, THF, rt, 16 h, 89%; (ii) bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium, boronic acid or ester, 1,4-dioxane, 70 °C, 16 h, 24–83%; (iii) 2-methyl-2-propanyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-1-carboxylate, tris(dibenzylideneacetone)dipalladium(0), potassium fluoride, tri-<i>tert</i>-butylphosphonium tetrafluoroborate, 120 °C, 20 min, microwave, then 4 N HCl in 1,4-dioxane, rt, 2 h, 91%; (iv) sodium hydride, haloalkane, DMF, rt, 1 h; (v) tetrabutylammonium hydrogensulfate, 33% sodium hydroxide, <i>p</i>-toluenesulfonyl chloride, toluene, rt, overnight, 92%; (vi) <i>N</i>-bromosuccinimide, DMF, rt, overnight, 14%; (vii) bis(pinacolato)diboron, bis(triphenylphosphine)palladium(II) dichloride, potassium acetate, 1,4-dioxane, 100 °C, 2 h, 85%; (viii) compound <b>85</b>, potassium fluoride, tris(dibenzylideneacetone)dipalladium(0), tri-<i>tert</i>-butylphosphonium tetrafluoroborate, acetonitrile/water (4:1), 120 °C, 5 h, then 1 M sodium hydroxide, 100 °C, 1 h, microwave, 12%; (ix) sodium hydride, iodomethane, DMF, rt, 30 min, 15%.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Key Boronic Ester and Pyrazolo[1,5-<i>b</i>]pyridazines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (A) (i) Intermediate <b>2</b>, potassium carbonate, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 36%; (ii) lithium hydroxide, MeOH, rt, 16 h then 1 M HCl, rt, 30 min, 74%; (iii) <i>N</i>-bromosuccinimide, DMF, rt, 3 h, 78%; (iv) bis(pinacolato)diboron, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with CH<sub>2</sub>Cl<sub>2</sub>, potassium acetate, 1,4-dioxane, 90 °C, 16 h. (B) (i) Sodium hydride, iodomethane, DMF, rt, 16 h; (ii) <b>92</b>, bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium, sodium carbonate, acetonitrile/water (10:1), 140 °C overnight. (C) (i) <b>92</b>, bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium, potassium carbonate, DMF, 60 °C, 1.5 h; (ii) 2 M dimethylamine in THF, 100 °C, 2 h. (D) (i) NXS, acetonitrile, rt, 2 h; (ii) sodium hydride, iodomethane, THF, rt, overnight.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Pyrimidine Isosteres<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) dimethylamine hydrochloride, <i>N</i>,<i>N</i>-diisopropylethylamine, THF, rt, 3 h; (ii) <b>92</b>, bis[2-(di-<i>tert</i>-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium, 2 M potassium carbonate, 1,4-dioxane, 80 °C, 16 h; (iii) iodomethane, sodium hydride, DMF, rt, overnight.</p></p></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/medium/jm1c01115_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. NanoBRET analysis of the direct binding of <b>11</b> to DYRK1A in HEK293 cells. Two biological replicates were made at different tracer concentrations, plotted separately on the graph. The IC<sub>50</sub> values were 576 nM in the presence of a 2 μM tracer and 434 nM in the presence of a 1 μM tracer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c01115/20210803/images/large/jm1c01115_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c01115&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52681" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52681" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 16 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejedor, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerle, B.</span></span> <span> </span><span class="NLM_article-title">MNB/DYRK1A as a Multiple Regulator of Neuronal Development</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2010.07954.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1111%2Fj.1742-4658.2010.07954.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=21156027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFGru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=223-235&author=F.+J.+Tejedorauthor=B.+Hammerle&title=MNB%2FDYRK1A+as+a+Multiple+Regulator+of+Neuronal+Development&doi=10.1111%2Fj.1742-4658.2010.07954.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">MNB/DYRK1A as a multiple regulator of neuronal development</span></div><div class="casAuthors">Tejedor, Francisco J.; Hammerle, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-235</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  MNB/DYRK1A kinase is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family that has been strongly conserved across evolution.  There are substantial data implicating MNB/DYRK1A in brain development and adult brain function, as well as in neurodegeneration and Down syndrome pathologies.  Here, the authors review the current understanding of the neurodevelopmental activity of MNB/DYRK1A.  The authors discuss how MNB/DYRK1A fulfils several sequential roles in neuronal development and the mol. mechanisms possibly underlying these functions.  The authors also summarize the evidence behind the hypotheses to explain how the imbalance in MNB/DYRK1A gene dosage might be implicated in the neurodevelopmental alterations assocd. with Down syndrome.  Finally, the authors highlight some research directions that may help to clarify the mechanisms and functions of MNB/DYRK1A signaling in the developing brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaEobI2pCfCLVg90H21EOLACvtfcHk0lissIPHEribng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFGru70%253D&md5=9f16a9bd441f24d2b860f1c322528162</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2010.07954.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2010.07954.x%26sid%3Dliteratum%253Aachs%26aulast%3DTejedor%26aufirst%3DF.%2BJ.%26aulast%3DHammerle%26aufirst%3DB.%26atitle%3DMNB%252FDYRK1A%2520as%2520a%2520Multiple%2520Regulator%2520of%2520Neuronal%2520Development%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D223%26epage%3D235%26doi%3D10.1111%2Fj.1742-4658.2010.07954.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wegiel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczmarski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frackowiak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur-Kolecka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Leon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adayev, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C. X.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Link Between DYRK1A Overexpression and Several-fold Enhancement of Neurofibrillary Degeneration with 3-Repeat Tau Protein in Down Syndrome</span>. <i>J. Neuropathol. Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1097/NEN.0b013e318202bfa1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1097%2FNEN.0b013e318202bfa1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=21157379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A280%3ADC%252BC3M3htl2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=36-50&author=J.+Wegielauthor=W.+Kaczmarskiauthor=M.+Baruaauthor=I.+Kuchnaauthor=K.+Nowickiauthor=K.+C.+Wangauthor=S.+M.+Yangauthor=J.+Frackowiakauthor=B.+Mazur-Koleckaauthor=W.+P.+Silvermanauthor=B.+Reisbergauthor=I.+Monteiroauthor=M.+de+Leonauthor=T.+Wisniewskiauthor=A.+Daltonauthor=F.+Laiauthor=Y.+W.+Hwangauthor=T.+Adayevauthor=F.+Liuauthor=K.+Iqbalauthor=I.+G.+Iqbalauthor=C.+X.+Gong&title=Link+Between+DYRK1A+Overexpression+and+Several-fold+Enhancement+of+Neurofibrillary+Degeneration+with+3-Repeat+Tau+Protein+in+Down+Syndrome&doi=10.1097%2FNEN.0b013e318202bfa1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome</span></div><div class="casAuthors">Wegiel Jerzy; Kaczmarski Wojciech; Barua Madhabi; Kuchna Izabela; Nowicki Krzysztof; Wang Kuo-Chiang; Wegiel Jarek; Yang Shuang Ma; Frackowiak Janusz; Mazur-Kolecka Bozena; Silverman Wayne P; Reisberg Barry; Monteiro Isabel; de Leon Mony; Wisniewski Thomas; Dalton Arthur; Lai Florence; Hwang Yu-Wen; Adayev Tatyana; Liu Fei; Iqbal Khalid; Iqbal Inge-Grundke; Gong Cheng-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuropathology and experimental neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triplication of chromosome 21 in Down syndrome (DS) results in overexpression of the minibrain kinase/dual-specificity tyrosine phosphorylated and regulated kinase 1A gene (DYRK1A).  DYRK1A phosphorylates cytoplasmic tau protein and appears in intraneuronal neurofibrillary tangles (NFTs).  We have previously shown significantly more DYRK1A-positive NFTs in DS brains than in sporadic Alzheimer disease (AD) brains.  This study demonstrates a gene dosage-proportional increase in the level of DYRK1A in DS in the cytoplasm and the cell nucleus, and enhanced cytoplasmic and nuclear immunoreactivity of DYRK1A in DS.  The results suggest that overexpressed DYRK1A may alter both phosphorylation of tau and alternative splicing factor (ASF).  Two-dimensional electrophoresis revealed modification of ASF phosphorylation in DS/AD and AD in comparison to controls.  Altered phosphorylation of ASF by overexpressed nuclear DYRK1A may contribute to the alternative splicing of the tau gene and an increase by 2.68 × of the 3R/4R ratio in DS/AD, and a several-fold increase in the number of 3R tau-positive NFTs in DS/AD subjects compared with that in sporadic AD subjects.  These data support the hypothesis that phosphorylation of ASF by overexpressed DYRK1A may contribute to alternative splicing of exon 10, increased expression of 3R tau, and early onset of neurofibrillary degeneration in DS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQohJz0qPg38DToTC3aBaesfW6udTcc2eavG-QNsJbkjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3htl2gsA%253D%253D&md5=70efaba307a11a62f14e822978642aec</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2FNEN.0b013e318202bfa1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FNEN.0b013e318202bfa1%26sid%3Dliteratum%253Aachs%26aulast%3DWegiel%26aufirst%3DJ.%26aulast%3DKaczmarski%26aufirst%3DW.%26aulast%3DBarua%26aufirst%3DM.%26aulast%3DKuchna%26aufirst%3DI.%26aulast%3DNowicki%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DK.%2BC.%26aulast%3DYang%26aufirst%3DS.%2BM.%26aulast%3DFrackowiak%26aufirst%3DJ.%26aulast%3DMazur-Kolecka%26aufirst%3DB.%26aulast%3DSilverman%26aufirst%3DW.%2BP.%26aulast%3DReisberg%26aufirst%3DB.%26aulast%3DMonteiro%26aufirst%3DI.%26aulast%3Dde%2BLeon%26aufirst%3DM.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DDalton%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DF.%26aulast%3DHwang%26aufirst%3DY.%2BW.%26aulast%3DAdayev%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DIqbal%26aufirst%3DI.%2BG.%26aulast%3DGong%26aufirst%3DC.%2BX.%26atitle%3DLink%2520Between%2520DYRK1A%2520Overexpression%2520and%2520Several-fold%2520Enhancement%2520of%2520Neurofibrillary%2520Degeneration%2520with%25203-Repeat%2520Tau%2520Protein%2520in%2520Down%2520Syndrome%26jtitle%3DJ.%2520Neuropathol.%2520Exp.%2520Neurol.%26date%3D2011%26volume%3D70%26spage%3D36%26epage%3D50%26doi%3D10.1097%2FNEN.0b013e318202bfa1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s Disease: the Amyloid Cascade Hypothesis: an Update and Reappraisal</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.3233/JAD-2006-9S317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.3233%2FJAD-2006-9S317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=16914853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=151-153&author=J.+Hardy&title=Alzheimer%E2%80%99s+Disease%3A+the+Amyloid+Cascade+Hypothesis%3A+an+Update+and+Reappraisal&doi=10.3233%2FJAD-2006-9S317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal</span></div><div class="casAuthors">Hardy, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">151-153</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  Here I recap the scientific and personal background of the delineation of the amyloid cascade hypothesis for Alzheimer's disease that I wrote with Gerry Higgins and the events leading to the writing of that influential review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO9h63kZgivLVg90H21EOLACvtfcHk0litnySW_afXqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKkt7Y%253D&md5=9c91d6b0cf34cfdffbd2b0bb4b9429d6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3233%2FJAD-2006-9S317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2006-9S317%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DAlzheimer%25E2%2580%2599s%2520Disease%253A%2520the%2520Amyloid%2520Cascade%2520Hypothesis%253A%2520an%2520Update%2520and%2520Reappraisal%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2006%26volume%3D9%26spage%3D151%26epage%3D153%26doi%3D10.3233%2FJAD-2006-9S317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunckley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulme, C.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: a New Avenue for a Disease Modifying Treatment of Alzheimer’s?</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1021/cn300094k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300094k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KmsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=857-872&author=B.+Smithauthor=F.+Meddaauthor=V.+Gokhaleauthor=T.+Dunckleyauthor=C.+Hulme&title=Recent+Advances+in+the+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Selective+DYRK1A+Inhibitors%3A+a+New+Avenue+for+a+Disease+Modifying+Treatment+of+Alzheimer%E2%80%99s%3F&doi=10.1021%2Fcn300094k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?</span></div><div class="casAuthors">Smith, Breland; Medda, Federico; Gokhale, Vijay; Dunckley, Travis; Hulme, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">857-872</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  With 24.3 million people affected in 2005 and an estd. rise to 42.3 million in 2020, dementia is currently a leading unmet medical need and costly burden on public health.  Seventy percent of these cases have been attributed to Alzheimer's disease (AD), a neurodegenerative pathol. whose most evident symptom is a progressive decline in cognitive functions.  Dual specificity tyrosine phosphorylation regulated kinase-1A (DYRK1A) is important in neuronal development and plays a variety of functional roles within the adult central nervous system.  The DYRK1A gene is located within the Down syndrome crit. region (DSCR) on human chromosome 21 and current research suggests that overexpression of DYRK1A may be a significant factor leading to cognitive deficits in people with Alzheimer's disease (AD) and Down syndrome (DS).  Currently, treatment options for cognitive deficiencies assocd. with Down syndrome, as well as Alzheimer's disease, are extremely limited and represent a major unmet therapeutic need.  Small mol. inhibition of DYRK1A activity in the brain may provide an avenue for pharmaceutical intervention of mental impairment assocd. with AD and other neurodegenerative diseases.  We herein review the current state of the art in the development of DYRK1A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSAw8CXNiP7Vg90H21EOLACvtfcHk0litnySW_afXqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KmsL3K&md5=2009c25bc00389971cd71f64ead2da4a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fcn300094k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300094k%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DMedda%26aufirst%3DF.%26aulast%3DGokhale%26aufirst%3DV.%26aulast%3DDunckley%26aufirst%3DT.%26aulast%3DHulme%26aufirst%3DC.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Selective%2520DYRK1A%2520Inhibitors%253A%2520a%2520New%2520Avenue%2520for%2520a%2520Disease%2520Modifying%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%253F%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D857%26epage%3D872%26doi%3D10.1021%2Fcn300094k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwen, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radnabaazar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. H.</span></span> <span> </span><span class="NLM_article-title">Dyrk1A-Mediated Phosphorylation of Presenilin 1: a Functional Link Between Down Syndrome and Alzheimer’s Disease</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">574</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2010.06769.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1111%2Fj.1471-4159.2010.06769.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=20456003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGlsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=574-584&author=Y.+S.+Ryuauthor=S.+Y.+Parkauthor=M.+S.+Jungauthor=S.+H.+Yoonauthor=M.+Y.+Kwenauthor=S.+Y.+Leeauthor=S.+H.+Choiauthor=C.+Radnabaazarauthor=M.+K.+Kimauthor=H.+Kimauthor=K.+Kimauthor=W.+J.+Songauthor=S.+H.+Chung&title=Dyrk1A-Mediated+Phosphorylation+of+Presenilin+1%3A+a+Functional+Link+Between+Down+Syndrome+and+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Fj.1471-4159.2010.06769.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dyrk1A-mediated phosphorylation of presenilin 1: a functional link between Down syndrome and Alzheimer's disease</span></div><div class="casAuthors">Ryu, Young Shin; Park, So Young; Jung, Min-Su; Yoon, Song-Hee; Kwen, Mi-Yang; Lee, Sun-Young; Choi, Sun-Hee; Radnaabazar, Chinzorig; Kim, Mi-Kyoung; Kim, Hangun; Kim, Kwonseop; Song, Woo-Joo; Chung, Sul-Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">574-584</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The dual-specificity tyrosine(Y)-phosphorylation-regulated kinase 1A (Dyrk1A) gene is located on human chromosome 21 and encodes a proline-directed protein kinase that might be responsible for mental retardation and early onset of Alzheimer's disease (AD) in Down syndrome (DS) patients.  Presenilin 1 (PS1) is a key component of the γ-secretase complex in the generation of β-amyloid (Aβ), an important trigger protein in the pathogenesis of AD.  Increased Dyrk1A expression has been reported in human AD and DS brains.  We previously showed that Dyrk1A increased Aβ prodn. in mammalian cells and transgenic mice that over-express Dyrk1A.  In this study, we describe a potential mechanism by which Aβ is increased in Dyrk1A-over-expressing DS and AD brains.  First, we show that PS1 is phosphorylated by the Dyrk1A at Thr354 and that this phosphorylation increases γ-secretase activity.  Then, using transgenic mice that over-express human Dyrk1A, we demonstrate that phospho-Thr354-PS1 (pT354-PS1) expression is enhanced when Dyrk1A level is increased.  We also show that pT354-PS1 is more stable than the unphosphorylated form of PS1.  These results reveal a potential regulatory link between Dyrk1A and PS1 in the Aβ pathway of DS and AD brains, suggesting that up-regulated Dyrk1A may accelerate AD pathogenesis through PS1 phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLqQna1ZNRMLVg90H21EOLACvtfcHk0litnySW_afXqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGlsb%252FJ&md5=c34feb9505bd69bb8e5242e0a23e8197</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2010.06769.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2010.06769.x%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DJung%26aufirst%3DM.%2BS.%26aulast%3DYoon%26aufirst%3DS.%2BH.%26aulast%3DKwen%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DRadnabaazar%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DW.%2BJ.%26aulast%3DChung%26aufirst%3DS.%2BH.%26atitle%3DDyrk1A-Mediated%2520Phosphorylation%2520of%2520Presenilin%25201%253A%2520a%2520Functional%2520Link%2520Between%2520Down%2520Syndrome%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neurochem.%26date%3D2010%26volume%3D115%26spage%3D574%26epage%3D584%26doi%3D10.1111%2Fj.1471-4159.2010.06769.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7687</span>– <span class="NLM_lpage">7699</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00658</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00658" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7687-7699&author=K.+Kumarauthor=P.+Wangauthor=R.+Sanchezauthor=E.+A.+Swartzauthor=A.+F.+Stewartauthor=R.+J.+DeVita&title=Development+of+Kinase-Selective%2C+Harmine-Based+DYRK1A+Inhibitors+that+Induce+Pancreatic+Human+%CE%B2-Cell+Proliferation&doi=10.1021%2Facs.jmedchem.8b00658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Sanchez, Roberto; Swartz, Ethan A.; Stewart, Andrew F.; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7687-7699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DYRK1A has been implicated as an important drug target in various therapeutic areas, including neurol. disorders and oncol.  DYRK1A has more recently been shown to be involved in pathways regulating human β-cell proliferation, thus making it a potential therapeutic target for both Type 1 and Type 2 diabetes.  Our group, using a high-throughput phenotypic screen identified harmine that is able to induce beta cell proliferation both in vitro and in vivo.  Since harmine has suboptimal kinase selectivity we sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity, while retaining human β-cell proliferation capability.  We carried out the optimization of the 1-position of harmine and synthesized 15 harmine analogs.  6 Compds. showed excellent DYRK1A inhibition with IC50 in the range of 49.5-264 nM.  Two compds., 2-2 and 2-8, exhibited excellent human β-cell proliferation at doses of 3-30 μM and compd. 2-2 showed improved kinase selectivity as compared to harmine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmFSDNEicChLVg90H21EOLACvtfcHk0lgr_fE6Ov8Ltw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsb7M&md5=e1b748db912ac5b0ef93b8729ad4b13e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00658%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DDevelopment%2520of%2520Kinase-Selective%252C%2520Harmine-Based%2520DYRK1A%2520Inhibitors%2520that%2520Induce%2520Pancreatic%2520Human%2520%25CE%25B2-Cell%2520Proliferation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7687%26epage%3D7699%26doi%3D10.1021%2Facs.jmedchem.8b00658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohilla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yar, M. S.</span></span> <span> </span><span class="NLM_article-title">DYRK1A Kinase Inhibition with Emphasis on Neurodegeneration: A Comprehensive Evolution Story-cum-perspective</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1016%2Fj.ejmech.2018.08.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=30243157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=559-592&author=A.+Pathakauthor=A.+Rohillaauthor=T.+Guptaauthor=M.+J.+Akhtarauthor=M.+R.+Haiderauthor=K.+Sharmaauthor=K.+Haiderauthor=M.+S.+Yar&title=DYRK1A+Kinase+Inhibition+with+Emphasis+on+Neurodegeneration%3A+A+Comprehensive+Evolution+Story-cum-perspective&doi=10.1016%2Fj.ejmech.2018.08.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective</span></div><div class="casAuthors">Pathak, Ankita; Rohilla, Ankit; Gupta, Tanya; Akhtar, Md Jawaid; Haider, Md Rafi; Sharma, Kalicharan; Haider, Kashif; Yar, M. Shahar</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">559-592</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Alzheimer, the fourth leading cause of death embodies a key responsible event including formation of β-amyloid protein clustering to amyloid plaque on blood vessels.  The origin of above events is Amyloid precursor protein (APP) which is an integral membrane protein known for its function in synapses formation.  Modern research had proposed that the over expression of DYRK1A (Dual specificity tyrosine phosphorylation regulated kinase1A), a family of protein kinases, positioned within the Down's syndrome crit. region (DSCR) on human chromosome 21 causes phosphorylation of APP protein resulting in its cleavage to Aβ 40, 42 and tau proteins (regulated by beta and gamma secretase) which plays crit. role in early onset of Alzheimer's disease (AD) detected in Down's syndrome (DS), leading to permanent functional and structural deformities which results ultimately into neuro-degeneration and neuronal death.  Therefore, DYRK1A emerges as a potential target for prevention of neuro-degeneration and hence Alzheimer.  Presently, the treatment methods for Down's syndrome, as well as Alzheimer's disease are extremely biased and represent a major deficiency for therapeutic necessities.  We hereby, focus our review on the current status of the research and contributions in the development of DYRK1A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHdKzoMC45tLVg90H21EOLACvtfcHk0lgr_fE6Ov8Ltw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FJ&md5=e13399fd58d17c25fdd19e63239c8cf5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.093%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DA.%26aulast%3DRohilla%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DT.%26aulast%3DAkhtar%26aufirst%3DM.%2BJ.%26aulast%3DHaider%26aufirst%3DM.%2BR.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DHaider%26aufirst%3DK.%26aulast%3DYar%26aufirst%3DM.%2BS.%26atitle%3DDYRK1A%2520Kinase%2520Inhibition%2520with%2520Emphasis%2520on%2520Neurodegeneration%253A%2520A%2520Comprehensive%2520Evolution%2520Story-cum-perspective%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D559%26epage%3D592%26doi%3D10.1016%2Fj.ejmech.2018.08.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmström, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreaux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazureau, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Leucettine L41, a DYRK1A-preferential DYRKs/CLKs Inhibitor, Prevents Memory Impairments and Neurotoxicity Induced by Oligomeric Aβ25-35 Peptide Administration in Mice</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_fpage">2170</span>– <span class="NLM_lpage">2182</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2015.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1016%2Fj.euroneuro.2015.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=26381812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFemsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=2170-2182&author=G.+Naertauthor=V.+Ferr%C3%A9author=J.+Meunierauthor=E.+Kellerauthor=S.+Malmstr%C3%B6mauthor=L.+Givaloisauthor=F.+Carreauxauthor=J.+P.+Bazureauauthor=T.+Maurice&title=Leucettine+L41%2C+a+DYRK1A-preferential+DYRKs%2FCLKs+Inhibitor%2C+Prevents+Memory+Impairments+and+Neurotoxicity+Induced+by+Oligomeric+A%CE%B225-35+Peptide+Administration+in+Mice&doi=10.1016%2Fj.euroneuro.2015.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice</span></div><div class="casAuthors">Naert, Gaelle; Ferre, Valentine; Meunier, Johann; Keller, Emeline; Malmstrom, Susanna; Givalois, Laurent; Carreaux, Francois; Bazureau, Jean-Pierre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2170-2182</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) are implicated in the onset and progression of Down syndrome (DS) and Alzheimer's disease (AD).  DYRK1A has emerged as a possible link between amyloid-β (Aβ) and Tau, the major pathol. proteins in AD.  We here assessed the neuroprotective potential of a novel inhibitor of DYRKs/CLKs.  The Leucettine L41, acting preferentially on DYRK1A, was tested in Aβ25-35-treated mice, a nontransgenic model of AD-like toxicity.  We co-injected intracerebroventricularly oligomeric Aβ25-35 peptide and L41 in Swiss male mice.  After 7 days, they were submitted to behavioral tests addressing spatial and non-spatial, short- and long-term memories.  The oxidative stress, apoptotic markers, kinases involved in Tau phosphorylation, and synaptic integrity were analyzed by Western blot and ELISA in the hippocampus.  L41, tested at 0.4, 1.2, 4 μg, prevented the Aβ25-35-induced memory deficits in the Y-maze, passive avoidance and water-maze tests, with the most active dose being 4 μg.  The inhibitor prevented the Aβ25-35-induced oxidative stress, as revealed by measures of lipid peroxidn. levels and reactive oxygen species accumulation, and abolished Aβ25-35-induced expression of pro-apoptotic markers.  L41 prevented the Aβ25-35-induced decrease of AKT activation and increase of glycogen synthase kinase-3β (GSK-3β) activation, resulting in a decrease of Tau phosphorylation.  Finally, L41 restored Aβ25-35-reduced levels of synaptic markers.  The novel DYRK1A-preferential inhibitor L41 therefore prevented Aβ25-35-induced memory impairments and neurotoxicity in the mouse hippocampus.  These in vivo data highlighted particularly DYRK1A as a major kinase involved in Aβ pathol. and suggested therapeutic developments for DYRK1A inhibitors in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSRN-4HYiJs7Vg90H21EOLACvtfcHk0lgr_fE6Ov8Ltw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFemsro%253D&md5=0ddd499193f1ef57d02b46a39f225abb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2015.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2015.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DNaert%26aufirst%3DG.%26aulast%3DFerr%25C3%25A9%26aufirst%3DV.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DS.%26aulast%3DGivalois%26aufirst%3DL.%26aulast%3DCarreaux%26aufirst%3DF.%26aulast%3DBazureau%26aufirst%3DJ.%2BP.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DLeucettine%2520L41%252C%2520a%2520DYRK1A-preferential%2520DYRKs%252FCLKs%2520Inhibitor%252C%2520Prevents%2520Memory%2520Impairments%2520and%2520Neurotoxicity%2520Induced%2520by%2520Oligomeric%2520A%25CE%25B225-35%2520Peptide%2520Administration%2520in%2520Mice%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2015%26spage%3D2170%26epage%3D2182%26doi%3D10.1016%2Fj.euroneuro.2015.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melchior, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittapalli, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Polk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Güner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofilena, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjitro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellamary, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swearingen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunil, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazici, Y.</span></span> <span> </span><span class="NLM_article-title">Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor: A Potential Therapeutic for Alzheimer’s Disease</span>. <i>Aging Cell.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">e13000</span> <span class="refDoi"> DOI: 10.1111/acel.13000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1111%2Facel.13000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=31267651" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&author=B.+Melchiorauthor=G.+K.+Mittapalliauthor=C.+Laiauthor=K.+Duong-Polkauthor=J.+Stewartauthor=B.+G%C3%BCnerauthor=B.+Hofilenaauthor=A.+Tjitroauthor=S.+D.+Andersonauthor=D.+S.+Hermanauthor=L.+Dellamaryauthor=C.+J.+Swearingenauthor=K.+C.+Sunilauthor=Y.+Yazici&title=Tau+Pathology+Reduction+with+SM07883%2C+a+Novel%2C+Potent%2C+and+Selective+Oral+DYRK1A+Inhibitor%3A+A+Potential+Therapeutic+for+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Facel.13000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Facel.13000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Facel.13000%26sid%3Dliteratum%253Aachs%26aulast%3DMelchior%26aufirst%3DB.%26aulast%3DMittapalli%26aufirst%3DG.%2BK.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DDuong-Polk%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DG%25C3%25BCner%26aufirst%3DB.%26aulast%3DHofilena%26aufirst%3DB.%26aulast%3DTjitro%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DS.%2BD.%26aulast%3DHerman%26aufirst%3DD.%2BS.%26aulast%3DDellamary%26aufirst%3DL.%26aulast%3DSwearingen%26aufirst%3DC.%2BJ.%26aulast%3DSunil%26aufirst%3DK.%2BC.%26aulast%3DYazici%26aufirst%3DY.%26atitle%3DTau%2520Pathology%2520Reduction%2520with%2520SM07883%252C%2520a%2520Novel%252C%2520Potent%252C%2520and%2520Selective%2520Oral%2520DYRK1A%2520Inhibitor%253A%2520A%2520Potential%2520Therapeutic%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAging%2520Cell.%26date%3D2019%26volume%3D18%26doi%3D10.1111%2Facel.13000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrassi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span> <span> </span><span class="NLM_article-title">Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2958</span>– <span class="NLM_lpage">2973</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01624</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01624" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlSqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2958-2973&author=Y.+A.+Liuauthor=Q.+Jinauthor=Y.+Zouauthor=Q.+Dingauthor=S.+Yanauthor=Z.+Wangauthor=X.+Haoauthor=B.+Nguyenauthor=X.+Zhangauthor=J.+Panauthor=T.+Moauthor=K.+Jacobsenauthor=T.+Lamauthor=T.+Y.+Wuauthor=H.+M.+Petrassiauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=W.+P.+Gordonauthor=B.+Liuauthor=J.+Baatenauthor=R.+Hillauthor=V.+Nguyen-Tranauthor=M.+Qiuauthor=Y.+Q.+Zhangauthor=A.+Kamireddyauthor=S.+Espinolaauthor=L.+Deatonauthor=S.+Haauthor=G.+Harbauthor=Y.+Jiaauthor=J.+Liauthor=W.+Shenauthor=A.+M.+Schumacherauthor=K.+Colmanauthor=R.+Glynneauthor=S.+Panauthor=P.+McNamaraauthor=B.+Laffitteauthor=S.+Meeusenauthor=V.+Molteniauthor=J.+Loren&title=Selective+DYRK1A+Inhibitor+for+the+Treatment+of+Type+1+Diabetes%3A+Discovery+of+6-Azaindole+Derivative+GNF2133&doi=10.1021%2Facs.jmedchem.9b01624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133</span></div><div class="casAuthors">Liu, Yahu A.; Jin, Qihui; Zou, Yefen; Ding, Qiang; Yan, Shanshan; Wang, Zhicheng; Hao, Xueshi; Nguyen, Bao; Zhang, Xiaoyue; Pan, Jianfeng; Mo, Tingting; Jacobsen, Kate; Lam, Thanh; Wu, Tom Y.-H.; Petrassi, H. Michael; Bursulaya, Badry; Di Donato, Michael; Gordon, W. Perry; Liu, Bo; Baaten, Janine; Hill, Robert; Nguyen-Tran, Van; Qiu, Minhua; Zhang, You-Qing; Kamireddy, Anwesh; Espinola, Sheryll; Deaton, Lisa; Ha, Sukwon; Harb, George; Jia, Yong; Li, Jing; Shen, Weijun; Schumacher, Andrew M.; Colman, Karyn; Glynne, Richard; Pan, Shifeng; McNamara, Peter; Laffitte, Bryan; Meeusen, Shelly; Molteni, Valentina; Loren, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2958-2973</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Autoimmune deficiency and destruction in either β-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes.  Thus, promoting β-cell proliferation could be one approach toward diabetes intervention.  In this report we describe the discovery of a potent and selective DYRK1A inhibitor GNF2133, which was identified through optimization of a 6-azaindole screening hit.  In vitro, GNF2133 is able to proliferate both rodent and human β-cells.  In vivo, GNF2133 demonstrated significant dose-dependent glucose disposal capacity and insulin secretion in response to glucose-potentiated arginine-induced insulin secretion (GPAIS) challenge in rat insulin promoter and diphtheria toxin A (RIP-DTA) mice.  The work described here provides new avenues to disease altering therapeutic interventions in the treatment of type 1 diabetes (T1D).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKP8bWozWpHrVg90H21EOLACvtfcHk0lgM6ZC9i5Vysw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlSqs7g%253D&md5=0ec2402f79b1b3fa338aab9672b8b669</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01624%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BA.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DJacobsen%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DT.%2BY.%26aulast%3DPetrassi%26aufirst%3DH.%2BM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DBaaten%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%2BQ.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DEspinola%26aufirst%3DS.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DSchumacher%26aufirst%3DA.%2BM.%26aulast%3DColman%26aufirst%3DK.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DLoren%26aufirst%3DJ.%26atitle%3DSelective%2520DYRK1A%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25201%2520Diabetes%253A%2520Discovery%2520of%25206-Azaindole%2520Derivative%2520GNF2133%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2958%26epage%3D2973%26doi%3D10.1021%2Facs.jmedchem.9b01624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamrui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2986</span>– <span class="NLM_lpage">3003</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01379</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01379" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2986-3003&author=K.+Kumarauthor=P.+Wangauthor=J.+Wilsonauthor=V.+Zlatanicauthor=C.+Berrouetauthor=S.+Khamruiauthor=C.+Secorauthor=E.+A.+Swartzauthor=M.+Lazarusauthor=R.+Sanchezauthor=A.+F.+Stewartauthor=A.+Garcia-Ocanaauthor=R.+J.+DeVita&title=Synthesis+and+Biological+Validation+of+a+Harmine-Based%2C+Central+Nervous+System+%28CNS%29-Avoidant%2C+Selective%2C+Human+%CE%B2-Cell+Regenerative+Dual-Specificity+Tyrosine+Phosphorylation-Regulated+Kinase+A+%28DYRK1A%29+Inhibitor&doi=10.1021%2Facs.jmedchem.9b01379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Wilson, Jessica; Zlatanic, Viktor; Berrouet, Cecilia; Khamrui, Susmita; Secor, Cody; Swartz, Ethan A.; Lazarus, Michael; Sanchez, Roberto; Stewart, Andrew F.; Garcia-Ocana, Adolfo; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2986-3003</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, our group identified that harmine is able to induce β-cell proliferation both in vitro and in vivo, mediated via the DYRK1A-NFAT pathway.  Since, harmine suffers from a lack of selectivity, both against other kinases and CNS off-targets, we therefore sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity for off-targets while retaining human β-cell proliferation activity.  We carried out optimization of the 9-N-position of harmine to synthesize 29 harmine-based analogs.  Several novel inhibitors showed excellent DYRK1A inhibition and human β-cell proliferation capability.  An optimized DYRK1A inhibitor, compd. I, was identified as a novel, efficacious in vivo lead candidate.  Compd. I also demonstrates improved selectivity for kinases and CNS off-targets, as well as in vivo efficacy for β-cell proliferation and regeneration at lower doses than harmine.  Collectively, these findings demonstrate that compd. I is a much improved in vivo lead candidate as compared to harmine for the treatment of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZXVR-g2rCbbVg90H21EOLACvtfcHk0lgM6ZC9i5Vysw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOgsr8%253D&md5=c739edc1358acafc412a122c272edceb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01379%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DZlatanic%26aufirst%3DV.%26aulast%3DBerrouet%26aufirst%3DC.%26aulast%3DKhamrui%26aufirst%3DS.%26aulast%3DSecor%26aufirst%3DC.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DLazarus%26aufirst%3DM.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520and%2520Biological%2520Validation%2520of%2520a%2520Harmine-Based%252C%2520Central%2520Nervous%2520System%2520%2528CNS%2529-Avoidant%252C%2520Selective%252C%2520Human%2520%25CE%25B2-Cell%2520Regenerative%2520Dual-Specificity%2520Tyrosine%2520Phosphorylation-Regulated%2520Kinase%2520A%2520%2528DYRK1A%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2986%26epage%3D3003%26doi%3D10.1021%2Facs.jmedchem.9b01379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins Navratilova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. E.</span></span> <span> </span><span class="NLM_article-title">Mining Public Domain Data to Develop Selective DYRK1A Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1620</span>– <span class="NLM_lpage">1626</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSju7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1620-1626&author=S.+H.+Hendersonauthor=F.+Sorrellauthor=J.+Bennettauthor=M.+T.+Hanleyauthor=S.+Robinsonauthor=I.+Hopkins+Navratilovaauthor=J.+M.+Elkinsauthor=S.+E.+Ward&title=Mining+Public+Domain+Data+to+Develop+Selective+DYRK1A+Inhibitors&doi=10.1021%2Facsmedchemlett.0c00279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mining Public Domain Data to Develop Selective DYRK1A Inhibitors</span></div><div class="casAuthors">Henderson, Scott H.; Sorrell, Fiona; Bennett, James; Hanley, Marcus T.; Robinson, Sean; Hopkins Navratilova, Iva; Elkins, Jonathan M.; Ward, Simon E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1620-1626</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases represent one of the most intensively pursued groups of targets in modern-day drug discovery.  Often it is desirable to achieve selective inhibition of the kinase of interest over the remaining ~ 500 kinases in the human kinome.  This is esp. true when inhibitors are intended to be used to study the biol. of the target of interest.  We present a pipeline of open-source software that analyzes public domain data to repurpose compds. that have been used in previous kinase inhibitor development projects.  We define the dual-specificity tyrosine-regulated kinase 1A (DYRK1A) as the kinase of interest, and by addn. of a single Me group to the chosen starting point we remove glycogen synthase kinase β (GSK3β) and cyclin-dependent kinase (CDK) inhibition.  Thus, in an efficient manner we repurpose a GSK3β/CDK chemotype to deliver 8b(I), a highly selective DYRK1A inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4_KxvU0_m5LVg90H21EOLACvtfcHk0ljBo04thfRBOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSju7bK&md5=d08a310f2b7f61243c46418d946d2d50</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00279%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DS.%2BH.%26aulast%3DSorrell%26aufirst%3DF.%26aulast%3DBennett%26aufirst%3DJ.%26aulast%3DHanley%26aufirst%3DM.%2BT.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DHopkins%2BNavratilova%26aufirst%3DI.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DWard%26aufirst%3DS.%2BE.%26atitle%3DMining%2520Public%2520Domain%2520Data%2520to%2520Develop%2520Selective%2520DYRK1A%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1620%26epage%3D1626%26doi%3D10.1021%2Facsmedchemlett.0c00279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preugschat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. Q.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-Phenyl-4-pyrazolo[1,5-<i>b</i>]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4716</span>– <span class="NLM_lpage">4730</span>, <span class="refDoi"> DOI: 10.1021/jm040063i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040063i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4716-4730&author=F.+X.+Tavaresauthor=J.+A.+Boucheronauthor=S.+H.+Dickersonauthor=R.+J.+Griffinauthor=F.+Preugschatauthor=S.+A.+Thomsonauthor=T.+Y.+Wangauthor=H.+Q.+Zhou&title=N-Phenyl-4-pyrazolo%5B1%2C5-b%5Dpyridazin-3-ylpyrimidin-2-amines+as+Potent+and+Selective+Inhibitors+of+Glycogen+Synthase+Kinase+3+with+Good+Cellular+Efficacy&doi=10.1021%2Fjm040063i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy</span></div><div class="casAuthors">Tavares, Francis X.; Boucheron, Joyce A.; Dickerson, Scott H.; Griffin, Robert J.; Preugschat, Frank; Thomson, Stephen A.; Wang, Tony Y.; Zhou, Hui-Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4716-4730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 regulates glycogen synthase, the rate-detg. enzyme for glycogen synthesis.  Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels.  Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics.  Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compds. with good cellular efficacy.  Mol. modeling studies have given insights into the mode of binding of these inhibitors.  Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b]pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2.  In addn., these inhibitors also exhibited very good cell efficacy and functional response.  A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting.  These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY8mmZ2qIdFLVg90H21EOLACvtfcHk0ljBo04thfRBOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFSgtL4%253D&md5=934bcecaed8f087510bfc8fb41e2e7a5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm040063i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040063i%26sid%3Dliteratum%253Aachs%26aulast%3DTavares%26aufirst%3DF.%2BX.%26aulast%3DBoucheron%26aufirst%3DJ.%2BA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DPreugschat%26aufirst%3DF.%26aulast%3DThomson%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DT.%2BY.%26aulast%3DZhou%26aufirst%3DH.%2BQ.%26atitle%3DN-Phenyl-4-pyrazolo%255B1%252C5-b%255Dpyridazin-3-ylpyrimidin-2-amines%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Glycogen%2520Synthase%2520Kinase%25203%2520with%2520Good%2520Cellular%2520Efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4716%26epage%3D4730%26doi%3D10.1021%2Fjm040063i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaenzer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarchak, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, J-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striker, R.</span></span> <span> </span><span class="NLM_article-title">GW779439X and its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act as Antibiotic Adjuvants Against β-Lactam-Resistant Staphylococcus Aureus</span>. <i>ACS Infect Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1508</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSnt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=1508-1518&author=A.+J.+Schaenzerauthor=N.+Wlodarchakauthor=D.+H.+Drewryauthor=W.+J.+Zuercherauthor=W.+E.+Roseauthor=C.+A.+Ferrerauthor=J-D.+Sauerauthor=R.+Striker&title=GW779439X+and+its+Pyrazolopyridazine+Derivatives+Inhibit+the+Serine%2FThreonine+Kinase+Stk1+and+Act+as+Antibiotic+Adjuvants+Against+%CE%B2-Lactam-Resistant+Staphylococcus+Aureus&doi=10.1021%2Facsinfecdis.8b00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against β-Lactam-Resistant Staphylococcus aureus</span></div><div class="casAuthors">Schaenzer, Adam J.; Wlodarchak, Nathan; Drewry, David H.; Zuercher, William J.; Rose, Warren E.; Ferrer, Carla A.; Sauer, John-Demian; Striker, Rob</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1508-1518</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As antibiotic resistance rises, there is a need for strategies such as antibiotic adjuvants to conserve already-established antibiotics.  A family of bacterial kinases known as the Penicillin-binding-protein And Serine/Threonine kinase-Assocd. (PASTA) kinases has attracted attention as targets for antibiotic adjuvants for β-lactams.  Here, we report that the pyrazolopyridazine GW779439X sensitizes methicillin-resistant Staphylococcus aureus (MRSA) to various β-lactams through inhibition of the PASTA kinase Stk1.  GW779439X potentiates β-lactam activity against multiple MRSA and MSSA isolates, including the sensitization of a ceftaroline-resistant isolate to ceftaroline.  In silico modeling was used to guide the synthesis of GW779439X derivs.  The presence and orientation of GW779439X's methylpiperazine moiety was crucial for robust biochem. and microbiol. activity.  Taken together, our data provide a proof of concept for developing the pyrazolopyridazines as Stk1 inhibitors which act across S. aureus isolates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokgmvad7sEv7Vg90H21EOLACvtfcHk0lgJ2yd_MYtIeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSnt7nJ&md5=d74112a692aef57e265862755bdc4dda</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00136%26sid%3Dliteratum%253Aachs%26aulast%3DSchaenzer%26aufirst%3DA.%2BJ.%26aulast%3DWlodarchak%26aufirst%3DN.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DRose%26aufirst%3DW.%2BE.%26aulast%3DFerrer%26aufirst%3DC.%2BA.%26aulast%3DSauer%26aufirst%3DJ-D.%26aulast%3DStriker%26aufirst%3DR.%26atitle%3DGW779439X%2520and%2520its%2520Pyrazolopyridazine%2520Derivatives%2520Inhibit%2520the%2520Serine%252FThreonine%2520Kinase%2520Stk1%2520and%2520Act%2520as%2520Antibiotic%2520Adjuvants%2520Against%2520%25CE%25B2-Lactam-Resistant%2520Staphylococcus%2520Aureus%26jtitle%3DACS%2520Infect%2520Dis.%26date%3D2018%26volume%3D4%26spage%3D1508%26epage%3D1518%26doi%3D10.1021%2Facsinfecdis.8b00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tear, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceballos-Pérez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas-Barros, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordon-Obras, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Moreno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Hernández, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Perez, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamarro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez Pacanowska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-<i>b</i>]pyridazines for the Treatment of Human African Trypanosomiasis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01741</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01741" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=756-783&author=W.+F.+Tearauthor=S.+Bagauthor=R.+Diaz-Gonzalezauthor=G.+Ceballos-P%C3%A9rezauthor=D.+I.+Rojas-Barrosauthor=C.+Cordon-Obrasauthor=G.+P%C3%A9rez-Morenoauthor=R.+Garc%C3%ADa-Hern%C3%A1ndezauthor=M.+S.+Martinez-Martinezauthor=L.+M.+Ruiz-Perezauthor=F.+Gamarroauthor=D.+Gonzalez+Pacanowskaauthor=C.+R.+Caffreyauthor=L.+Ferrinsauthor=P.+Manzanoauthor=M.+Navarroauthor=M.+P.+Pollastri&title=Selectivity+and+Physicochemical+Optimization+of+Repurposed+Pyrazolo%5B1%2C5-b%5Dpyridazines+for+the+Treatment+of+Human+African+Trypanosomiasis&doi=10.1021%2Facs.jmedchem.9b01741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis</span></div><div class="casAuthors">Tear, Westley F.; Bag, Seema; Diaz-Gonzalez, Rosario; Ceballos-Perez, Gloria; Rojas-Barros, Domingo I.; Cordon-Obras, Carlos; Perez-Moreno, Guiomar; Garcia-Hernandez, Raquel; Martinez-Martinez, Maria Santos; Ruiz-Perez, Luis Miguel; Gamarro, Francisco; Gonzalez Pacanowska, Dolores; Caffrey, Conor R.; Ferrins, Lori; Manzano, Pilar; Navarro, Miguel; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">756-783</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From a high-throughput screen of 42 444 known human kinases inhibitors, a pyrazolo[1,5-b]pyridazine scaffold was identified to begin optimization for the treatment of human African trypanosomiasis.  Previously reported data for analogous compds. against human kinases GSK-3β, CDK-2, and CDK-4 were leveraged to try to improve the selectivity of the series, resulting in 23a which showed selectivity for T. b. brucei over these three human enzymes.  In parallel, properties known to influence the absorption, distribution, metab., and excretion (ADME) profile of the series were optimized resulting in 20g being progressed into an efficacy study in mice.  Though 20g showed toxicity in mice, it also demonstrated CNS penetration in a PK study and significant redn. of parasitemia in four out of the six mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnVej-9mnZibVg90H21EOLACvtfcHk0lgJ2yd_MYtIeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqsLnJ&md5=a214fe962c7e0b38f45b27eedb37fe2a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01741%26sid%3Dliteratum%253Aachs%26aulast%3DTear%26aufirst%3DW.%2BF.%26aulast%3DBag%26aufirst%3DS.%26aulast%3DDiaz-Gonzalez%26aufirst%3DR.%26aulast%3DCeballos-P%25C3%25A9rez%26aufirst%3DG.%26aulast%3DRojas-Barros%26aufirst%3DD.%2BI.%26aulast%3DCordon-Obras%26aufirst%3DC.%26aulast%3DP%25C3%25A9rez-Moreno%26aufirst%3DG.%26aulast%3DGarc%25C3%25ADa-Hern%25C3%25A1ndez%26aufirst%3DR.%26aulast%3DMartinez-Martinez%26aufirst%3DM.%2BS.%26aulast%3DRuiz-Perez%26aufirst%3DL.%2BM.%26aulast%3DGamarro%26aufirst%3DF.%26aulast%3DGonzalez%2BPacanowska%26aufirst%3DD.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26aulast%3DFerrins%26aufirst%3DL.%26aulast%3DManzano%26aufirst%3DP.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DSelectivity%2520and%2520Physicochemical%2520Optimization%2520of%2520Repurposed%2520Pyrazolo%255B1%252C5-b%255Dpyridazines%2520for%2520the%2520Treatment%2520of%2520Human%2520African%2520Trypanosomiasis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D756%26epage%3D783%26doi%3D10.1021%2Facs.jmedchem.9b01741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heroven, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganotra, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfreys, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Montalván, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Halogen-Aromatic π Interactions Modulate Inhibitor Residence Times</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7220</span>– <span class="NLM_lpage">7224</span>, <span class="refDoi"> DOI: 10.1002/anie.201801666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=10.1002%2Fanie.201801666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFSmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=7220-7224&author=C.+Herovenauthor=V.+Georgiauthor=G.+K.+Ganotraauthor=P.+Brennanauthor=F.+Wolfreysauthor=R.+C.+Wadeauthor=A.+E.+Fern%C3%A1ndez-Montalv%C3%A1nauthor=A.+Chaikuadauthor=S.+Knapp&title=Halogen-Aromatic+%CF%80+Interactions+Modulate+Inhibitor+Residence+Times&doi=10.1002%2Fanie.201801666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen-aromatic π interactions modulate inhibitor residence times</span></div><div class="casAuthors">Heroven, Christina; Georgi, Victoria; Ganotra, Gaurav K.; Brennan, Paul; Wolfreys, Finn; Wade, Rebecca C.; Fernandez-Montalvan, Amaury E.; Chaikuad, Apirat; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7220-7224</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Prolonged drug residence times may result in longer-lasting drug efficacy, improved pharmacodynamic properties, and "kinetic selectivity" over off-targets with high drug dissocn. rates.  However, few strategies have been elaborated to rationally modulate drug residence time and thereby to integrate this key property into the drug development process.  Herein, we show that the interaction between a halogen moiety on an inhibitor and an arom. residue in the target protein can significantly increase inhibitor residence time.  By using the interaction of the serine/threonine kinase haspin with 5-iodotubercidin (5-iTU) derivs. as a model for an archetypal active-state (type I) kinase-inhibitor binding mode, we demonstrate that inhibitor residence times markedly increase with the size and polarizability of the halogen atom.  The halogen-arom. π interactions in the haspin-inhibitor complexes were characterized by means of kinetic, thermodn., and structural measurements along with binding-energy calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWtgKql8TUw7Vg90H21EOLACvtfcHk0ljHmAWzmufoNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFSmt7Y%253D&md5=6356e6800c6a03801cf4fef66af7e76a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fanie.201801666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201801666%26sid%3Dliteratum%253Aachs%26aulast%3DHeroven%26aufirst%3DC.%26aulast%3DGeorgi%26aufirst%3DV.%26aulast%3DGanotra%26aufirst%3DG.%2BK.%26aulast%3DBrennan%26aufirst%3DP.%26aulast%3DWolfreys%26aufirst%3DF.%26aulast%3DWade%26aufirst%3DR.%2BC.%26aulast%3DFern%25C3%25A1ndez-Montalv%25C3%25A1n%26aufirst%3DA.%2BE.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DHalogen-Aromatic%2520%25CF%2580%2520Interactions%2520Modulate%2520Inhibitor%2520Residence%2520Times%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D7220%26epage%3D7224%26doi%3D10.1002%2Fanie.201801666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1I','PDB','6S1I'); return false;">PDB: 6S1I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1B','PDB','6S1B'); return false;">PDB: 6S1B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S17" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S17','PDB','6S17'); return false;">PDB: 6S17</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S14" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S14','PDB','6S14'); return false;">PDB: 6S14</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1J','PDB','6S1J'); return false;">PDB: 6S1J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1H" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S1H','PDB','6S1H'); return false;">PDB: 6S1H</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i57"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c01115">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_67261"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c01115?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01115</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">DSF analysis of selected compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_001.xlsx">XLSX</a>)</p></li><li><p class="inline">KINOMEscan analysis of compounds in <a class="ref showTableEvent internalNav" href="#tbl9">Table <a class="ref showTableEvent internalNav" href="#tbl9">9</a></a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_002.xlsx">XLSX</a>)</p></li><li><p class="inline">SMILES (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_003.csv">CSV</a>)</p></li><li><p class="inline">Materials and methods for synthetic chemistry, protein expression, purification, crystallization, data collection, and structure determination; characterization of compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_004.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_001.xlsx">jm1c01115_si_001.xlsx (20.36 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_002.xlsx">jm1c01115_si_002.xlsx (155.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_003.csv">jm1c01115_si_003.csv (4.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c01115/suppl_file/jm1c01115_si_004.pdf">jm1c01115_si_004.pdf (7.94 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c01115&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c01115%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c01115" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799622e8d2e3d76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
